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A B S T R A C T
Background
Honey is a viscous, supersaturated sugar solution derived from nectar gathered and modified by the honeybee, Apis mellifera. Honey
has been used since ancient times as a remedy in wound care. Evidence from animal studies and some trials has suggested that honey
may accelerate wound healing.
Objectives
The objective of this review was to assess the effects of honey compared with alternative wound dressings and topical treatments on the
of healing of acute (e.g. burns, lacerations) and/or chronic (e.g. venous ulcers) wounds.
Search methods
For this update of the review we searched the CochraneWounds Group Specialised Register (searched 15 October 2014); The Cochrane
Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2014, Issue 9); Ovid MEDLINE (1946 to October Week 1
2014); Ovid MEDLINE (In-Process & Other Non-Indexed Citations 13 October 2014); Ovid EMBASE (1974 to 13 October 2014);
and EBSCO CINAHL (1982 to 15 October 2014).
Selection criteria
Randomised and quasi-randomised trials that evaluated honey as a treatment for any sort of acute or chronic wound were sought. There
was no restriction in terms of source, date of publication or language. Wound healing was the primary endpoint.
Data collection and analysis
Data from eligible trials were extracted and summarised by one review author, using a data extraction sheet, and independently verified
by a second review author. All data have been subsequently checked by two more authors.
Main results
We identified 26 eligible trials (total of 3011 participants). Three trials evaluated the effects of honey in minor acute wounds, 11 trials
evaluated honey in burns, 10 trials recruited people with different chronic wounds including two in people with venous leg ulcers, two
trials in people with diabetic foot ulcers and single trials in infected post-operative wounds, pressure injuries, cutaneous Leishmaniasis
and Fournier’s gangrene. Two trials recruited a mixed population of people with acute and chronic wounds. The quality of the evidence
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varied between different comparisons and outcomes. We mainly downgraded the quality of evidence for risk of bias, imprecision and,
in a few cases, inconsistency.
There is high quality evidence (2 trials, n=992) that honey dressings heal partial thickness burns more quickly than conventional
dressings (WMD -4.68 days, 95%CI -5.09 to -4.28) but it is unclear if there is a difference in rates of adverse events (very low quality
evidence) or infection (low quality evidence).
There is very low quality evidence (4 trials, n=332) that burns treated with honey heal more quickly than those treated with silver
sulfadiazine (SSD) (WMD -5.12 days, 95%CI -9.51 to -0.73) and high quality evidence from 6 trials (n=462) that there is no difference
in overall risk of healing within 6 weeks for honey compared with SSD (RR 1.00, 95% CI 0.98 to 1.02) but a reduction in the overall
risk of adverse events with honey relative to SSD. There is low quality evidence (1 trial, n=50) that early excision and grafting heals
partial and full thickness burns more quickly than honey followed by grafting as necessary (WMD 13.6 days, 95%CI 9.82 to 17.38).
There is low quality evidence (2 trials, different comparators, n=140) that honey heals a mixed population of acute and chronic wounds
more quickly than SSD or sugar dressings.
Honey healed infected post-operative wounds more quickly than antiseptic washes followed by gauze and was associated with fewer
adverse events (1 trial, n=50, moderate quality evidence, RR of healing 1.69, 95%CI 1.10 to 2.61); healed pressure ulcers more quickly
than saline soaks (1 trial, n= 40, very low quality evidence, RR 1.41, 95%CI 1.05 to 1.90), and healed Fournier’s gangrene more quickly
than Eusol soaks (1 trial, n=30, very low quality evidence, WMD -8.00 days, 95%CI -6.08 to -9.92 days).
The effects of honey relative to comparators are unclear for: venous leg ulcers (2 trials, n= 476, low quality evidence); minor acute
wounds (3 trials, n=213, very low quality evidence); diabetic foot ulcers (2 trials, n=93, low quality evidence); Leishmaniasis (1 trial,
n=100, low quality evidence); mixed chronic wounds (2 trials, n=150, low quality evidence).
Authors’ conclusions
It is difficult to draw overall conclusions regarding the effects of honey as a topical treatment for wounds due to the heterogeneous nature
of the patient populations and comparators studied and the mostly low quality of the evidence. The quality of the evidence was mainly
downgraded for risk of bias and imprecision. Honey appears to heal partial thickness burns more quickly than conventional treatment
(which included polyurethane film, paraffin gauze, soframycin-impregnated gauze, sterile linen and leaving the burns exposed) and
infected post-operative wounds more quickly than antiseptics and gauze. Beyond these comparisons any evidence for differences in the
effects of honey and comparators is of low or very low quality and does not form a robust basis for decision making.
P L A I N L A N G U A G E S U M M A R Y
Honey as a topical treatment for acute and chronic wounds
We reviewed the evidence about the effects of applying honey on the healing of any kind of wound. We found 26 studies involving
3011 people with many different kinds of wounds. Honey was compared with many different treatments in the included studies.
The differences in wound types and comparators make it impossible to draw overall conclusions about the effects of honey on wound
healing. The evidence for most comparisons is low or very low quality. This was largely because we thought that problems with the
design of some of the studies made their results unreliable and for many outcomes there was only a small amount of information
available. In some cases the results of the studies varied considerably.
There is high quality evidence that honey heals partial thickness burns around 4 to 5 days more quickly than conventional dressings.
There is moderate quality evidence that honey is more effective than antiseptic followed by gauze for healing wounds infected after
surgical operations.
It is not clear if honey is better or worse than other treatments for burns, mixed acute and chronic wounds, pressure ulcers, Fournier’s
gangrene, venous leg ulcers, minor acute wounds, diabetic foot ulcers and Leishmaniasis as most of the evidence that exists is of low or
very low quality.
This evidence is current up to October 2014.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Honey compared with conventional dressings for minor acute wounds
Patient or population: patients with Minor acute wounds
Settings: Any
Intervention: Honey
Comparison: Conventional dressings
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Conventional dressings Honey
Complete healing (time
to healing)(days)
The mean complete heal-
ing (time to healing) in the
intervention groups was
2.26 higher
(3.09 lower to 7.61
higher)
213
(3 studies)
⊕©©©
very low1,2,3
Adverse events Study population RR 1.19
(0.69 to 2.05)
82
(1 study)
⊕©©©
very low1,2,4
357 per 1000 425 per 1000
(246 to 732)
Infection Study population RR 0.91
(0.13 to 6.37)
151
(3 studies)
⊕©©©
very low1,2,5
14 per 1000 13 per 1000
(2 to 88)
Costs
Average dressing cost per
patient
The mean cost of dressing materials per patient was
0.49 ZAR in the honey
group and 12.06 ZAR in the control (hydrogel) group
82
(1 study)
⊕©©©
very low7,8,9
Quality of Life6 Not reported N/A N/A N/A3
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*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Downgraded due to risk of bias (one level): High risk of attrition bias in all three included studies
2 Downgraded due to inconsistency (one level): the patient populations and comparator interventions differed between the studies
3 Downgraded due to imprecision (two levels): The plausible range of effects extends from a three day reduction in healing time with
honey up to a more than seven day extension in healing time
4 Downgraded due to imprecision (two levels): The 95% confidence interval ranges from 0.69 and 2.05
5 Downgraded due to imprecision (two levels): The relative risk of infection for honey-treated wounds compared with conventional
dressings lies somewhere between 0.13 and 6.37
6 None of the studies reported quality of life
7 ITT analysis not done; cost data from withdrawn patients not included
8 Only report cost of dressing material not other related costs e.g., nursing care, other treatments
9 Only one small study reported costs: honey a non-proprietary product in this study
4
H
o
n
e
y
a
s
a
to
p
ic
a
l
tre
a
tm
e
n
t
fo
r
w
o
u
n
d
s
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
5
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
B A C K G R O U N D
Description of the condition
Acute and chronic wounds are terms in regular use in clinical
practice, yet definition of these terms has received little attention.
Lazarus 1994 suggested acute wounds proceed through to healing
“in an orderly and timely reparative process”. Orderliness refers to
the healing sequence of inflammation, angiogenesis, matrix depo-
sition, wound contraction, epithelialisation, and scar remodelling.
Timeliness is subjective, but refers to a healing time that could
be reasonably expected. A chronic wound is, therefore, a wound
where the orderly biological progression to healing has been dis-
rupted and healing is delayed.
Description of the intervention
Honey is a viscous, supersaturated sugar solutionderived fromnec-
tar gathered and modified by the honeybee, Apis mellifera. Honey
contains approximately 30% glucose, 40% fructose, 5% sucrose,
and 20% water, as well as many other substances, such as amino
acids, vitamins, minerals and enzymes (Sato 2000). Honey has
beenused inwound care since ancient times and is frequentlymen-
tioned in early pharmacopeia, althoughmore usually as an ingredi-
ent or carrier vehicle rather than a specific treatment. Dioscorides
(40-80 CE) oftenmentioned honey as a vehicle for carrying thera-
peutic agents in demateriamedicis (Riddle 1985), andHippocrates
(460-377 BCE), who is often cited as advocating honey for wound
care, simply listed it as one of many ingredients in a multitude
of unguents (Adams 1939). Probably the first deliberate advo-
cacy of honey as a wound treatment was by the anonymous au-
thor of the Edwin Smith papyrus, an Egyptian surgical text writ-
ten between 2600-2200 BCE (Breasted 1930). A dressing made
from honey and plant material was also recommended for treat-
ing burns in the London Medical Papyrus written around 1325
BCE (Trevisanato 2006). Other early medical customs, including
Ayurvedic (Johnson 1992), Chinese (Fu 2001) and Roman tradi-
tions (Hajar 2002), also used honey in wound care.
How the intervention might work
Between 1996 and 2006 there was a surge in interest about honey
as a wound treatment, with 40 case reports or series in 875 patients
published (Jull 2008). Recent research has tended to concentrate
on the antibacterial activity of the many different types of honey,
rather than its effect on wound healing (Molan 1999). Manuka
honey, a monofloral honey derived from the Leptospermum tree
in New Zealand and Australia, has been of particular interest, as
it has antibacterial activity independent of the effect of honey’s
peroxide activity and osmolarity (Molan 2001). The substance (or
substances) responsible for this non-peroxide activity has not been
definitively identified, but has been termed Unique Manuka Fac-
tor (UMF). Manuka honey with a UMF rating has an antibacte-
rial activity equivalent to a similar percentage of phenolic acid in
solution. Recent research suggests methylglyoxal is the substance
responsible for the non-peroxide activity (Mavric 2008).
There is evidence from different animal models that honey may
accelerate healing (Bergman 1983; Oryan 1998; Postmes 1997).
Fifteen of the 16 controlled trials in five different animal models
(mice, rat, rabbit, pig, and buffalo calf ) found that honey-treated
incisional and excisional wounds, and standard burns, healed faster
than control wounds (Jull 2008). In addition, a systematic review
of honey as a wound dressing found seven randomised trials in
humans, six in burns patients and one in infected post-operative
wounds (Moore 2001). Although the poor quality of the trial
reports prevented any recommendations, the findings did suggest
an effect in favour of honey.
Honey may exert multiple microscopic actions on wounds. It ap-
pears to drawfluid from the underlying circulation, providingboth
a moist environment and topical nutrition that may enhance tis-
sue growth (Molan 1999). Histologically, honey appears to stim-
ulate tissue growth in animal and human controlled trials, with
earlier tissue repair noted (Bergman 1983; Subrahmanyam 1998),
fewer inflammatory changes (Oryan 1998; Postmes 1997), and
improved epithelialisation (Oryan 1998).Macroscopically, reports
have also noted the debriding action of honey (Blomfield 1973;
Efem 1988; Ndayisaba 1993; Subrahmanyam 1991).
Why it is important to do this review
Honey dressings are widely available and promoted as effective
wound treatments. A systematic review of the evidence is therefore
warranted as a basis for clinical and policy decision making. This
version comprises a substantive update.
O B J E C T I V E S
To assess the effects of honey compared with alternative wound
dressings and topical treatments on the healing of acute (e.g. burns,
lacerations) and/or chronic (e.g. venous ulcers) wounds.
The publication of the first version of this review (Jull 2008a) was
preceded by a published protocol (Jull 2004).
M E T H O D S
Criteria for considering studies for this review
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Types of studies
Randomised controlled trials (RCTs) and quasi-randomised con-
trolled trials were included. Quasi-randomised controlled trials are
trials which use a quasi-random allocation strategy, such as alter-
nate days, date of birth, or hospital number.
Types of participants
Trials involving participants of any age with an acute or chronic
wound were included. For the purposes of this review an acute
wound was considered to be any of the following: burns, lacera-
tions or other skin injuries resulting from minor trauma, and mi-
nor surgical wounds healing by primary or secondary intention.
Chronic wounds were considered to be: skin ulcers of any type,
pressure ulcers and infected wounds healing by secondary inten-
tion.
Types of interventions
The primary intervention was any formulation of honey topically
applied by any means, alone or in combination with other dress-
ings or components, to an acute or chronic wound. Eligible com-
parison interventions were dressings or other topical agents ap-
plied to the wound.
Types of outcome measures
Trials had to provide data on one of the primary outcomes listed
below, and the unit of analysis had to be by participant (See “Dif-
ferences between protocol and review” for further information
about unit of analysis issues).
Primary outcomes
• Time to complete wound healing;
• proportion of participants with completely healed wounds.
Secondary outcomes
• Incidence of adverse events;
• length of hospital stay;
• change in wound size:
• incidence of infection;
• cost;
• quality of life.
Search methods for identification of studies
Electronic searches
For the search methods used in the original version of this review
see Appendix 1.
For this second update we searched the following databases for
reports of eligible randomised controlled trials:
• The Cochrane Wounds Group Specialised Register
(searched 15 October 2014);
• The Cochrane Central Register of Controlled Trials
(CENTRAL) (The Cochrane Library 2014, Issue 9);
• Ovid MEDLINE (1946 to October Week 1 2014);
• Ovid MEDLINE (In-Process & Other Non-Indexed
Citations 13 October, 2014);
• Ovid EMBASE (1974 to 13 October, 2014);
• EBSCO CINAHL (1982 to 15 October, 2014).
The following search strategy was used in CENTRAL and adapted
appropriately for other databases:
#1 MeSH descriptor Skin Ulcer explode all trees
#2 MeSH descriptor Pilonidal Sinus explode all trees
#3 MeSH descriptor Wounds, Penetrating explode all trees
#4 MeSH descriptor Lacerations explode all trees
#5 MeSH descriptor Burns explode all trees
#6 MeSH descriptor Wound Infection explode all trees
#7 MeSH descriptor Surgical Wound Dehiscence explode all trees
#8 MeSH descriptor Bites and Stings explode all trees
#9 MeSH descriptor Cicatrix explode all trees
#10 ((plantar or diabetic or heel* or foot or feet or ischaemic or
ischemic or venous or varicose or stasis or arterial or decubitus or
pressure or skin or leg or mixed or tropical or rheumatoid or sickle
cell) NEAR/5 (wound* or ulcer*)):ti,ab,kw
#11 (bedsore* or (bed NEXT sore*)):ti,ab,kw
#12 (pilonidal sinus* or pilonidal cyst*):ti,ab,kw
#13 (cavity wound* or sinus wound*):ti,ab,kw
#14 (laceration* or gunshot stab or stabbing or stabbed or bite*):
ti,ab,kw
#15 (“burn” or “burns” or “burned” or scald*):ti,ab,kw
#16 (surg* NEAR/5 infection*):ti,ab,kw
#17 (surg* NEAR/5 wound*):ti,ab,kw
#18 (wound* NEAR/5 infection*):ti,ab,kw
#19 (malignant wound* or experimental wound* or traumatic
wound*):ti,ab,kw
#20 (infusion site* or donor site* or wound site* or surgical site*):
ti,ab,kw
#21 (skin abscess* or skin abcess*):ti,ab,kw
#22 (hypertrophic scar* or keloid*):ti,ab,kw
#23 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR
#9 OR #10 OR #11 OR
#12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #
19 OR #20 OR #21 OR #22)
#24 MeSH descriptor Honey explode all trees
#25 honey:ti,ab,kw
#26 (#24 OR #25)
#27 (#23 AND #26)
The search strategies for Ovid MEDLINE, Ovid EMBASE and
EBSCO CINAHL can be found in Appendix 2. We combined
the Ovid MEDLINE search with the Cochrane Highly Sensi-
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tive Search Strategy for identifying randomized trials in MED-
LINE: sensitivity- and precision-maximizing version (2008 revi-
sion) (Lefebvre 2011). TheOvidEMBASE andEBSCOCINAHL
searches were combinedwith the trial filters developed by the Scot-
tish Intercollegiate Guidelines Network (SIGN) (SIGN 2008).
There were no restrictions with respect to language, date of pub-
lication (taking into account searches from the original review) or
study setting.
Searching other resources
For the initial review we contacted experts in the field, authors of
the included trials andmanufacturers of honey products forwound
care (Comvita NZ Ltd and MediHoney Australia Pty Ltd), but
did not repeat this for updates. The bibliographies of all obtained
studies and review articles were searched for potentially eligible
trials for both the initial review and the first update. No language
or date restrictions were applied to the trials and both published
and unpublished trials were sought.
Data collection and analysis
Selection of studies
Two authors (either AJ and NW, or for this update JD and NC)
independently examined titles and abstracts of potentially relevant
trials. Full text copies of all relevant trials, or trials that might be
relevant to the review were obtained. The two review authors in-
dependently selected the trials using the inclusion criteria. Dis-
agreements were resolved by discussion.
Data extraction and management
Data were extracted from included trials by one review author and
recorded on a standardised form. The extracted data were inde-
pendently reviewed for accuracy by a second review author and
disagreements resolved by discussion. All data have subsequently
been verified by a third (MW) and fourth author (NC). If the data
from the trial report were inadequate, or ambiguous, additional
information was sought from the trial authors. We collected data
on the topics listed below:
1. Author; title; source of reference.
2. Study setting.
3. Study design.
4. A priori sample size calculation; sample size.
5. Inclusion/exclusion criteria.
6. Age of participants; sex of participants.
7. Wound type.
8. Intervention and comparison.
9. Outcomes.
10. Withdrawals and reason for withdrawal.
11. Funding source.
12. Co-interventions
Assessment of risk of bias in included studies
For the first update, one review author (SD) assessed each included
study using the Cochrane Collaboration tool for assessing risk of
bias (Higgins 2011), and this assessment was checked by a second
(AJ) review author. For this second update two more pairs of re-
view authors/editors checked risk of bias (either MW and JD or
JD and NC) and reviewed by the lead review author (AJ). This
tool addresses six specific domains, namely sequence generation,
allocation concealment, blinding, incomplete outcome data, se-
lective outcome reporting and other issues, such as extreme base-
line imbalance (see Appendix 3 for details of criteria on which
the judgement was based). Blinding and completeness of outcome
data were assessed for each outcome separately. We completed a
risk of bias table for each eligible study and discussed any disagree-
ment amongst all review authors to achieve a consensus.
We present an assessment of risk of bias using a ’risk of bias sum-
mary figure’, which presents all of the judgements in a cross-tabu-
lation of study by entry. This display of internal validity indicates
the weight the reader may give the results of each study.
Data synthesis
Where trials were sufficiently alike in terms of population and
comparison interventions, their results were combined. Mean dif-
ferences (MD) and 95% confidence intervals (95% CI) were re-
ported for continuous outcomes, and risk ratio (RR) and 95%con-
fidence intervals (95% CI) were reported for dichotomous vari-
ables. Statistical heterogeneity was tested by comparing Cochran’s
Q statistic and the chi-squared distribution. Heterogeneity was as-
sumed with P values of less than 0.1 (Higgins 2011). In addition,
the I2 statistic was used to determine the percentage of variation
due to heterogeneity rather than chance (Higgins 2003), and any
sources of heterogeneity were explored. Where significant statis-
tical heterogeneity was present, a random-effects model was used
when combining trials (Ioannidis 2008).
Summary of findings
The evidence was summarised in summary of findings tables us-
ing the approach of the Grades of Recommendation, Assessment,
Development and EvaluationWorking Group (GRADEWorking
Group) (Langendam 2013). This approach assesses the quality of
the body of evidence per comparison and outcome, taking into
account five factors: risk of bias across all studies reporting that
outcome; indirectness of population, interventions and outcomes,
across all studies reporting the outcome; inconsistency amongst
studies; imprecision (taking into account the optimum informa-
tion size and the confidence intervals) and publication bias. The
results are reported below according to condition, comparison
and outcome and then the different outcomes are brought to-
gether in summary of findings tables (Summary of findings for the
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main comparison; Summary of findings 2; Summary of findings
3; Summary of findings 4), which are discussed in the final section
(Discussion).
R E S U L T S
Description of studies
Included studies
Twenty six trials met the inclusion criteria (please see the
Characteristics of included studies) and were available for analy-
sis; eight trials were added in updates (Baghel 2009; Gulati 2014;
Kamaratos 2014;Mashood 2006;Memon 2005; Nilforoushzadeh
2007; Robson 2009; Shukrimi 2008), including one trial that
was mistakenly excluded in the previous review, but was found
in the first update to meet the inclusion criteria on re-screening
(Mashood 2006). Another trial was previously wrongly included
andhas nowbeen excluded in this update (Subrahmanyam 1996c).
Three trials are awaiting assessment while attempts are made to
contact the authors to request further data (Askarpour 2009; Jan
2012; Maghsoudi 2011).
Ten separate trials were conducted by the same investigator
(Subrahmanyam 1991; Subrahmanyam 1993a; Subrahmanyam
1993b; Subrahmanyam 1994; Subrahmanyam 1996a;
Subrahmanyam 1996b; Subrahmanyam 1998; Subrahmanyam
1999; Subrahmanyam 2001a; Subrahmanyam 2004) based in In-
dia. Important information was missing from the published re-
ports of these studies however some was provided on request.
Fourteen trials recruited participants with acute wounds: 11
with burns (Baghel 2009; Mashood 2006; Memon 2005;
Subrahmanyam 1991; Subrahmanyam 1993b; Subrahmanyam
1994;
Subrahmanyam 1996a; Subrahmanyam 1996b; Subrahmanyam
1998; Subrahmanyam 1999; Subrahmanyam 2001a), two with
minor surgical excisions (Marshall 2005; McIntosh 2006), and
one with minor trauma (Ingle 2006). Ten trials recruited partici-
pants with chronic wounds including venous leg ulcers (Jull 2008;
Gethin 2007), infected surgical wounds (Al Waili 1999), pressure
injuries (Weheida 1991), Fournier’s gangrene (Subrahmanyam
2004), cutaneous Leishmaniasis (ulcers caused by protozoans in-
jected by sandfly bite) (Nilforoushzadeh 2007), diabetic foot ul-
cers (Kamaratos 2014; Shukrimi 2008), and a variety of chronic
wounds healing by secondary intention though mainly venous
leg ulcers (Gulati 2014; Robson 2009). Two trials recruited par-
ticipants with either chronic or acute wounds (Mphande 2007;
Subrahmanyam 1993a).
Eight trials were conducted in community settings or outpa-
tient clinics (Gulati 2014; Kamaratos 2014; Gethin 2007; Ingle
2006; Jull 2008;Marshall 2005;McIntosh 2006;Nilforoushzadeh
2007). The remaining trials were conducted in hospital settings,
or a mixed inpatient and outpatient setting (Robson 2009). Eight
trials reported recruiting only adults (Al Waili 1999; Gulati 2014;
Gethin 2007; Ingle 2006; Jull 2008; Kamaratos 2014; Shukrimi
2008; Subrahmanyam 2004). The remaining trials did not specify
an age range (Marshall 2005; McIntosh 2006; Robson 2009), or
recruited both children and adults.
Monofloral honey (aloe, jarrah, jamun, jambhul or manuka) was
used in ten trials (Gethin 2007;Gulati 2014; Ingle 2006; Jull 2008;
Kamaratos 2014; Marshall 2005; McIntosh 2006; Robson 2009;
Subrahmanyam 2001a; Subrahmanyam 2004); the type of honey
used was not specified in the remaining trials. Honey was delivered
as a honey impregnated gauze dressing in six trials (Kamaratos
2014; Mphande 2007; Nilforoushzadeh 2007; Subrahmanyam
1993a; Subrahmanyam 1994; Subrahmanyam 2004); as a honey
impregnated alginate dressing in two (Jull 2008;McIntosh 2006);
as honey spread between gauze in one trial (Memon 2005) and
as topical honey covered with either a film dressing (Ingle 2006;
Gulati 2014) or with gauze in the remaining trials. Six trials inves-
tigated honey as an adjunct treatment: four included people with
venous leg ulcers, and, for these, honey was used as an adjunct
to compression (Gethin 2007; Gulati 2014; Jull 2008; Robson
2009). One trial in people with Leishmaniasis gave honey along-
side an injection of glucantamine (Nilforoushzadeh 2007). In a
further trial, 50% patients receiving honey also received delayed
autologous skin grafting, as necessary (Subrahmanyam 1999).
There was a range of comparison treatments in this review,
which have been grouped under the broad categories of conven-
tional dressings, silver sulfadiazine (SSD), antiseptics, early ex-
cision and atypical dressings. Seven trials compared honey with
SSD, and of these, the comparator was a SSD impregnated dress-
ing in four trials (Subrahmanyam 1991; Subrahmanyam 1993b;
Subrahmanyam 1998; Subrahmanyam 2001a) and SSD cream in
three (Baghel 2009; Mashood 2006; Memon 2005). Two stud-
ies compared honey with hydrogel (Gethin 2007; Ingle 2006).
In the adjunct trials, the comparators were either other dressings
plus compression (Gethin 2007; Gulati 2014; Jull 2008; Robson
2009) or glucantamine injection alone (Nilforoushzadeh 2007).
The comparator for the trial giving honey plus delayed skin graft-
ingwas early tangential excision and skin grafting (Subrahmanyam
1999).
In view of the clinical diversity of the evidence, this review is
organised by wound type, and then by comparison type.
There was a great deal of variation in the outcomes reported by the
included studies which makes the drawing of overall conclusions
very difficult. Many of the included studies report “mean time to
healing” but it was frequently not clear whether every participant’s
wound had healed during follow up (in which case the mean time
with associated SD or 95% confidence interval would be accept-
able). However if all wounds in a study do not heal during the
period of observation, simple calculation of the mean (or median)
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time to healing without accounting for censoring is inappropriate
since, by definition, this approach excludes people who did not
heal during follow up (as they cannot contribute to the numer-
ator). Importantly excluding people who failed to heal from the
data excludes treatment failures and will over-estimate treatment
success. Time to healing is a type of “time to event” outcome and
should be analysed as such using a survival approach which allows
people who did not heal to contribute data to the analysis for the
period for which theywere observed.Only three studies (Jull2008;
Nilforoushzadeh 2007; Robson 2009) analysed time to healing as
time to event data. One study (Shukrimi 2008) reported time to
readiness for wound closure surgery.
The multiplicity of time points at which healing was reported was
a further problem which had not been anticipated in the protocol.
We opted to analyse the outcomes for the longest point of follow
up shared by several trials of the same comparison (since to extract
and analyse all time points risks a Type I error).
Excluded studies
For details on the excluded studies please see Characteristics of
excluded studies table. Of the 57 excluded studies, 24 were not
RCTs or quasi-RCTs (Abdelatif 2008; Ahmed 2003; Al Waili
2004c; Al Waili 2005; Bose 1982; Dunford 2004; Freeman
2010; Gethin 2005; Lusby 2002; Marshall 2002; Mayer 2014;
Misirligou 2003; Moghazy 2010; Molan 2002; Molan 2006;
Mwipatayi 2004; Nagane 2004; Robson 2002; Schumacher 2004;
Subrahmanyam 1993; Thurnheer 1983; Tostes 1994; Vijaya
2012; Visscher 1996). Seven of the excluded studies were not
in wounds (Al Waili 2003; Albietz 2006; Biswal 2003; Johnson
2005; Quadri 1998; Quadri 1999; Somaratne 2012). Three were
studies in animal models (Al Waili 2004a; Al Waili 2004b;
Subrahmanyam 2001b). Thirteen studies did not report suffi-
cient information on healing (Bangroo 2005; Chokotho 2005;
Gad 1988; Heidari 2013; Jeffery 2008; Lund-Nielsen 2011; Mat
Lazim 2013; Robson 2012; Rogers 2010; Rucigaj 2006; Saha
2012; Subrahmanyam2003;Ur-Rehman2013). Three studies did
not evaluate honey (Berchtold 1992; Muller 1985), one evaluated
the effect of adding vitamins and polyethylene glycol to honey
(Subrahmanyam 1996c) and a further two could not be obtained
for assessment (CalderonEspina 1989; RiveroVarona 1999). Four
studies had unit of analysis issues, they had randomised, or re-
ported, by wound rather than by the participant. Such unit of
randomisation or analysis issues were not considered in the proto-
col for the review, but we considered that such studies could not
contribute usefully to this review. For further discussion on the
rationale for this decision see “Differences between protocol and
review” (Malik 2010; Okeniyi 2005; Oluwatosin 2000; Yapucu
Gunes 2007).
Risk of bias in included studies
Risk of bias is summarised in the figures (Figure 1; Figure 2) with
judgements explained in the Characteristics of included studies.
Risk of bias was a key consideration in assessing the quality of
the evidence and used (and justified) in the Summary of Findings
Tables to downgrade the evidence where appropriate. Overall the
quality of reporting was poor and it was frequently not possible
to determine whether allocation was fully concealed. Two studies
(Mphande 2007; Kamaratos 2014) used quasi-random methods
of allocation and these are at high risk of selection bias as a conse-
quence. Most of the included studies were at risk of performance
bias as neither participants nor health care providers were blinded
to treatment allocation. The main outcomes of complete healing,
adverse events and infection have, to varying extents, an element
of subjectivity inherent in them and 14 out of 26 included studies
reported having used blinded outcome assessment.
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Figure 1. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
Effects of interventions
See: Summary of findings for the main comparison Honey
compared with conventional dressings for minor acute wounds;
Summary of findings 2 Honey compared with conventional
dressings for burns; Summary of findings 3 Honey compared
with silver sulfadiazine for burns; Summary of findings 4Honey
for venous leg ulcers
The 26 trials included 3011 participants. The trials were gener-
ally small (median sample size 83.5, range 30 to 900), and there
was very obvious clinical and methodological heterogeneity. It
was not appropriate, therefore, to combine the trials in a single
meta-analysis to produce a summary statistic for honey overall,
or even subgroup summary statistics for acute, chronic, or mixed
wounds. Within the subgroups (acute, mixed acute and chronic,
and chronic wounds) trials have been combined in meta-analy-
sis where appropriate. Otherwise the trials have been summarised
narratively.
In common with wounds research in general, adverse event re-
porting was variable in nature and often poor in quality. Five tri-
als did not report adverse events (Baghel 2009; Kamaratos 2014;
Subrahmanyam 1996a; Subrahmanyam 1998; Weheida 1991),
and five trials stated that there were no adverse events or no adverse
events related to treatment (Gethin 2007; Gulati 2014; Marshall
2005;McIntosh 2006; Subrahmanyam 1996b).One trial reported
the number of people with any adverse event (Jull 2008), as well as
itemising specific types of events. The remaining trials appear to
have limited reporting of events to specific types of events, rather
than encouraging reports of any event. Adverse events are pre-
sented by wound type, and the comparators indicated in footnotes
and any meta-analysis uses a random-effects model due to the het-
erogeneity. Although only one trial explicitly reported frequency
of events by participant (Jull 2008), it is assumed one event equals
one participant in all other trials (this may be an erroneous as-
sumption).
The “infection” data in these studies are not well reported and im-
possible to analyse in a robust manner and interpret reliably across
all wound types. One of the main problems is the lack of a defi-
nition of infection within most trial reports and an inconsistency
between trials. Most of the burns trials reported “positive” swab
cultures at baseline and then the proportion rendered “sterile” at
subsequent time points (usually 7 days). However a positive swab
culture is NOT the same as a clinical infection (the diagnosis of the
latter being dependent on signs and symptoms as well as culture).
Consequently we cannot draw conclusions about the treatment
effects of honey dressings and comparators from these data. We
have confined our analysis of the burns studies to the outcome
of “proportion of burns with negative swabs at 7 days” however
this is a less clinically relevant outcome than healing, or clinical
infection.
1. Acute wounds
1.1 Minor acute wounds
1.1.1 Honey compared with conventional dressings
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Three trials (213 participants) recruited participants with minor
acute wounds (Ingle 2006; Marshall 2005; McIntosh 2006). In
two trials, the wounds were surgical wounds created after partial
or total toenail avulsions (Marshall 2005; McIntosh 2006), with
the control group treated with paraffin gauze in one trial and an
iodophor dressing in the other. The remaining trial recruited mine
workers with lacerations or shallow abrasions and treated control
participants with a hydrogel (Ingle 2006).
Outcome: healing
We combined the results of the three trials using a random effects
model. It is unclear whether there is a difference in time to healing
between honey and control (difference inmean days to healingwas
2.26 days longer with honey, 95% CI -3.09 to 7.61 days (Analysis
1.1). Moderate heterogeneity (I² = 47%). Very low quality evidence
(downgraded for risk of bias, inconsistency and imprecision) (
Summary of findings for the main comparison).
Outcome: adverse events
Ingle and colleagues reported the frequency of itching, burning
and pain (Ingle 2006). There was no significant difference in the
rates of these events between honey and hydrogel RR 1.19, 95%
CI 0.69 to 2.05) (Analysis 1.2). No patient stopped treatment
due to these sensations. It remains unclear as to whether there are
more or fewer adverse events with honey dressings compared with
non-honey dressings in people with minor acute wounds. Very low
quality evidence (downgraded for risk of bias, serious inconsistency
and imprecision) (Summary of findings for themain comparison).
Outcome: infection
Infection was not reported by Ingle 2006. There was only one
instance of infection reported in each of the other two trials (
Marshall 2005;McIntosh 2006): in 1/27 participants in the honey
group compared with 0/24 in the iodine group of Marshall 2005,
and in 1/48 participants of the iodine group compared with 0/
52 in the honey group of McIntosh 2006 (pooled RR of infection
0.91, 95%CI0.13 to 6.37, fixed effect, Analysis 1.3). It is therefore
unclear if honey affects rates of wound infection in minor acute
wounds. Very low quality evidence (downgraded for the reasons
outlined above) (Summary of findings for the main comparison).
Outcome: costs
Only Ingle 2006 reported on costs, and then only in terms of
average costs of dressing materials per patient in each group. These
were lower in the honey group (average cost per patient 0.49Rand)
than the hydrogel group (average cost per patient 12.06 Rand)
however this does not appear to have been a commercial honey
preparation (hence low cost).
Outcome: quality of life
Not reported.
1.2 Burns
There were six comparison treatments, which have been grouped
under the four broad categories of conventional dressings, early
excision, silver sulfadiazine (SSD) and atypical dressings for this
review.
1.2.1 Honey compared with conventional dressings
Two trials (992 participants) compared honey with conven-
tional dressings for the treatment of partial-thickness burns
(Subrahmanyam 1993a; Subrahmanyam 1996a). In one trial
(Subrahmanyam 1993a) the comparison was a polyurethane film
dressing and in the other trial (Subrahmanyam 1996a) the con-
trol participants were treated with a range of interventions:
polyurethane film (OpSite, n = 90), paraffin gauze (n = 90),
sterile linen dressings (n = 90), antimicrobial impregnated gauze
(Soframycin, n = 90) or left exposed (n = 90).
Outcome: healing
Mean days to healing were reported but not the standard de-
viations, though this information was later provided by the au-
thor (personal communication: M Subrahmanyam). The two tri-
als were pooled using a fixed effect model (I2 = 0%). Burns treated
with honey healed more quickly (WMD -4.68 days, 95% CI -
5.09 to -4.28 days, Analysis 2.1).High quality evidence (Summary
of findings 2).
Outcome: adverse events
In Subrahmanyam 1993a there were two cases of over-granulation
and two of contracture in the honey group compared with two
of over-granulation and one of contracture in the control group.
In Subrahmanyam 1996a there were five cases of hypergranula-
tion and 28 of scarring with honey and 12 of hypergranulation
and 87 of scarring with conventional dressings. These data were
pooled (random effects). Overall there was no clear difference in
risk of adverse events (RR 0.56, 95% CI 0.15 to 2.06) (Analysis
2.2).Very low quality evidence (downgraded for inconsistency i.e.,
high heterogeneity, and imprecision) (Summary of findings 2).
Outcome: infection
Subrahmanyam 1996a did not report infection rates.
Subrahmanyam 1993a reported a greater proportion of honey par-
ticipants having a negative swab at Day 8 (38/46 participants in
the honey group cf. 29/46 in the polyurethane film group), (RR
of a negative swab 1.31, 95%CI 1.01 to 1.70), Analysis 2.3. Low
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quality evidence (downgraded for imprecision and indirectness, in
that a negative swab on a particular day is not a measure of infec-
tion per se)(Summary of findings 2).
Outcomes: costs and quality of life
Not reported.
1.2.2 Honey plus delayed grafting compared with early
excision and grafting (no honey)
One trial (50 participants) compared early tangential excision and
skin grafting with honey dressings plus delayed skin grafting where
needed, for the treatment of mixed partial- and full-thickness
burns (Subrahmanyam 1999).
Outcome: healing
Mean time to healing was not published, but was later provided by
the author (personal communication: M Subrahmanyam). Burns
healed more slowly when treated with honey (followed by delayed
grafting where needed) than with early excision and grafting (no
honey) (WMD 13.6 days, 95% CI 9.82 to 17.38 days, Analysis
3.1). The quality of this evidence was downgraded for imprecision
on the basis that there is only one trial with a total of 50 partici-
pants and whilst the difference in time to healing was statistically
significant and clinically important, this is a small single study.We
also downgraded the quality of the evidence for indirectness, since
honey is not the only systematic difference in the treatments for
this comparison as the burn excision and grafting interventions
were also different (therefore the trial does not directly address the
question of whether honey dressings are effective for burns). Low
quality evidence.
Outcome: adverse events
In Subrahmanyam 1999 there was a total of 6 adverse events in
the honey group (3 deaths, 3 contractures), compared with one
death in the early excision group. Low quality evidence (see above).
Outcome: infection
Infection rates per se were not reported for Subrahmanyam 1999
however days of antibiotic therapy (which is a proxy for infection),
were. Participants in the honey group received a mean of 32 (SD
18) days of antibiotics compared with 16 (SD 3) in the early
excision and graft group (difference in mean days of antibiotic
therapy 16.00, 95% CI 8.85 to 23.15) (Analysis 3.2). Low quality
evidence (downgraded two levels for indirectness since honey is
not the only systematic difference between treatments and the
outcome “days of antibiotic therapy” is only a proxy for infection).
Outcomes: costs
Not reported.
Outcomes: quality of life
Not reported.
1.2.3 Honey compared with silver sulfadiazine
Six trials (462 participants) compared honey with SSD (Baghel
2009; Mashood 2006; Memon 2005; Subrahmanyam 1991;
Subrahmanyam1998; Subrahmanyam 2001a). The trials used dif-
ferent burn grading systems to report the depth of burns, which
reflected the age of the trials and the lack of a clinical consensus
on reporting burn depth. The burns, however, did tend towards
the less severe end of the spectrum, although early staging sys-
tems (e.g. first-, second- and third-degree burns, or superficial,
partial-thickness and full-thickness) do not have the sensitivity of
more recent systems (i.e. epidermal, superficial dermal, mid-der-
mal, deep dermal and full-thickness), and participants with deep
partial-thickness and deep dermal burns are likely to require skin
grafting (NZGG 2007).
Trials recruited participants with superficial and partial-thickness
burns (Baghel 2009), superficial burns (Subrahmanyam 1991;
Subrahmanyam 1998), superficial, partial- and deep partial-thick-
ness burns (Mashood 2006), and one recruited participants with
superficial, dermal, mid and deep dermal burns (Memon 2005).
The remaining trial did not report their eligibility criteria but
some of the participants had full thickness burns (Subrahmanyam
2001a).
The studies used different treatment regimens. All applied honey
topically, covered with gauze. Three studies gave SSD as a topical
cream covered by gauze (Baghel 2009; Mashood 2006; Memon
2005) and the rest as SSD impregnated gauze. Two studies changed
both types of dressings daily (Mashood 2006; Subrahmanyam
1991); two changed both types of dressing on alternate days (
Memon 2005; Subrahmanyam 2001a) and the other study did
not report the frequency of dressing change (Baghel 2009). The
study by Subrahmanyam 1998 changed the SSD dressings daily
and the honey dressings on alternate days.
Outcome: healing
One trial reported mean time to healing and the risk of healing
at different times (Subrahmanyam 2001a), and five trials reported
either mean time to healing without standard deviations (Baghel
2009;Memon 2005), or risk of complete healing (Mashood 2006;
Subrahmanyam 1991; Subrahmanyam 1998), but at different
time points i.e., two, four, and six weeks (Mashood 2006), and
seven, 10, 15, 21 and 30 days (Subrahmanyam 1998).
Additional information was sought from authors and provided by
one author (personal communication:MSubrahmanyam). Baghel
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2009 reported an exact p-value for the comparison of time to heal-
ing and this was used to calculate the standard error for mean time
to healing. Thus mean time to healing was used as the outcome,
with the result that four trials out of six could be pooled for the
outcome of mean time to healing using a random effects model
(heterogeneity was extremely high, I² = 93%). In these four trials,
people whose burns were treated with honey experienced an aver-
age reduction in healing time of 5 days (WMD -5.12 days, 95%
CI -9.51 to -0.73) (Analysis 4.1). This was very low quality evi-
dence (downgraded for inconsistency and imprecision) (Summary
of findings 3).
In the trial that did not report standard deviations with mean time
to healing (Memon 2005), the honey-treated group had a mean
time to healing of 15.3 days and it was 20.0 days in the SSD group
(Memon 2005). In the remaining trial (Mashood 2006), all 25
participants in the honey-treated group were healed by four weeks,
while all patients in the SSD group were healed by six weeks.
All six trials reported the risk of complete healing at either 4 or six
weeks (or both) as well as several earlier time points. We wished
to reduce the risk of Type I errors inherent in multiple endpoint
analysis. We therefore report the pooled risk of complete healing
for all six trials at 4 to 6 weeks (Mashood 2006; Subrahmanyam
1991; Subrahmanyam1998; Subrahmanyam2001a; Baghel 2009;
Memon 2005) using a random effects model because although the
I2 was 0% these trials are clearly different in terms of frequency of
dressing changes, types of burns and duration of follow up. There
was no difference in the risk of burns healing by 4 to 6 weeks when
treated with honey compared with SSD (RR 1.00 95% CI 0.98
to 1.02). High quality evidence (Summary of findings 3).
Outcome: adverse events
Burns trials tended to report the frequencies of hypergranula-
tion, contracture, hypertrophic scarring, minor scarring, itching
and burning as adverse events however it was generally unclear if
events were reported by individual without double counting, or
(more likely) some individuals experienced more than one adverse
event. Consequently we are not confident of the accuracy of the
adverse events data. The adverse event data across the five trials
that reported them (Baghel 2009; Mashood 2006; Memon 2005;
Subrahmanyam 1991; Subrahmanyam 2001a) were pooled (ran-
dom effects); importantly Mashood 2006 stated that there was
“no difference” between groups in rates of contracture and hyper-
trophic scarring but only reported rates of itching and burning.
Overall there were significantly fewer adverse events with honey
than SSD (RR 0.29 95% CI 0.20 to 0.42) (Analysis 4.3). High
quality evidence (Summary of findings 3).
Outcome: infection
Infection related outcomes were reported in a variety of ways: most
consistently five out of six trials reported the proportion of burns
yielding negative swabs at Day 7 (Baghel 2009; Memon 2005;
Subrahmanyam 1991; Subrahmanyam 1998; Subrahmanyam
2001a). The report of Mashood 2006 merely stated the time to
sterility (with no SD or other measure of variance) in each group.
There was very high statistical heterogeneity when pooling the five
studies (I2=94%). Overall wound swabs from honey treated burns
were more likely to be negative at 7 days than were swabs from
SSD treated burns (RR 3.92 95% CI 1.32 to 11.63) (Analysis 4.4)
however this is very low quality evidence (downgraded for incon-
sistency, imprecision and indirectness) (Summary of findings 3).
Outcomes: costs
Only Mashood 2006 reported any cost data and then only as
standardised unit costs (per percentage of (total body surface area)
TBSA) of dressing treatments. They reported that the honey cost
0.75 Rupees per percentage TBSA compared with SSD which
costs 10 Rupees per percentage TBSA.
Outcomes: quality of life
Not reported.
1.2.4 Honey compared with atypical dressings
Two trials (164 participants) by the same investigator compared
honey with atypical dressings or materials (Subrahmanyam 1994;
Subrahmanyam 1996b). The first trial recruited 64 participants
with partial-thickness burns and compared honey-impregnated
gauze with treatment with amniotic membranes (Subrahmanyam
1994) and the second recruited 100 people with partial thickness
burns and compared honey with boiled potato peel dressings (
Subrahmanyam 1996b).
Outcome: healing
The mean time to healing was reported for both trials without
SDs which were subsequently supplied by the author (personal
communication: M Subrahmanyam). Burns treated with honey
healed approximately 8 days more quickly than those treated with
amnioticmembranes (WMD-8.10days, 95%CI -10.88 to -5.32).
In the second trial, burns treated with honey healed approximately
6 days more quickly than those treated with boiled potato peel
(WMD -5.80 days, 95% CI -6.68 to -4.92).
The comparator treatments for these two trials are too different
to pool them. The evidence for both these comparisons should be
downgraded for imprecision (due to the relative lack of evidence)
and therefore this constitutes moderate quality evidence.
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Outcome: adverse events
Subrahmanyam 1994 reported that 4/40 and 3/40 people in the
honey group experienced scarring/contractures and severe pain re-
spectively compared with 5/24 and 6/24 in the amniotic mem-
brane group (we cannot assume that the people experiencing pain
were separate from the people having scarring or contractures).
It was stated that there were no allergies or side effects in either
group in the other study (Subrahmanyam 1996b).
Outcome: infection
Both studies reported the outcome of a negative swab at Day 7. In
Subrahmanyam 1994, 36/40 (90%) of honey treated burns had
negative swabs at Day 7 compared with 18/24 (75%) of burns
treated with amniotic membrane. In Subrahmanyam 1996b, 36/
50 (72%) of burns treated with honey had negative swabs at Day
7 compared with 8/50 (16%) treated with potato peel.
Outcomes: costs
Not reported.
Outcomes: quality of life
Not reported.
2. Mixed acute and chronic wounds
Two trials (140 participants) each recruited participants with a
range of different acute and chronic wounds. Subrahmanyam
1993b recruited 100 participants with burns (50% of the study
population), lower limb ulcers caused by trauma, pressure, dia-
betes, and venous disease, or trophic ulcers and compared honey
with SSD. In a quasi-randomised study, Mphande 2007 recruited
40 participants with ulcers, chronic osteomyelitis, abscesses, post-
surgical or traumatic wounds; the comparison treatment was sugar
dressings.
Outcome: healing
For the Subrahmanyam 1993b study, information on overall mean
time to healing was provided by the author (personal communi-
cation: M Subrahmanyam). Wounds treated with honey healed
more quickly than those treated with SSD (difference in mean
days to healing -13.0 days, 95% CI -10.76 to -15.24) (Analysis
6.1)
In theMphande 2007 study, median time to complete healing was
31.5 days in the honey-treated group and 56.0 days in the sugar-
treated group.
Outcome: adverse events
Subrahmanyam 1993b reported hypergranulation, hypertrophic
scarring, contractures and irritation as adverse events: 2/50 (4%)
in the honey group experienced these compared with 14/50 (28%)
in the SSD group. Mphande 2007 did not refer to adverse events
generally but did report on pain in terms of being pain free during
dressing changes at 3 weeks and also pain during mobilisation
at 3 weeks. 19/22 participants (86.4%) in the honey group were
pain free during dressing changes at 3 weeks compared with 13/18
(72.2%) in the sugar dressing group. 20/22 participants (90.9%)
in the honey group and 13/18 (72.2%) in the sugar group were
pain free during mobilisation.
Outcome: infection
BothMphande 2007 andSubrahmanyam 1993b reported the out-
come of negative swabs at 7 days however these results cannot be
pooled as the comparator treatments are so different. It is unclear
whether honey is associated with more negative swabs at 7 days
than either SSD or sugar dressings due to imprecision and risk of
(performance) bias (Analysis 6.2).
Overall there is low quality evidence (downgraded for imprecision
on account of the two small studies, and indirectness on account
of the mixed patient population and difficulties of interpretation)
that, on average, honey heals a heterogeneous population of acute
and chronic wounds more quickly than SSD or sugar dressings
though the comparative rates of adverse events and infection are
unclear.
Outcomes: costs
Not reported.
Outcomes: quality of life
Not reported.
3. Chronic Wounds
Ten trials (819 participants) evaluated the effects of honey in
chronic wounds. Two trials recruited people with venous leg ulcers
(Gethin 2007; Jull 2008); one study (Robson 2009) recruited par-
ticipants with any type of wound healing by secondary intention
butmost of these were leg ulcers (70%); one study recruited people
with a range of chronic wounds though most were venous leg ul-
cers (Gulati 2014). Two studies recruited people with diabetic foot
ulcers (Kamaratos 2014; Shukrimi 2008) and one study for each
of the following: ulcers caused by Leishmaniasis (Nilforoushzadeh
2007); pressure injuries (Weheida 1991); infected post-operative
wounds (AlWaili 1999), and Fournier’s gangrene (Subrahmanyam
2004). Five of these ten studies were added at the first or second
update (Gulati 2014; Kamaratos 2014; Nilforoushzadeh 2007;
Robson 2009; Shukrimi 2008),
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Three trials reported either the mean or median time to healing
(Al Waili 1999; Jull 2008), or the mean time to surgical closure
(Shukrimi 2008); seven trials reported the proportion of partici-
pants with completely healed wounds (Gethin 2007; Gulati 2014;
Jull 2008; Kamaratos 2014; Nilforoushzadeh 2007; Robson 2009;
Weheida 1991). One trial only reported the outcome, “mean hos-
pital stay”, but data on mean time to healing were provided by the
author (Subrahmanyam 2004). Given the clinical and method-
ological heterogeneity between the trials, it was not possible to
combine the trials to produce an overall summary statistic for the
effect of honey on chronic wounds and instead we consider the
evidence by wound type below.
3.1 Infected post-operative wounds
One trial (50 participants) randomly allocated participants with
infected caesarean or hysterectomy wounds to twice daily applica-
tions of honey or antiseptic washes of 70% ethanol and povidone-
iodine, followed by gauze dressings (Al Waili 1999), in addition
to systemic antibiotics. There was very limited information on
baseline comparability and no real indication of the duration of
treatment or length of follow-up.
Outcome: healing
More people healed with honey (84.6%) than with antiseptic
washes followed by gauze dressings (50.0%); RR 1.69 (95% CI
1.10 to 2.61) (Analysis 7.1) (moderate quality evidence; down-
graded for imprecision). This equates to an increase in the absolute
risk of healing of 35% (95%CI 8.7% to 55.4%).
Outcome: adverse events
People were less likely to be recorded as having experienced adverse
events with honey: 4/26 honey treated wounds (15.3%) compared
with 12/24 (50%) of control wounds dehisced; 6/24 (25%) of
control wounds needed resuturing compared with none in the
honey group (moderate quality evidence; downgraded for impreci-
sion).
Outcome: infection
AlWaili 1999 reported themean time (days) to a negative swab as a
measure of infection; this was 6 days (SD 1.9) for honey compared
with 14.8 days (SD 4.2) for antiseptics and gauze (moderate quality
evidence, downgraded for imprecision).
Outcomes: costs
Not reported.
Outcomes: quality of life
Not reported.
3.2 Pressure injuries
One trial (40 participants) randomly allocated participants with
uninfected grade I or grade II pressure injuries greater than 2 cm
in diameter to daily applications of honey or saline-soaked gauze
dressings for 10days treatment (Weheida 1991). Therewas limited
information on baseline comparability.
Outcome: healing
More people treated with honey were healed at 10 days (100%)
than those treated with saline soaks (70%); RR 1.41 (95%CI 1.05
to 1.90) Analysis 7.1 (very low quality evidence due to imprecision
and potential selection bias as assessed by baseline imbalance).
Outcome: adverse events
Not reported.
Outcome: infection
Not reported.
Outcomes: costs
Not reported.
Outcomes: quality of life
Not reported.
3.3 Fournier’s gangrene
One trial in which 30 men with Fournier’s gangrene (23 of whom
were chronic alcoholics) were randomly allocated to be treated
with monofloral (jamun) honey-soaked gauze dressings or an-
tiseptic EUSOL-soaked gauze dressings (Subrahmanyam 2004).
Fournier’s gangrene is an infection of the scrotum that can also
involve the perineum and abdominal wall.
Outcome: healing
Secondary suturing and skin grafting were required in 9/14
(64.3%) of the honey group and 9/16 (56.3%) of the EUSOL
group. Only mean length of hospital stay was reported in the pa-
per, but mean time to healing was supplied by the author (per-
sonal communication M Subrahmanyam). Mean time to healing
was shorter in the honey-treated group (MD -8.00 days, 95% CI
-6.08 to -9.92 days, Analysis 7.2), but we note this was a very
small sample size and the high rates of further surgical intervention
(secondary suturing and skin grafting) required by participants in
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both groups is worth noting (very low quality evidence, on account
of the very small sample size and single study).
Outcome: adverse events
Oneparticipant in the honey-treated group and two in theEUSOL
group died.
Outcome: infection
The primary condition (Fournier’s gangrene) is itself the result of
infection; rates of secondary infection were not reported.
Outcomes: costs
Not reported.
Outcomes: quality of life
Not reported.
3.4 Cutaneous Leishmaniasis
One trial (100 participants) randomly allocated participants
with ulcers caused by Leishmaniasis to treatment with intrale-
sional injections of meglumine antimoniate (glucantamine) plus
honey-soaked gauze dressings or intralesional injections alone
(Nilforoushzadeh 2007).
Outcome: healing
Thirteen participants withdrew from the honey dressings arm due
to treatment failure (n=12) or contact dermatitis (n=1) (and there-
fore remain in this analysis in the denominator) whilst 10 with-
drew from the meglumine antimoniate alone group due to treat-
ment failure (similarly remaining in the denominator). Fewer peo-
ple treated with injections plus honey had healed lesions compared
with those not receiving honey at 4 months although this differ-
ence was not statistically significant (51.1% versus 71.1%) (RR
0.72; 95% CI 0.50 to 1.04) (Analysis 7.1) (low quality evidence
due to imprecision and high risk of bias).
Outcome: adverse events
The study by Nilforoushzadeh 2007 reported one withdrawal due
to sensitivity in the honey group and none in the control group.
Outcome: infection
Not reported.
Outcomes: costs
Not reported.
Outcomes: quality of life
Not reported.
3.5 Venous leg ulcers
Two trials recruited only participants with venous leg ulcers. One
trial (368 participants) recruited patients presenting to commu-
nity-based nursing services for assessment and treatment of their
venous ulcers (Jull 2008). Participants were allocated to receive
either manuka honey-impregnated calcium alginate dressings or
usual care. Participants allocated usual care could receive any dress-
ing that was clinically indicated from the wide range normally
available to community nurses (non-adherent, alginate, hydro-
gel, hydrofibre, hydrocolloid, silver or iodophor dressings). Both
groups received compression bandaging as a standard background
treatment. Participants were treated for 12 weeks. The second trial
recruited 108 participants with uninfected venous ulcers, the sur-
faces of which were at least 50% covered by slough (Gethin 2007).
Participants were allocated to receive either manuka honey dress-
ings or hydrogel dressings for four weeks and then standard care
(the nature of which was individually determined by the clinician)
for the remaining eight weeks of the 12 week follow-up. Both
groups received compression bandaging as a standard background
treatment. A third trial (Robson 2009) compared honeywith usual
care in a population that included approximately 70% people with
venous leg ulcers. Although it was not possible to separate out the
results for people with venous leg ulcers that study also found no
difference in risk of healing between honey and usual care (see
section 3.6 below).
Outcome: healing
The Jull 2008 trial appropriately analysed healing as a time to
event outcome using a survival approach. There was no difference
in healing between groups treated with honey and usual (non-
honey) care (adjusted hazard ratio, HR, 1.1, 95% CI 0.8 to 1.5,
P=0.451). There was no difference in the risk of healing at 12
weeks with or without honey (RR 1.12, 95% CI 0.92 to 1.37).
The Gethin 2007 study had change in area of slough at four weeks
as the primary outcome and proportion of ulcers healed at 12
weeks as a secondary outcome. In this study 24/54 (44.4%) par-
ticipants in the honey group had healed at 12 weeks compared
with 18/54 (33.3%) in the control group (RR of healing 1.33,
95% CI 0.82 to 2.16).
Although the duration of treatment was dissimilar across the two
trials, they were considered sufficiently alike to be able to pro-
vide meaningful information when combined (I² 0%). Overall it
is not clear whether honey increases the healing of venous leg ul-
cers compared with no honey (RR 1.15, 95% CI 0.96 to 1.38)
(Analysis 7.3) (lowquality evidence;downgraded for risk of bias due
to unblinded outcome assessment and imprecision) (Summary of
findings 4).
17Honey as a topical treatment for wounds (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Outcome: adverse events
The Jull 2008 trial (368 participants) reported all adverse events,
whether or not the event was believed to be related to the treat-
ment, whereas the Gethin 2007 trial (108 participants) only re-
ferred to events that were attributable to the wound agent, of
which there were none (and this approach is subject to ascertain-
ment bias in an open label study). In the Jull 2008 trial there were
significantly more adverse events (including deterioration of the
ulcer) reported in the honey-treated group than the control group
(RR 1.28, 95% CI 1.05 to 1.56). The frequency of the different
adverse events is presented in Table 1. It is notable that there were
high frequencies of pain (47/187 versus 18/181) and of ulcer dete-
rioration (19/187 versus 9/181) with honey (low quality evidence,
downgraded for risk of bias and imprecision, Summary of findings
4).
Outcome: infection
The Jull 2008 trial reported risk of infection whilst the Gethin
2007 study reported withdrawals due to infection. Infection was
operationally defined as clinical signs of infection or a positive
swab result, and treatment with antibiotics in Jull 2008.These data
were pooled (fixed effect) and it remains unclear if honey reduces
leg ulcer infection rates relative to no honey (RR 0.71, 95% CI
0.49 to 1.04) (Analysis 7.4) (low quality evidence, downgraded for
risk of bias, Summary of findings 4).
Outcome: cost
Jull 2008 and colleagues conducted a full cost-effectiveness anal-
ysis using a New Zealand health service perspective. Information
was collected on dressings and related products, district nursing
time, general practitioner and laboratory time, outpatient consul-
tations, antibiotic use, and hospitalisation. In the base case anal-
ysis, the average cost of treatment with honey was NZD 917.00
per participant compared with NZD 972.68 per participant for
usual care. This cost was driven by a small difference in hospital-
isations that was considered likely to be due to chance variation
(three participants in the honey group were hospitalised for ulcer-
related reasons for 10 days, compared to six participants hospi-
talised for 40 days). A sensitivity analysis excluding the hospitali-
sations found the average cost of treatment was reversedwith usual
care being cheaper (NZD 811.12 per participant) than treatment
with honey (NZD 877.90 per participant).
Outcome: quality of life
The trial by Jull 2008 reported quality of life. Two generic instru-
ments (SF-36, EQ5D) and one disease-specific instrument (Char-
ing Cross Venous Ulcer Questionnaire) were used. There was little
difference between the groups, with narrow confidence intervals,
for both the physical summary component of SF-36 (mean differ-
ence 1.1, 95% CI -0.8 to 3.0; scale 0 to 100, high is better, for a
control groupmean of 37.9) and themental component summary
score (mean difference 0.7, 95%CI -1.1 to 2.4, for a control group
mean of 50.4). There was also little difference on EQ-5D (mean
difference 1.6, 95% CI -1.5 to 4.7; scale 0 to 100, high is better,
for a control group mean of 73.5) or the Charing Cross Venous
Ulcer Questionnaire.
3.5 Diabetic foot ulcers
Two trials (93 participants) recruited people with diabetes and
foot ulcers of Wagner grade I or II (Kamaratos 2014) or Wagner
grade II (Shukrimi 2008) and compared the effects of honey with
either saline soaks (Kamaratos 2014) or povidone-iodine gauze
(Shukrimi 2008). In both studies participants also received initial
debridement and antibiotics as necessary. Each trial measured and
reported healing in a different way which precludedmeta-analysis.
Outcome: healing
There was no difference in healing between honey and saline gauze
in the trial by Kamaratos 2014 (31/32 people completed healed
by 16 weeks (97%) in the honey-treated group compared with
28/31 (90%) in the saline-gauze group). This equate to a RR for
healing with honey of 1.07 (95% CI 0.94 to 1.22) (Analysis 7.1).
In Shukrimi 2008 the mean time to surgical closure was 14.4 days
in the honey-treated group and 15.4 days in the povidine-iodine
group, but it was unclear whether all wounds healed. The study
did not report standard deviations or the numbers analysed, but
stated the difference was not statistically significant.
Overall the evidence suggests there is little difference in the healing
of diabetic foot ulcers between honey and saline-soaked gauze or
povidone iodine however this is low quality evidence (downgraded
for high risk of bias and imprecision).
Outcome: adverse events
The study by Shukrimi 2008 reported subjective, impressions of
pain and exudate only. Kamaratos 2014 did not mention adverse
events or side effects.
Outcome: infection
Kamaratos 2014 reported negative wound swabs at 4 weeks: there
was no difference between honey and saline dressings (100% of
swabs in the honey group were negative at 4 weeks compared with
87% in the saline group; RR1.07, 95%CI 0.94 to 1.22). Shukrimi
2008 did not report infection.
Outcomes: costs
Not reported.
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Outcomes: quality of life
Not reported.
3.6 Mixed chronic wounds
One trial (105 participants) recruited participants with different
chronic wounds, of whom approximately 70% had venous leg
ulcers (Robson 2009). Participants were allocated to receive either
manuka honey or a usual care dressing. If slough was present,
control participants were to be treated in the first instance with a
hydrogel. Compression treatments were given as appropriate.
A second trial (45 participants) also recruited people with a range
of chronic wounds, of whom 47% had venous leg ulcers (Gulati
2014). Participants received either sterilized honey followed by
a film dressing or povidone iodine covered with a film dressing.
People with venous ulcers also received elastic compression.
In Robson 2009 the reported healing rates at 12 weekswere 46.2%
for honey compared with 34.0% for usual care (RR 1.36, 95% CI
0.84 to 2.19) and at 24 weeks, 72.7% versus 63.3% (RR 1.14,
95% CI 0.88 to 1.48) (Analysis 7.5). Robson 2009 also reported
an unadjusted hazard ratio for healing of 1.30 (95% CI 0.77 to
2.19), with an adjusted analysis (for wound type, age, sex, wound
area) of HR 1.51 (95% CI 0.88 to 2.58), Analysis 7.5.
In Gulati 2014 7/23 (30.4%) in the honey group completely
healed at 6 weeks, compared with 0/22 in the povidone iodine
group. We decided it was inappropriate to pool the healing data
from Gulati 2014 and Robson 2009 due to the different patient
populations, comparator interventions and durations of followup.
Overall it is unclear whether honey speeds the healing of a mixed
population of chronic wounds relative to usual care or povidone
iodine; this evidence is of low quality (downgraded for risk of bias
and imprecision).
Outcome: adverse events
In the Robson 2009 study there were 7 adverse events in the honey
group (1 death, 1 pain, 2 cases of ulcer deterioration and 3 peo-
ple discontinuing treatment due to other concomitant treatment)
compared with 5 in the usual care group (1 death, 1 deterioration
of the ulcer, 3 discontinuation due to other treatment). In Gulati
2014 there were no reported adverse events.
Outcome: infection
Not reported in either study.
Outcomes: costs
Not reported.
Outcomes: quality of life
Not reported.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Honey compared with conventional dressings for burns
Patient or population: patients with Burns
Settings: Any
Intervention: Honey
Comparison: conventional dressings
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Conventional dressings Honey
Complete healing (time
to healing)(days)
Mean time to healing
Follow-up: median 4
weeks
The mean complete heal-
ing (time to healing) in the
intervention groups was
4.68 lower
(5.09 to 4.28 lower)
992
(2 studies)
⊕⊕⊕⊕
high
Adverse events
Follow-up: median 4
weeks
Study population RR 0.56
(0.15 to 2.06)
992
(2 studies)
⊕©©©
very low1,2
206 per 1000 115 per 1000
(31 to 424)
Negative wound swab
Follow-up:median 8 days
Study population RR 1.31
(1.01 to 1.7)
92
(1 study)
⊕©©©
very low3,4
630 per 1000 826 per 1000
(637 to 1000)
Costs5 Not reported Not estimable5 N/A N/A
Quality of life5 Not reported Not estimable5 N/A N/A
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*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Downgraded due to inconsistency (one level): High heterogeneity was detected with an I-squared of 70%
2 Downgraded due to imprecision (two levels): The 95% confidence interval ranges from 0.15 to 2.06
3 Downgraded due to indirectness (one level). The outcome of a negative wound swab at 8 days is only a proxy for clinical infection and
difficult to interpret
4 Downgraded for imprecision (two levels): this outcome is only reported for one study involving 92 participants
5 Neither study reported costs or quality of life
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Honey compared with silver sulfadiazine for burns
Patient or population: patients with Burns
Settings: Any
Intervention: Honey
Comparison: Silver sulfadiazine
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Silver sulfadiazine Honey
Complete healing
Follow-up: 4-6 weeks
Study population RR 1.00
(0.98 to 1.02)
462
(6 studies)
⊕⊕⊕⊕
high
1000 per 1000 1000 per 1000
(980 to 1000)
Mean time to complete
healing (days)
Follow-up: 21-60 days
The mean time to com-
plete healing in the inter-
vention groups was
5.12 lower
(9.51 to 0.73 lower)
332
(4 studies)
⊕©©©
very low1,2
Adverse events
Follow-up: 4-6 weeks
Study population RR 0.29
(0.2 to 0.42)
412
(6 studies)
⊕⊕⊕⊕
high
413 per 1000 120 per 1000
(83 to 174)
Negative wound swab
Follow-up:median 7 days
Study population RR 3.92
(1.32 to 11.63)
412
(5 studies)
⊕©©©
very low3,4,5
236 per 1000 923 per 1000
(311 to 1000)
2
2
H
o
n
e
y
a
s
a
to
p
ic
a
l
tre
a
tm
e
n
t
fo
r
w
o
u
n
d
s
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
5
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
Costs
Cost of dressing per per-
cent TBSA affected
The cost of dressing treatment per % TBSA affected
was 0.75 PKR for honey and 10 PKR for silver
sulfadiazine
50
(1 study)
⊕⊕©©
low7,8
Quality of Life6 Not reported N/A N/A N/A
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Downgraded due to inconsistency (two levels): Very high level of statistical heterogeneity (I squared of 93%)
2 Downgraded due to imprecision (one level): Although the direction of effect is consistently in favour of honey, the confidence interval
around the mean difference ranges from a reduction in healing time of less than one day up to nearly 10 days
3 Downgraded two levels due to inconsistency: Very high level of statistical heterogeneity (I squared of 94%)
4 Downgraded due to indirectness (one level) since the outcome of a negative wound swab at 7 days is only an indirect measure of
wound infection.
5 Downgraded due to imprecision (one level): The risk of a negative swab at 7 days favour honey however the confidence interval is
extremely wide
6 Quality of life not reported in any of the studies
7 Only cost of dressing materials reported not other associated health care costs
8 Only one small study reported cost of materials
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Honey for venous leg ulcers
Patient or population: patients with Venous leg ulcers
Settings: Any
Intervention: Honey
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Honey
Complete healing (time
to healing)
Follow-up: 12 weeks
Study population HR 1.1
(0.8 to 1.5)
368
(1 study)
⊕⊕©©
low1,2
497 per 1000 531 per 1000
(423 to 644)
Complete healing (pro-
portion wounds healed)
Study population RR 1.15
(0.96 to 1.38)
476
(2 studies)
⊕⊕©©
low3,4
460 per 1000 529 per 1000
(441 to 634)
Adverse events Study population RR 1.28
(1.05 to 1.56)
368
(1 study)
⊕⊕©©
low1,5
464 per 1000 594 per 1000
(487 to 724)
Infection
Follow-up: 12 weeks
Study population RR 0.71
(0.49 to 1.04)
476
(2 studies)
⊕⊕©©
low6
221 per 1000 157 per 1000
(108 to 230)
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Costs
Incremental cost effec-
tiveness ratio
Follow-up: 12 weeks
The mean cost in the intervention group was
9.45 NZD lower
(95%CI 39.63 NZD lower to 16.07 NZD higher)7
368
(1 study)
⊕©©©
very low8,9
The ICER was sensitive to
the inclusion
of hospitalisation costs.
Hospitalisation
unlikely related to treat-
ment and when
these were excluded the
ICER was in favour of
control.
Quality of Life
SF-36 PCS
Follow-up: 12 weeks
The mean PCS in the intervention group was
1.1 higher (95% CI 0.8 lower to 3 higher)
368
(1 study)
⊕⊕⊕©
moderate10
Quality of Life
SF-36 MCS
Follow-up: 12 weeks
The mean MCS in the intervention groups was
0.7 higher (95% CI 1.1 lower to 2.4 higher)
368
(1 study)
⊕⊕⊕©
moderate10
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio; HR: Hazard ratio;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Downgraded due to risk of bias (one level): Unblinded outcome assessment
2 Downgraded due to imprecision (one level): The confidence interval around the estimate of the hazard ratio ranges from a 20% reduction
to a 50% increase in the hazard for healing with honey
3 Downgraded due to risk of bias (one level): Neither study used blinded outcome assessment
4 Downgraded due to imprecision (one level): The result is consistent with there being no important difference between the dressings up
to honey increasing the risk of healing by just over a third
5 Downgraded due to imprecision (one level): Wide confidence intervals; only one study
6 Downgraded due to risk of bias (two levels): The diagnosis of infection is partly subjective: both trials were open label
7 Including hospitalisation costs (and $11.34 (-$2.24 to $26.25) in favour of usual care when hospitalisation costs excluded.
8 Large difference in rates of hospitalisations and therefore associated costs between arms unlikely to be related to treatments. ICER
sensitive to inclusion/exclusion of hospitalisation costs
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9 Large uncertainty on cost data
10 Patients not blinded to treatment
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D I S C U S S I O N
This is a complex review addressing a diverse range of wound types
and with many trials at high or unclear risk of bias. Generally,
the evidence, when assessing using GRADE, is of low or very low
quality. Thismeans that new, better quality research is highly likely
to change the overall conclusions of this review. The findings are
discussed below with respect to specific wound types and using a
GRADE approach to addressing the quality of the evidence.
Summary of main results
1. Acute wounds
1.1 Minor acute wounds
It is unclear, on the basis of the very low quality evidence from
three small trials (two in toenail bed avulsion and one in minor
traumatic wounds) whether honey affects time to wound healing
in minor acute wounds compared with conventional dressings. It
is also unclear if honey and conventional dressings have different
effects on adverse events or rates of infection in people with minor
acute wounds (Summary of findings for the main comparison).
1.2 Burns
The 11 trials of honey for burns used a wide range of
comparator treatments, viz. various conventional dressings (
Subrahmanyam 1993a; Subrahmanyam 1996a), early burn exci-
sion and grafting (Subrahmanyam 1999), silver sulfadiazine (SSD)
(Baghel 2009; Mashood 2006; Memon 2005; Subrahmanyam
1991; Subrahmanyam 1998; Subrahmanyam 2001a), amni-
otic membrane (Subrahmanyam 1994) and potato peelings (
Subrahmanyam 1996b).
The evidence for the effects of honey relative to these comparators
is mixed, and is generally of low or very low quality. The strongest
(high quality) evidence suggests that honey dressings heal partial
thickness burns, on average, between 4 and 5 days more quickly
than conventional dressings, however it is not clear if there is a
difference in the rates of adverse events or infection (Summary of
findings 2).
One trial (low quality evidence) suggests that early excision and
grafting heals burns on average 13.6 days more quickly (95% CI
9.82 days to 17.3 days) than honey followed by grafting as neces-
sary, however the relative effects on adverse events and infection
rates are unclear (Subrahmanyam 1999).
There is very low quality evidence that honey reduces the time
for burns to heal by between 0.73 and 9.51 days (average differ-
ence was 5.12 days) compared with SSD dressings/cream and high
quality evidence of a reduction in adverse events with honey and
more negative wound swabs at day 7. There was no difference for
the outcome of risk of complete healing by 4 to 6 weeks (high
quality evidence) (Summary of findings 3).
Perhaps unsurprisingly, the current evidence suggests that burns
heal more quickly with honey than with amniotic membranes (by
approximately 8 days) (Subrahmanyam 1994) and approximately
6 days more quickly than with potato peelings (Subrahmanyam
1996b) (single small studies, moderate quality evidence). The rel-
ative effects of these interventions on adverse events and infection
are unclear.
2. Mixed acute and chronic wounds
The rationale for conducting trials in which the participants have
either burns or a mix of chronic wounds is unclear. The aetiologies
are so different that no matter what the results, the findings will
be difficult to interpret and unlikely to influence clinical practice.
Overall we found low quality evidence from two studies Mphande
2007; Subrahmanyam 1993b), that on average honey heals a het-
erogeneous population of acute and chronic wounds more quickly
than sugar dressings or SSD. The comparative rates of adverse
events and infection are unclear.
3. Chronic wounds
Most of the evidence for the effects of honey on chronic wounds is
of low or very lowquality.Most trials were small, with comparators
that may not be relevant to current practice and at high or unclear
risk of bias.
3.1 Infected post-operative wounds
There is moderate quality evidence that honey increases the abso-
lute risk of healing by 35% (95%CI 8.7% to 55.4%) relative to
antiseptic (povidone iodine) washes followed by gauze. The single
trial (Al Waili 1999) was small (50 participants) and the report
lacked sufficient detail to permit the risk of bias to be determined
accurately for most domains. The comparator was an antiseptic
which has been proposed to impair wound healing although clin-
ical evidence for such an effect is lacking (Leaper 1986). In the
same study there were fewer adverse events and a shorter time to
a negative wounds swab with honey.
3.2 Pressure ulcers
There is very low quality evidence that honey increases the relative
risk of healing of pressure ulcers by 41% (95% CI 5% to 90%)
relative to saline soaked gauze (Weheida 1991). This equates to an
increase in the absolute risk of healing with honey of 30% (95%CI
7.7% to 51.9%). The quality of the evidence for the effect on
healing from this trial was downgraded to very low quality for
27Honey as a topical treatment for wounds (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
imprecision and possible selection bias. There were no data on
adverse events or infection.
3.3 Fournier’s gangrene
There is very low quality evidence that honey healed Fournier’s
gangrene, on average, 8 daysmore quickly thanEusol soaks (1 trial,
WMD-8.00 days, 95%CI -6.08 to -9.92 days). In this small study
(30 participants) Subrahmanyam 2004), 64% (honey group) and
69% (EUSOL group) of participants also required secondary su-
turing and grafting. In addition, the comparator was EUSOL, an
antiseptic that has been shown to impair wound healing in animal
model studies (Brennan 1985).
3.4 Cutaneous Leishmaniasis
It is not clear whether honey influences the healing of lesions
caused by Leishmaniasis when used as an adjuvant to meglu-
mine antimoniate. The low quality evidence from a single small
trial suggests that honey may impair healing compared with
meglumine antimoniate alone (RR 0.72; 95% CI 0.50 to 1.04)
(Nilforoushzadeh 2007) however the quality of this evidence for
an effect on healing was downgraded for imprecision and high
risk of bias. In terms of adverse events, there was one reported
withdrawal from the honey group for sensitivity and none in the
control group. Infection rates were not reported.
3.5 Venous leg ulcers
There is currently no clear evidence that honey improves the rate
of healing of venous ulcers. Such evidence that there is, from two
trials (Gethin 2007; Jull 2008) is low quality and finds no overall
difference in healing (RR 1.15, 95% CI 0.96 to 1.38) (Summary
of findings 4). The larger of the two studies (Jull 2008) analysed
healing (appropriately) as a time-to-event outcome which is more
informative (and uses more of the information on healing) than
crudely analysing the proportions of participants healed at a par-
ticular (arbitrary) time point. This study found no difference in
the hazard of healing between honey and usual care (hazard ratio
1.1, 95%CI 0.8 to 1.5). These trials reported adverse events dif-
ferently with Gethin 2007 only reporting those they “attributed”
to the wound treatment (there were none). This approach has an
inherently high risk of ascertainment bias in an open label study.
By contrast Jull 2008 documented and reported all adverse events
and there were more in the honey group than the control group,
with pain and ulcer deterioration being frequent (absolute increase
in risk of adverse events with honey was 12.9%, 95%CI 2.7% to
22.8%).
3.6 Diabetic foot ulcers
The effect of honey on diabetic foot ulcers cannot be determined.
The two included studies (Kamaratos 2014; Shukrimi 2008) were
small and the evidence for honey in this patient group was low
quality.
Overall completeness and applicability of
evidence
There are significant weaknesses in the completeness and applica-
bility of the evidence overall.Most of the studies in burns have been
conducted by one team in India (10 out of 26 included studies;
Subrahmanyam 1991; Subrahmanyam 1993a; Subrahmanyam
1993b; Subrahmanyam 1994; Subrahmanyam 1996a;
Subrahmanyam 1996b; Subrahmanyam 1998; Subrahmanyam
1999; Subrahmanyam 2001a; Subrahmanyam 2004) and we re-
lied on further information supplied by the authors to supplement
an absence of detail in the original published trial reports. This re-
view is therefore disproportionately reliant on evidence from one
single research team from one part of the world and this evidence
may not be applicable elsewhere (particularly since the prevailing
microbiological environment, health care facilities and climate are
likely to have strong effects on burn outcomes and infection rates).
Only one study (Jull 2008) reported costs and quality of life.
Clearly any impact of treatments on patients’ quality of life is in-
valuable information for all decision makers but particularly pa-
tients. The relative cost-effectiveness of competing treatments is
essential information for health care funders and providers. We
therefore urge that future research in this field uses contemporary
methodologies to measure these outcomes.
There is relatively little replication of studies, with single, small
studies for most comparisons. This weak evidence base makes it
impossible to draw firm conclusions with confidence.
Some of the comparators chosen have little or no relevance to
current clinical decisionmaking (e.g., amniotic membrane, potato
peelings). Other comparators will have relevance in some parts of
the world but not others. For example antiseptics such as EUSOL
and povidone iodine are used less frequently in open wounds than
they used to be, in the developed world at least, because in vitro
studies were interpreted as evidence that they may impair wound
healing (Leaper 1986). Silver sulfadiazine, which is commonly
used in burns and was the comparator in several of the studies
included here, has been shown in a related review (Wasiak 2013) to
impair the healing of burns relative to several comparator dressings.
Quality of the evidence
In common with most wounds-related topic areas, the quality of
the evidence in this review was generally low or very low - mainly
due to imprecision, risk of bias and inconsistency. Imprecision
of effect estimates was usually low because there are only one or
two small studies for each comparison. Risk of bias was gener-
ally high due to unblinded outcome assessment. Most studies did
not guard against performance bias (by blinding participants and
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health care professionals) however the importance of performance
bias inwound care studies is not clear. Blinded outcome assessment
is however a substantial threat to validity (Hróbjartsson 2012).We
downgraded the quality of the evidence for inconsistency where
there was obvious clinical or statistical heterogeneity. Poor report-
ing is a major issue and the majority of studies were unclear for
one or more important bias domains in the risk of bias assessment.
We carefully considered downgrading the evidence for risk of bias
where trial reports were unclear (most studies, see Figure 1). We
decided against downgrading for unclear risk of bias (because it
does not appear to be the norm) however this means that, if any-
thing, the evidence is lower quality than we have rated it. The
importance of following international standards for trial reporting
(i.e., CONSORT, Schulz 2010), which most of the studies in this
review did not adhere to, cannot be over-emphasised .
The reporting of adverse events was poor in most trials, and non-
existent in a few trials. This makes accurate assessment of the risk
of adverse events associated with honey dressings compared with
comparators, difficult. The International Conference on Harmo-
nization’s Guideline for Good Clinical Practice (ICH GCP) de-
fines an adverse event as any untoward medical occurrence in a
trial subject who has been administered an intervention, whether
related to the intervention or not.With the exception of Jull 2008,
it was not clear if trials reported all adverse events as required by
ICH GCP. Therefore the adverse event findings should be inter-
preted very cautiously, as the full adverse event profile of honey
vs. comparators in different wounds is unknown.
The evidence regarding the effect of honey on wound infection
rates was poor quality and difficult to interpret. The accurate iden-
tification of wound infection is problematic and since wound in-
fection is dependent to some extent on the host response to the
micro-organism (e.g., manifesting as inflammation and pain), and
the assessment of this is partly subjective, there is no “gold stan-
dard” diagnostic tool . Clinical presentation is an important indi-
cator, but presentationmay vary with wound type (Cutting 2005),
therefore, trialists should strive for unambiguous definitions of
infection to ensure that study results are interpretable and their
meta-analyses both feasible and sensible.
Infection is a significant and threatening consequence of burns.
Wound sterility after a burn is maintained by careful attention
to asepsis during wound care and the use of preventive agents.
Honey dressings appear to increase the probability that a cultured
swab from a burn will remain negative compared with a range of
control treatments but the clinical importance of negative swabs
at day 7 is unclear. Future trialists should identify and use reliable
and valid measures of infection that can be applied in a range of
settings.
Only one study conducted a full cost-effectiveness analysis using
a health services perspective (Jull 2008). As the effectiveness of
honey was not established by the trial, honey cannot be considered
the dominant strategy. In the same vein, this was also the only
study that reported health related quality of life.
Potential biases in the review process
This review has a number of limitations, driven largely by the na-
ture of the included studies. Firstly one of the included studies
was led by one of the authors of this review (Jull 2008). This situ-
ation is not uncommon in Cochrane reviews and there are robust
policies in place to reduce or eliminate any bias this may bring.
Specifically data extraction, risk of bias assessment and analysis
were checked by three further authors or editors (MW, NC, JD).
Secondly, several studies report and analyse mean time to healing
as the main effect measure. Time to healing should be treated as a
type of time-to-event outcome rather than a continuous measure,
as this enables all participants to contribute data to the analysis
irrespective of whether they experienced the outcome or remained
in the study (only people who healed can contribute data to an
analysis of mean time to healing as a continuous outcome). How-
ever, we were limited to using a common means of measurement
wherever possible. Third, we attempted to contact authors where
the original publication did not provide sufficient data, and then
incorporate that data into the review. Where authors did not re-
spond, we excluded the studies that did not report sufficient data
even to be included in a narrative analysis. Finally it was not possi-
ble to evaluate the overall possibility of publication bias, as not all
trials reported the same outcomes and overall the trials were too
heterogeneous to combine.
Agreements and disagreements with other
studies or reviews
Two relevant systematic reviews have been published since the last
update of this review. In 2013 Vandamme 2013 concluded that
honey stimulates wound healing in human burns, ulcers and other
wounds, and that it debrides, removes odour, has anti-inflamma-
tory and pain reducing properties. There are key methodologi-
cal differences between our review and the review by Vandamme
2013. They did not restrict inclusion to study designs at lowest
risk of bias (but included published controlled trials, clinical trials
and case reports as well as RCTs). Secondly there appears to have
been no systematic assessment of study quality in the review by
Vandamme 2013, but rather allusion to strengths and weaknesses
of the included studies in an ad hoc way. Thirdly GRADE was
not used to assess the quality of the evidence in the Vandamme
2013 review and conclusions were reached by vote counting rather
than meta-analysis. There is a great deal of overlap of study inclu-
sion however (though we had excluded several studies included in
their review e.g., Malik 2010, Yapucu Gunes 2007, Oluwatosin
2000, Lund-Nielsen 2011,Misirligou 2003). Elsewhere the expla-
nation for excluding studies from our review that were included
in Vandamme 2013 was the different eligibility criteria for study
population (they included studies of oral mucositis and radiation
damage to skin).Notwithstanding these differences therewas some
agreement in the conclusions reached, viz. their conclusion that
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“Many of the included studies have methodological problems, and
the quality of certain studies is low, making it difficult to formulate
conclusive guidelines” (Vandamme 2013). Another systematic re-
view was also published in 2013 (Rttermann 2013). This review
was prepared to support new German wound care guidelines and
used the GRADE approach in summarising the quality of the evi-
dence. Again the patient population differed slightly from ours in
that they excluded studies in people with burns and other acute
wounds. The review by Rttermann 2013 concluded that honey
does not accelerate wound healing and increases pain (a conclu-
sion based solely on the studies of Gethin 2007 and Jull 2008
included here). There is much agreement therefore between our
conclusions represented in this review update and those of other
recent systematic reviews.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The main challenge to practitioners in considering this evidence
is deciding whether the patient populations and comparator in-
terventions are clinically relevant to their practice.
There is high quality evidence from two trials that honey dress-
ings heal partial thickness burns more quickly than conventional
dressings by around five days however practitioners must con-
sider whether the comparator dressings in these trials are clinically
meaningful to them. In one of the two trials the control dress-
ing was a polyurethane film dressing whilst in the other the con-
trol group received a range of interventions (polyurethane film,
paraffin gauze, sterile linen, framyecetin-impregnated tulle, left
exposed). It is unclear whether there is a difference in rates of ad-
verse events (very low quality evidence) or infection (low quality
evidence) between honey and conventional dressings for partial
thickness burns.
It is unclear whether there is a difference in the effect on the healing
of burns between honey and SSD, since the result is very sensitive
to the outcome measure used. Furthermore, SSD has been shown
to slow the healing of burns relative to other comparators in a
related Cochrane review (Wasiak 2013).
There is low quality evidence from one small trial that early exci-
sion and grafting of partial and full thickness burns may be more
effective than honey followed by later grafting as necessary.
Low quality evidence from two small trials with different com-
parators suggests that honey may heal a mixed population of acute
and chronic wounds more quickly than SSD or sugar dressings.
Again practitioners will need to consider the relevance of this evi-
dence to current practice.
Moderate quality evidence from one trial suggests that honey heals
infected post-operative wounds more quickly than povidone io-
dine washes followed by gauze and is associated with fewer adverse
events.
Very low quality evidence from one small trial suggests that honey
may heal pressure ulcers more quickly than saline soaks.
Very low quality evidence from one trial suggests that honey may
heal Fournier’s gangrene more quickly than Eusol soaks.
The effect of honey relative to comparators is unclear for: venous
leg ulcers (2 trials, low quality evidence); minor acute wounds (3
trials, very low quality evidence); diabetic foot ulcers (2 trials, low
quality evidence); Leishmaniasis (1 trial, low quality evidence);
mixed chronic wounds (2 trials, low quality evidence).
Implications for research
The implications for further research arising from this review fall
into two categories: important research questions and improving
the conduct and reporting of future research.
An important research question may well be whether honey dress-
ings heal partial thickness burns more quickly than relevant, cur-
rent comparator dressings, since currently the only evidence com-
pares honey with film dressings or with a range of very different
dressings. It is consequently impossible to determine the effective-
ness of honey relative to competing dressings. Evidence from this
and a related review (Wasiak 2013) is beginning to accumulate
that suggests SSD may not be an effective treatment for burns
and yet it is still widely used. Given the quality of the existing
evidence, substantial doubt remains and therefore there may be an
argument for a definitive, high quality three-arm trial comparing
honey dressings with SSD and another widely used conventional
dressing.
People with surgical wounds that are infected or have broken down
may be another patient group in which to evaluate honey dressings
since there is some evidence from one study in this review that they
may be effective; again the comparator dressing used in this trial
(povidone iodine wash followed by gauze) is no longer relevant in
some parts of the world.
For those wounds that are a consequence of underlying systemic
disease (chronic wounds such as pressure ulcers, venous ulcers
and diabetic foot ulcers, and Leishmaniasis) it seems likely that
management of the underlying health problem (or reduction of
the applied pressure in the case of diabetic foot and pressure ulcers)
will make more difference to healing than the type of dressing and
we would suggest that these trials are of lower priority.
In terms of improving the quality of future research we would
make the following recommendations:
1. Where trials are measuring a time to event outcome such as
time to healing, they should employ survival approaches which
account for censoring.
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2. Trials should focus on populations that share a single
wound aetiology rather people with wounds of different
underlying causes.
3. Trials should be appropriately powered based on identifying
a clinically important difference for a pre-specified primary
outcome.
4. Trials should apply properly random and concealed
allocation strategies and these should be clearly reported.
5. Future studies should use either blinded outcome
assessment or some form of masked, remote adjudication of
outcomes e.g., photography.
6. It is important to follow up as great a proportion of
randomised participants for clinical outcomes as possible, even
when they withdraw from trial treatments.
7. Analysis should use the intention-to-treat principle and
include all participants in the denominator. Where participants
have been lost to follow-up, appropriate and valid methods of
imputation should be used and reported.
8. The patient should be the unit of randomisation and
analysis, rather than individual wounds.
9. Future trials should measure and report health-related
quality of life using valid and reliable measures (both generic and
wound specific). Similarly future trials should measure the costs
of alternative treatments and ideally assess cost-effectiveness.
10. Trialists should ensure that the above elements of trial
quality are adequately reported, and journals should require that
trial reporting is consistent with the Consolidated Statement on
Reporting of Trials. Data for outcomes relevant to wound
healing should be reported to support full evaluation and reuse.
11. All trials should be registered with a trials register that meets
the WHO criteria, and principal investigators should keep their
contact details on the register up to date.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Al Waili 1999
Methods Single-centred, 2-armed parallel group RCT.
Participants 50 participants who had had Caesarean sections or hysterectomies.
Setting: hospital.
Country: United Arab Emirates.
Inclusion criteria: acute post-operative bacterial wound infections confirmed by culture
and sensitivity.
Exclusion criteria: not reported.
Interventions Group 1 (n = 26): Yemeni honey covered with dry gauze.
Group 2 (n = 24): 70% ethanol with povidone-iodine covered with dry gauze.
Treatment duration: not reported, dressing changed 12-hourly
All participants received systemic antibiotics.
Outcomes Complete healing:
Group 1: 22/26 (84.6%); definition of complete wound healing included freedom from
dehiscence
Group 2: 12/24 (50.0%).
Notes The authors have not responded to requests for additional information
Funding source: Not reported.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “After informed consent the pa-
tients were allocated randomly into two
groups”.
Comment: method of generating the ran-
dom schedule not reported.
Allocation concealment (selection bias) Unclear risk Comment: not stated.
Blinding (performance bias and detection
bias)
Blinding of participants? All outcomes
Unclear risk Comment: not stated.
Blinding (performance bias and detection
bias)
Blinding of healthcare providers?All out-
comes
Unclear risk Comment: not stated.
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Al Waili 1999 (Continued)
Blinding (performance bias and detection
bias)
Blinding of outcome assessors? All out-
comes
Unclear risk Comment: not stated.
Incomplete outcome data (attrition bias)
Drop-out rate described and acceptable -
All outcomes
Low risk Comment: Table 6 shows that all the ran-
domised participants completed follow-up
Incomplete outcome data (attrition bias)
ITT analysis -All outcomes
Low risk Comment: ITT analysis was assumed to
have been done and to be acceptable, since
there were no drop-outs reported, and all
the randomised participants completed the
study
Selective reporting (reporting bias) Low risk Comment: the study protocol was not
available, but the important outcome mea-
sures stated in the methods section were re-
ported in the results
Other bias Low risk Quote: “Both groups were comparable
with regards to age, sex, and duration of
symptoms, type and severity of bacterial in-
fections, clinical signs and symptoms and
use of systematic antibiotics”
Comment: there was no obvious imbal-
ance in the baseline characteristics, and the
study seemed to be free from other forms
of bias
Baghel 2009
Methods Single-centered, 2-arm parallel group RCT.
Participants 78 participants admitted to burn unit ofMYhospital Indore over a period of 2 years (June
2006-June 2008). 1st degree (57%) and 2nd degree burns, Positive swabs at admission:
26/37 (70%) and 34/41 (83%).Setting: hospital.
Country: India.
Inclusion criteria: 10-50 years of age, with 1st- and 2nd-degree burns, burn area < 50%
of TBSA.
Exclusion criteria: patients on chemotherapy, with renal and/or liver failure, immuno-
compromised state and those with bronchial asthma
Interventions Group 1 (n = 37): honey dressing (honey covered with gauze) applied daily.
Group 2 (n = 41): SSD (cream covered with gauze) applied daily.
Treatment duration: not reported, duration of follow-up 2 months
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Baghel 2009 (Continued)
Outcomes Complete recovery which was defined as ’complete healing without scar or contracture’
(30/37 in the honey group and 15/41 in the SSD group)
Numbers of patients whose burns completely healed, whilst not explicitly reported, can
be inferred from Table 3 in the paper (viz. all patients)
The duration of follow up was 42 days.
Complete healing at 42 days:
Group 1: 37/37 ;
Group 2: 41/41
Mean time to healing:
Group 1: 18.1 days (No SD);
Group 2: 32.6 days (No SD).
p value for the difference 0.05, allows calculation of standard error: mean difference -
14.5 (SE 7.28)
Notes Complete recovery included healing without scarring or contractures. Formation of soft
scar, hypertrophic scar and/or contracture was counted as incomplete recovery. The
authors have not responded to requests for additional information
Funding source: Not reported.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “After taking consent from the pa-
tients/parents or guardians, patients were
randomly attributed into two study groups;
Honey group and SSD group . . .”.
Comment: method of generation of the
random sequence not reported.
Allocation concealment (selection bias) Unclear risk Comment: not stated.
Blinding (performance bias and detection
bias)
Blinding of participants? All outcomes
Unclear risk Comment: not stated.
Blinding (performance bias and detection
bias)
Blinding of healthcare providers?All out-
comes
Unclear risk Comment: not stated.
Blinding (performance bias and detection
bias)
Blinding of outcome assessors? All out-
comes
Unclear risk Comment: not stated.
Incomplete outcome data (attrition bias)
Drop-out rate described and acceptable -
All outcomes
Low risk Comment: Tables 3 and 5 showed there
were no drop-outs, all the randomised par-
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ticipants were followed-up
Incomplete outcome data (attrition bias)
ITT analysis -All outcomes
Low risk Comment: ITT analysis was not reported,
but since no drop-outs were reported, and
all the randomised participants completed
the study, ITTanalysiswas assumed tohave
been done and to be acceptable.
Selective reporting (reporting bias) Low risk Comment: the study protocol was not
available, but the important outcome mea-
sures stated in the methods section were re-
ported in the results
Other bias Unclear risk Comment: although the baseline charac-
teristics were broadly similar, a greater pro-
portion of patients treated with honey were
admitted to hospital within 1-8 h of the
burn (65%) compared to the SSD group
(11%). At baseline, 70% and 82% respec-
tively had positive swabs for bacteria. The
study seemed to be free from other forms
of bias
Gethin 2007
Methods Multi-centred, 2-armed, open label RCT.
Participants 108 participants recruited February 2003-January 2006. People with uninfected venous
leg ulcers of duration 39.5 and 29.9 weeks for honey and hydrogel respectively; median
area 5.4 and 4.2 cm2; Margolis index 0,1,2 = 33%, 30%, 37% for honey group and
46%, 31%, 22% for hydrogel group; 86% and 78% covered in slough.
Setting: hospital and community leg ulcer clinics.
Country: Ireland.
Inclusion criteria: > 18 years, wound area < 100 cm2, > 50% of wound covered by slough,
able to provide written informed consent.
Exclusion criteria: current wound infection, medicated with antibiotics or steroids for
any reason, cavity or malignant lesion
Interventions Group 1 (n = 54): monofloral (manuka) honey (Woundcare 18+) at dose of 5 g/20 cm
2 plus compression applied weekly.
Group 2 (n = 54): hydrogel (IntraSite) at dose of 3 g/20 cm2 plus compression applied
weekly.
Treatment duration: 4 weeks, dressing changed with compression
Then both groups received follow-on treatment according to clinical assessment
Outcomes Complete healing at 12 weeks:
Group 1: 24/54 (44.4%);
Group 2: 18/54 (33.3%).
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The authors’ regression analysis was adjusted for Margolis score: they reported an OR
3.1 (95%CI 1.15 to 8.35) and a RR of 1.38 (95%CI 1.02 to 1.88)
Notes Healing was a secondary outcome. The primary outcome was change in area of slough
at 4 weeks
Funding source: Research and Education Foundation in Sligo General Hospital, Euro-
pean Wound Management Association and the Health Research Board of Ireland
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: ”78 pieces of both green and yellow
card were counted, checked, and shuffled
by a person independent of the trial. The
card was then inserted into opaque brown
envelopes, counted, sealed, and shuffled
by another person independent of the
trial. The envelopes were then, sequentially
numbered. This process represented
generation of an unpredictable allocation
sequence. Yellow indicated allocation to the
Manuka honey treatment and green alloca-
tion to the IntraSite treatment.“
Comment: shuffling is an adequatemethod
of sequence generation
Allocation concealment (selection bias) Low risk Quote: “Envelopes were given to a person
independent of participant enrolment at a
remote location. This process ensured allo-
cation concealment. When a person agreed
to participate and having met the inclusion
criteria and signed the consent form, the
recruiting nurse phoned the remote num-
ber, gave details of the patient including,
name, gender, trial centre, ABPI, percent-
age of wound covered in slough and ul-
cer size. The external person then, using
the pre-generated allocation sequence, allo-
cated the trial number for the patient and
the treatment allocation.”
Comment: centrally randomised via re-
mote phone allocation.
Blinding (performance bias and detection
bias)
Blinding of participants? All outcomes
High risk Quote: “The consequence of this for the
writers RCT is that patients cannot be
blinded to the treatment as the interven-
tion is an orange/brown ointment, while
the comparator IntraSite GelTM is a clear
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gel, thus the difference between treatments
is obvious.”
Comment: Blinding of participants not
done.
Blinding (performance bias and detection
bias)
Blinding of healthcare providers?All out-
comes
High risk Quote:
Comment: Blinding of healthcare
providers not done.
Blinding (performance bias and detection
bias)
Blinding of outcome assessors? All out-
comes
High risk Quote: “Blinded outcome assessment is
not possible for two reasons. As stated,
honey leaves an orange staining on the peri-
wound skin (photo 3.1) which would iden-
tify which treatment the patient is receiv-
ing and secondly, within the main study
centre clinic and in community leg ulcer
clinics, a person trained in wound man-
agement would not be available toassess
wounds. Photographs would not be used
for blinded outcome assessment, as the abil-
ity to achieve high quality photos from each
centre for each patient was not possible.
Therefore, the trial would be classified as
open label.”
Comment:primary outcome assessorswere
not blinded.
Quote: “However, to add some element of
blinding, the laboratory would not bemade
aware of which treatment the patient was
receiving and the statistician would not be
aware of the identity of each group.“
Comment: Secondary outcome assessors
were blinded.
Incomplete outcome data (attrition bias)
Drop-out rate described and acceptable -
All outcomes
Low risk Comment: Figure 5.2 (PhD p243) shows
that no patients were lost to follow-up, but
there were 9/54 and 17/54 withdrawals; 6
and 12 because of infection in the wound.
This is small compared with the event rate,
so acceptable
Incomplete outcome data (attrition bias)
ITT analysis -All outcomes
Low risk Quote: “Data was analysed on an intention
to treat (ITT) basis.”.
Comment: ITT analysis had been done,
as all the randomised participants were in-
cluded in the final results.
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Selective reporting (reporting bias) Low risk Comment: the study protocol was not
available, but the important outcome mea-
sures stated in the methods section were re-
ported in the results
Other bias Unclear risk Quote: “Analysis using independent t-test
determined there was no statistically signif-
icant difference between treatment groups
for any of the baseline continuous variables
such as wound duration, size, patient age,
and slough. Chi-square analysis did not re-
port any statistically significant differences
between groups for baseline categorical.”
Comment: ulcers in the honey group were
larger (median ulcer areas 5.4 cm2 vs 4.2
cm2; mean ulcer areas 10.52 cm2 vs. 9.87
cm2), present for longer (median durations
18 weeks vs 14 weeks; mean durations 39.
4 weeks vs 29.9 weeks) and had a greater
area covered by slough (85.5% vs 78.2%),
however, these factors would affect the like-
lihood of healing in the honey group. The
Margolis index had a higher proportion of
score 2 patients in the honey group (37%
versus 22%). The study seems to be free
from other forms of bias
In addition, the randomised treatments
were for only 4 weeks and then treatment
was given according to clinical assessment;
this was not reported, so no information on
comparability of treatments
Gulati 2014
Methods Single centre, 2-armed, parallel group RCT.
Participants Setting: surgical outpatients, India.
Inclusion criteria: people aged ≥ 18 years with chronic wounds of duration ≥ 6 weeks
Exclusion criteria: people with wounds with signs of acute inflammation or infection,
postoperative wounds, burns, skin graft donor sites, wounds >5cmmax diameter, known
allergy to honey, povidone iodine or Tegaderm dressing. Osteomyelitis ruled out
Types of wound: 21/42 venous ulcer (50%); 1/42 arterial ulcer (2.4%); 8/42 diabetic
ulcer (19%); 2/42 pressure ulcer (4.8%); 9/42 traumatic wound (21.4%); 1/42 not stated
(2.4%)
Interventions Group I: 23 people. Honey applied to wounds sufficient to fill any cavity. Wounds then
covered with film dressing (Tegaderm). Dressings changed on alternate days for 6 weeks.
People with venous leg ulcers wore compression “garments”
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Group II: 22 people. 10% povidone iodine applied to wounds sufficient to fill any cavity.
Wounds then covered with film dressing (Tegaderm). Dressings changed on alternate
days for 6 weeks. People with venous leg ulcers wore compression “garments”
Outcomes Wound size (tracings); complete healing; adverse reactions noted. Primary outcome was
complete healing at 6 weeks (healing not defined). Secondary outcome was reduction in
wound surface area, pain during dressing change (VAS 0 to 10 where 0 no pain), and
overall comfort. The latter two are not outcomes for this review
Results only provided for those completing trial (complete case analysis) i.e., 1 lost from
honey group and 2 from control group
Group I: 7/22 healed at 6 wks
Group II: 0/20 healed at 6 wks
Group I: final median area 0.55 (0-12.1) cm2
Group II: final median area 1.95 (0-7.8) cm2
Explicitly stated no adverse events with honey; did not state for povidone iodine
Notes Honey from beehive on a neem tree, sterilized by gamma irradiation. Wounds observed
at two weekly intervals. Wounds swabbed each visit
They seem to have tested for within not between group differences for 2’ outcomes
(change scores within groups)
Funding source: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “computer generated random
numbers using block randomization were
used to develop the randomization sched-
ule”
Allocation concealment (selection bias) Low risk Quote: “The subjects were randomized
into two groups - the honey dressing group
and the povidone iodine dressing group -
with the help of numbered opaque sealed
envelopes”
Blinding (performance bias and detection
bias)
Blinding of participants? All outcomes
High risk Quote: “There was no blinding”
Blinding (performance bias and detection
bias)
Blinding of healthcare providers?All out-
comes
High risk Quote: “There was no blinding”
Blinding (performance bias and detection
bias)
Blinding of outcome assessors? All out-
High risk Quote: “There was no blinding”
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comes
Incomplete outcome data (attrition bias)
Drop-out rate described and acceptable -
All outcomes
Low risk Comment: Three people (total sample size
45) were excluded from the analysis (1 from
the honey group and 2 from the povidone
iodine group) (7% of those randomised).
This is unlikely to impact on the findings
Incomplete outcome data (attrition bias)
ITT analysis -All outcomes
Low risk Comment: Three people were excluded
from the final analysis as above. No ITT
analysis but unlikely to have had a substan-
tial impact on results
Selective reporting (reporting bias) Low risk Comment: The study protocol was not
available, but the important outcome mea-
sures stated in the methods section were re-
ported in the results
Other bias Low risk Comment: The two groups seemed com-
parable for important prognostic factors at
baseline
Ingle 2006
Methods Single-centred, 2-armed, double-blind, parallel group RCT.
Participants 87 participants with uninfected shallow wounds and abrasions recruited September
1995-July 1996.
Setting: community.
Country: South Africa.
Inclusion criteria: patients with wounds < 2 cm deep, abrasions 10 cm2-100 cm2 (in-
cluding donor sites for skin grafting and partial-thickness burns).
Exclusion criteria: patients with wounds > 100 cm2; unwilling to have an HIV test;
infected wound; genital or malignant ulcers; wounds on legs, perineum, fingers or toes
that would make measurement difficult; systemic disease; chronic alcoholism
Interventions Group 1 (n = 40; 25 shallow wounds and 15 abrasions, stratified randomisation):
monofloral (Aloe vera) honey, covered with OpSite dressing, applied daily.
Group 2 (n = 42; 25 shallow wounds 17 abrasions, stratified randomisation): hydrogel
(IntraSite), covered with OpSite dressing, applied daily.
Treatment duration: until complete healing (abrasion) or wound < 3 cm2 (shallow
wound).
Outcomes Mean time to healing (all wounds) - information supplied by authors:
Group 1: 16.48 days (SD 8.40); all wounds healed
Group 2: 16.88 days (SD 11.31); all wounds healed
Costs (average costs of dressing materials only):
Group 1: average cost per patient 0.49 Rand
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Group 2: average cost per patient 12.06 Rand
Notes Diet supplemented with zinc sulphate and vitamins A, B and C for all participants. 5
participants excluded from analysis after randomisation
Funding source: Not reported although it is noted that research presented was one of
the author’s degree dissertation
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “then randomised (using random
permuted blocks of size 10) to treatment
with either honey or IntraSite Gel”.
Comment: method of generation of ran-
dom schedule not clearly reported
Allocation concealment (selection bias) Unclear risk Comment: not stated.
Blinding (performance bias and detection
bias)
Blinding of participants? All outcomes
Low risk Quote: “A prospective, randomised, dou-
ble-blind controlled trial was carried out by
authors . . . Patients did not know which
agent was being used”.
Comment: the study is described by the
authors as double blind although quite how
blinding was maintained is not reported.
Nevertheless we have rated this as low risk
for performance bias on the basis of the
blinding
Blinding (performance bias and detection
bias)
Blinding of healthcare providers?All out-
comes
Unclear risk Quote: “A prospective, randomised, dou-
ble-blind controlled trial was carried out by
authors . . . Patients did not know which
agent was being used”.
Comment: whilst reported as double-
blind, the information given was insuffi-
cient to permit judgement as it did not
state whether the healthcare providers were
blinded
Blinding (performance bias and detection
bias)
Blinding of outcome assessors? All out-
comes
Unclear risk Quote: “A prospective, randomised, dou-
ble-blind controlled trial was carried out by
authors . . . When the healing endpoint
was approaching [KP]measured the surface
area daily, still blinded, the applied agent
from the previous day having been washed
off with normal saline”.
Comment: Both Gethin and Jull have re-
ported how it was difficult or impossible
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to blind outcome assessment due to dis-
colouration of peri-ulcer skin by honey.We
have therefore classed all studies as either
high or unclear risk for blinding of outcome
assessors.
Incomplete outcome data (attrition bias)
Drop-out rate described and acceptable -
All outcomes
Low risk Quote: “Of 87 patients enrolled, 5 were
excluded from the analysis . . . ”.
Comment: the loss to follow-up was less
than 10%, and judged to be acceptable
Incomplete outcome data (attrition bias)
ITT analysis -All outcomes
High risk Quote: “Of 87 patients enrolled, 5 were
excluded from the analysis . . .”.
Comment: ITT analysis was not done, as
5 of the 87 patients defaulted, and were not
included in the results
Selective reporting (reporting bias) Low risk Comment: the study protocol was not
available, but the important outcome mea-
sures stated in the methods section were re-
ported in the results
Other bias Low risk Quote: “The composition of the groups
did not differ significantly in terms of
recorded characteristics”.
Comment: there was no imbalance in
the baseline characteristics and the study
seemed to be free of other forms of bias
Jull 2008
Methods Multi-centred, 2-armed, parallel group RCT.
Participants 368 participants with venous (97% honey and 98% control) or mixed venous/arterial
leg ulcers recruited May 2004-September 2005. Infection levels at baseline were not
reported. The median wound size was 2.7 and 2.6 cm2 for honey and control groups
respectively, and the median duration of ulcer was 20 and 16 weeks; the Margolis index
was 0,1,2 = 46%, 37%, 17 % for both groups.
Setting: community nursing services.
Country: New Zealand.
Inclusion criteria: venous ulcer (clinical presentation + AB I > 0.8) or mixed venous/
arterial ulcer (clinical presentation + ABI > 0.7), receiving compression, able to provide
informed consent, residing in one of 4 study regions.
Exclusion criteria: diagnosis of diabetes, rheumatoid arthritis or significant peripheral
arterial disease, allergy to honey or calcium alginate, currently using honey treatment
Interventions Group 1 (n = 187): monofloral (manuka) honey-impregnated calcium alginate dressing
(ApiNate) + compression bandaging system normally available at study centre.
Group 2 (n = 181): usual care: choice of any dressing clinically indicated + compression
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system normally available at study centre
Treatment duration: until healing or 12 weeks, dressing changed with compression
Outcomes Complete healing at 12 weeks:
Group 1: 104/187 (55.6%);
Group 2: 90/181 (49.7%).
Hazard Ratio (unadjusted) 1·1 (95% CI 0·8 to 1·5); P = 0·451
Adverse events:
Group 1: 111/187
Group 2: 84/181
Incidence of infection:
Group 1: 32/187 (17.1%)
Group 2: 40/181 (22.1%)
HRQoL (SF-36, Charing Cross Venous Ulcer Questionnaire (CXVUQ), EQ-5D):
SF-36 Physical Component Summary (PCS) Mean difference 1.1 (-0.8 to 3.0); p=0.
0256
SF-36 Mental Component Summary (MCS) Mean difference 0.7 (-1.1 to 2.4); p=0.
0437
CXVUQ (overall) Mean difference -1.6 (-4.2 to 0.9); p=0.204
EQ-5D VAS Mean difference 1.6 (-1.5 to 4.7); p=0.313
Cost effectiveness:
ICER (NZD) -$9.45 ($39.63 to $16.07) in favour of honey (including hospitalizations
- 3 in Group 1 for total of 10 days vs. 6 in Group 2 for total of 40 days)
ICER (NZD) $11.34 ($-$2.24 to $26.25) in favour of usual care (excluding hospital-
izations)
Notes No difference between groups, change in ulcer area, or health-related quality of life
Funding source: Health Research Council of New Zealand and Comvita New Zealand
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “The allocation sequence was strat-
ified by study centre and Margolis index
using minimization”.
Comment: sequence generated using min-
imization technique.
Allocation concealment (selection bias) Low risk Quote: “Participants were randomly as-
signed to one of two groups by an indepen-
dent central telephone service”.
Comment: allocation concealed using an
independent central telephone service
Blinding (performance bias and detection
bias)
Blinding of participants? All outcomes
High risk Quote: “open-label, multicentre ran-
domised controlled trial was conducted”.
Comment: open label RCT, so blinding of
participants not done.
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Blinding (performance bias and detection
bias)
Blinding of healthcare providers?All out-
comes
High risk Quote: “open-label, multicentre ran-
domised controlled trial was conducted”.
Comment: open label RCT, so blinding of
healthcare providers not done
Blinding (performance bias and detection
bias)
Blinding of outcome assessors? All out-
comes
High risk Quote: “The primary outcome measure
was the proportion of participants with
completely healed reference ulcers at 12
weeks, as determined by the research nurse.
The research nurse was not blind to alloca-
tion”
Comment: primary outcome assessor not
blinded.
Incomplete outcome data (attrition bias)
Drop-out rate described and acceptable -
All outcomes
Low risk Quote: “Three hundred and sixty two (98.
4%) participants were followed up at 12
weeks. Six participants were lost to follow
up, all in the usual care group. Two partic-
ipants died (both for reasons unrelated to
treatment), three participants moved out of
the area (one to Samoa, one to England and
one within New Zealand, but could not be
traced) and one participant could not be
contacted. All participants who withdrew
from treatment with honey were followed
up at 12 weeks.”. (NB this quote comes
from p.90 of Jull’s PhD thesis).
Comment: The overall loss to follow-up
was < 10% and judged to be acceptable
Incomplete outcome data (attrition bias)
ITT analysis -All outcomes
Low risk Quote: “The primary analysis was by in-
tention to treat, with all participants in-
cluded, and participants lost to follow-up
deemed treatment failures”.
Comment: ITT analysis was done, as all
the randomised participants were included
in the final results.
Selective reporting (reporting bias) Low risk Comment: the study protocol was not
available, but the important outcome mea-
sures stated in the methods section were re-
ported in the results. The trial was regis-
tered in a publicly available trials register
(ISRCTN06161544)
Other bias Low risk Quote: “Baseline datawere similar for both
study groups”.
Comment: there was no imbalance in
the baseline characteristics and the study
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seemed to be free from other forms of bias
Kamaratos 2014
Methods Single centre, two-armed trial (alternate allocation) with 16 weeks follow up
Participants Setting: Diabetic foot ulcer clinics (outpatients) in tertiary hospital, Greece
Inclusion criteria: people with Type II diabetes and neuropathic foot ulcers of Wagner
grade I and II
Exclusion criteria: allergy to honey/bee products; end stage renal failure; serious medical
illness; chronic steroid treatment; ABPI of less than 0.9
Note - all participants had a positive swab culture at initial visit
Interventions Debridement on initial visit and when necessary thereafter.
Group I: 32 people Medihoney tulle dressing.
Group II: 31 people allocated saline soaked gauze.
Wounds dressed on daily basis initially then reducing frequency as necessary. All patients
received off loading
Outcomes Wound area (max length x max width by two independent observers in duplicate)
Swabs cultured on weekly basis.
PEDIS system for assessment of wound infection (Perfusion, Extent, Depth tissue loss,
Infection, Sensation)
Use of antibiotics.
Report number of wounds healed (healing not defined).
Results:
Group I: 31/32 completely healed
Group II: 28/31 completely healed
Negative wound swabs at 4 weeks:
Group I: 32/32
Group II: 27/31
No mention of adverse events or side effects.
Notes Themean duration of healing data have been ignored as not everyone healed and survival
methods we e not used (therefore disregarded non healers). Healing was not defined
Funding source: Diabetes Center Research Fund.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Quote: “The patients were randomly as-
signed to twogroups…Thefirst patientwas
enrolled in group I and the subsequent pa-
tients were enrolled between groups II and
I in alternating fashion”
Comment: Although in principle alternate
allocation of patients to groups may result
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in randomised groups, the sequence is en-
tirely predictable and therefore open toma-
nipulation
Allocation concealment (selection bias) High risk Quote: “The patients were randomly as-
signed to twogroups…Thefirst patientwas
enrolled in group I and the subsequent pa-
tients were enrolled between groups II and
I in alternating fashion”
Comment: The allocation was not con-
cealed and therefore at high risk of selec-
tion bias
Blinding (performance bias and detection
bias)
Blinding of participants? All outcomes
Unclear risk Comment: Not stated. Study described
as “double blind” but treating staff were
clearly aware of which dressings were be-
ing used they were merely unaware of the
protocol. Not clear the extent to which pa-
tients were aware as the dressings may have
appeared similar to them however they had
provided “written informed consent”
Blinding (performance bias and detection
bias)
Blinding of healthcare providers?All out-
comes
High risk Quote: “Preparation and application of
dressings were performed by qualified
nurses unaware of the study protocol”
Comment: This implies they could see
what the dressings were but were unaware
of the detail of the study therefore the po-
tential for performance bias is there
Blinding (performance bias and detection
bias)
Blinding of outcome assessors? All out-
comes
Unclear risk Quote: “Patients were followed up in the
outpatient diabetic foot clinic by a distinct
research team unaware of the study proto-
col”
Comment:This implies that thosemeasur-
ing wound progress did not see the dress-
ings removed or reapplied but not suffi-
ciently clear. Furthermore both Gethin and
Jull have reported how it was difficult or
impossible to blind outcome assessment
due to discolouration of peri-ulcer skin by
honey.We have therefore classed all studies
as either unclear or high risk for blinding
of outcome assessors
Incomplete outcome data (attrition bias)
Drop-out rate described and acceptable -
All outcomes
Low risk The report implies that all patients re-
mained in follow up those this is not ex-
plicitly stated
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Incomplete outcome data (attrition bias)
ITT analysis -All outcomes
Low risk The report does not specifically state that
ITT analysis was undertaken however there
do not appear to have been dropouts and it
is implied that people were analysed in the
groups to which they had been allocated
Selective reporting (reporting bias) Unclear risk The study protocol was not available.
Whilst most of the outcomes stated in the
methods section were reported in the re-
sults, the PEDIS data were not reported
Other bias Unclear risk Study report thin on detail; only base-
line comparability data are for mean ages,
HbA1c of patients in each group which
were similar.
Marshall 2005
Methods Single-centred, 2-armed, single-blind, parallel group RCT.
Participants 51 participants.
Setting: outpatient clinic.
Country: England.
Inclusion criteria: patients suitable for toenail removal (unilateral or bilateral, partial or
total) with matrix phenolisation.
Exclusion criteria: unable to give informed consent, unable to attend follow-up clinics,
peripheral vascular disease, peripheral neuropathy
Interventions Group 1 (n = 27): monofloral (jarrah) honey dressing (honey covered with gauze) daily.
Group 2 (n = 24): povidone iodine (Inadine) dressing daily.
Treatment duration: until complete epithelialisation of nail bed
Outcomes Mean time to healing:
Group 1: 33 days (SD 15.71); 23 patients
Group 2: 25days (SD 8.70); 21 patients
Notes Imbalance in numbers of diabetics in honey group compared to comparison treatment
(9 vs 4) and in total avulsions (16 vs 7) both of which favoured the comparison treatment
Funding source: Not reported - appears that a company provided some trial material
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “random tables were used to deter-
mine group allocation”.
Comment: method of generation of ran-
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dom schedule adequate.
Allocation concealment (selection bias) Low risk Quote: “Those given written informed
consent were randomly assigned to the in-
tervention groups by telephone randomi-
sation. This involved a phone call to an in-
dependent assistant located outside of the
clinical settings with no prior knowledge of
the participants”.
Comment: allocation concealed using an
independent central telephone service
Blinding (performance bias and detection
bias)
Blinding of participants? All outcomes
High risk Quote: “The study was single blind trial.
While the operating clinician and the pa-
tients could not be blinded to the interven-
tion . . .”.
Comment: blinding of participants not
done.
Blinding (performance bias and detection
bias)
Blinding of healthcare providers?All out-
comes
High risk Quote: “The study was single blind trial.
While the operating clinician and the pa-
tients could not be blinded to the interven-
tion . . .”.
Comment: blinding of healthcare
providers not done.
Blinding (performance bias and detection
bias)
Blinding of outcome assessors? All out-
comes
Unclear risk Quote: “ . . . the outcome assessor was un-
aware of group allocation”.
Comment: although outcome assessors
were described as blinded to treatment, at
least two trialists (Gethin and Jull) have re-
ported that discolouration of the peri-ulcer
skin by honey unblinds the outcome asses-
sors so we have graded as unclear risk
Incomplete outcome data (attrition bias)
Drop-out rate described and acceptable -
All outcomes
High risk Quote: “A total of 7/51 participants with-
drew from the trial: 4/27 in the honey
group, of which 2/4 were lost to follow up
and 2/4 were withdrawn due to non-com-
pliance. In the iodine group, 3/24 with-
drew from the trial; 1/3 lost to follow up,
1/3 withdrawn for non-compliance, and 1/
3 required further surgical intervention.”
Comment: reasons for drop-outs were
given, but the rate was > 10%, and judged
to be unacceptable
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Incomplete outcome data (attrition bias)
ITT analysis -All outcomes
High risk Quote: “All the seven participants were ex-
cluded from the primary analysis.”
Comment: ITT analysis not done, as the
randomised participants were not all in-
cluded in the final analyses
Selective reporting (reporting bias) Low risk Comment: the study protocol was not
available, but the important outcome mea-
sures stated in the methods section were re-
ported in the results
Other bias High risk Quote: “In respect of prognostic factors
randomisation allocatedmore patients who
smoked (7 vs 3), and more patients with
diabetes (9 vs 4) to the honey group”.
Comment: there was baseline imbalance
with respect to demographics, as more par-
ticipants who smoked and had diabetes
were allocated to the honey group and there
were more total avulsions in the honey
group (16 vs 7)
Mashood 2006
Methods Single-centered, 2-armed, parallel group RCT.
Participants 50 participants recruited September 2002-August 2003.
Setting: hospital.
Country: Pakistan.
Inclusion criteria: patients of all ages who sustained superficial and partial-thickness
burns of < 15% TBSA, and with no co-morbidities present.
Exclusion criteria: patients with deep burns and those who sustained burns of > 15%
TBSA, whether was superficial or deep
Interventions Group 1 (n = 25): honey (pure, undiluted, unprocessed; covered with gauze), applied
daily.
Group 2 (n = 25): 1% SSD (cream covered with gauze), applied daily.
Treatment until healed.
Duration of follow-up: 6 months.
Outcomes Complete healing in weeks:
Group 1: 2 weeks = 13/25, 4 weeks = 25/25;
Group 2: 2 weeks = 5/25, 4 weeks = 15/25, 6 weeks = 25/25.
Cost of treatment/% TBSA:
Group 1: 0.75 Rupees (5ml honey)
Group 2: 10 Rupees (2g SSD)
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Notes Patientswith deep partial-thickness burnswere included.The authors have not responded
to requests for additional information
Funding source: not reported.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “They were randomly assigned to
two groups. Each group contained 25 pa-
tients”.
Comment: method of generating the ran-
dom sequence not reported.
Allocation concealment (selection bias) Unclear risk Comment: not stated.
Blinding (performance bias and detection
bias)
Blinding of participants? All outcomes
Unclear risk Comment: not stated.
Blinding (performance bias and detection
bias)
Blinding of healthcare providers?All out-
comes
Unclear risk Comment: not stated.
Blinding (performance bias and detection
bias)
Blinding of outcome assessors? All out-
comes
Unclear risk Comment: not stated.
Incomplete outcome data (attrition bias)
Drop-out rate described and acceptable -
All outcomes
Low risk Comment: Tables 1 and 2 show that there
were no drop-outs; all the randomised par-
ticipants were followed-up
Incomplete outcome data (attrition bias)
ITT analysis -All outcomes
Low risk Comment: ITT analysis was not reported,
but since no drop-outs were reported, and
all the randomised participants completed
the study, ITTanalysiswas assumed tohave
been done and to be acceptable.
Selective reporting (reporting bias) Low risk Comment: the study protocol was not
available, but the important outcome mea-
sures stated in the methods section were re-
ported in the results
Other bias Unclear risk Comment: the baseline characteristics
were not reported, so there was insufficient
information to judgewhether any other im-
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portant form of bias existed
McIntosh 2006
Methods Single-centred, 2-armed, double-blind, parallel group RCT.
Participants 100 participants.
Setting: outpatient clinic.
Country: England.
Inclusion criteria: patients suitable for toenail surgery (unilateral or bilateral, partial or
total) with matrix phenolisation.
Exclusion criteria: age < 16 years, unable to give informed consent, unable to attend
follow-up clinics, communication barriers, unsuitable for toenail surgery (patients with
peripheral vascular disease, unstable diabetes, or where local anaesthetic was contra-
indicated)
Interventions Group 1 (n = 52): monofloral (manuka) honey-impregnated calcium alginate dressing
(ApiNate) twice weekly.
Group 2 (n = 48): paraffin-impregnated gauze (Jelonet), twice weekly
Treatment duration: until healed.
Outcomes Mean time to healing:
Group 1: 40.30 days (SD 18.21); 47 patients analysed
Group 2: 39.98 days (SD 25.42); 40 patients analysed
Notes Funding source: not reported but declarations of interest are noted as ’none’
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Random tables were used to de-
termine intervention allocation”.
Comment: method of generation of ran-
dom schedule adequate.
Allocation concealment (selection bias) Low risk Quote: “Participants were assigned to in-
tervention groups by remote randomisa-
tion. This involved a telephone call to an
independent assistant located outside of the
study setting who had no prior knowledge
of the participants”.
Comment: allocation concealed using an
independent central telephone service
Blinding (performance bias and detection
bias)
Blinding of participants? All outcomes
Low risk Quote: “This was a double blind study.
Both the outcomes assessors and par-
ticipants were blind to the intervention
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throughout. Removal and application of all
dressings were performed in a treatment
group with only the investigator and par-
ticipant present; a screen concealed the par-
ticipant’s feet during dressing removal and
application”.
Comment: blinding of participants was
done.
Blinding (performance bias and detection
bias)
Blinding of healthcare providers?All out-
comes
High risk Quote: “Removal and application of all
dressings were performed in a treatment
group with only the investigator and par-
ticipant present”.
Comment: blinding of healthcare
providers not done.
Blinding (performance bias and detection
bias)
Blinding of outcome assessors? All out-
comes
Unclear risk Quote: “This was a double blind study.
Both the outcomes assessors and par-
ticipants were blind to the intervention
throughout ... All evidence of the interven-
tion was removed and wounds were irri-
gated before the outcome assessors entered
the room”.
Comment: Both Gethin and Jull have re-
ported how it was difficult or impossible
to blind outcome assessment due to dis-
colouration of peri-ulcer skin by honey.We
have therefore classed all studies as either
unclear or high risk for blinding of outcome
assessors.
Incomplete outcome data (attrition bias)
Drop-out rate described and acceptable -
All outcomes
High risk Quote: “A total of 13/100 participants
withdrew from the trial: 5/52 from the
honey group (one was lost to follow-up
and four withdrew because of non-concor-
dance) and 8/48 from the paraffin tulle gras
group (five were lost to follow-up and three
withdrew due to non-concordance)”.
Comment: Reasons for drop-outs were
given, but the rate was more than 10% and
judged to be unacceptable
Incomplete outcome data (attrition bias)
ITT analysis -All outcomes
High risk Quote: “All 13 withdrawals were excluded
from primary analyses”.
Comment: ITT analysis not done, as not
all the randomised participants were in-
cluded in the final analyses
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Selective reporting (reporting bias) Low risk Comment: the study protocol was not
available, but the important outcome mea-
sures stated in the methods section were re-
ported in the results
Other bias Unclear risk Quote: “There were disparities in baseline
demographics. Established prognostic fac-
tors differed between groups: more smok-
ers were assigned to the paraffin tulle gras
group, and more diabetics to the honey
group.”.
Comment: whilst the study report stated
that there were more smokers assigned to
the paraffin tulle gras group, the data in
Table 1 (baseline demographics) indicates
that slightly more smokers were assigned to
the honey group but the difference was not
great and unlikely to impact on the results
(33% of the honey group were smokers in
Table 1 vs 27% of the control group).
Memon 2005
Methods Single-centred, 2-armed, parallel group RCT.
Participants 80 participants with superficial-dermal, mid-dermal or deep-dermal burns recruited
January 2002-December 2003.
Setting: hospital.
Country: Pakistan.
Inclusion criteria: age 4-62 years, TBSA burnt 10-40%.
Exclusion criteria: patients with chemical or electrical burns, superficial burns, full-
thickness burns or burns involving > 40% TBSA
Interventions Group 1 (n = 40): natural, unprocessed honey-gauze dressings every other day
Group 2 (n = 40): SSD-dressings (SSD cream covered with occlusive dressing) every
other day.
Treatment duration: not reported.
Follow-up duration: until healed.
Outcomes Number healed:
Group 1: by day 16 (n = 20), by day 26 (n = 12), by day 30 (n = 8). Mean 15.3 days (no
SD).
Group 2: by day 20 (n = 16), by day 36 (n = 18), by day 46 (n = 6). Mean 20.0 days (no
SD)
Notes The authors have not responded to requests for additional information
Funding source: not reported.
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “The patients were allotted at ran-
dom in two different groups”.
Comment: in addition, it was reported in
the abstract that the design was “a quasi-
experimental study”. The method for gen-
erating the random sequence was not re-
ported
Allocation concealment (selection bias) Unclear risk Comment: not stated.
Blinding (performance bias and detection
bias)
Blinding of participants? All outcomes
Unclear risk Comment: not stated.
Blinding (performance bias and detection
bias)
Blinding of healthcare providers?All out-
comes
Unclear risk Comment: not stated.
Blinding (performance bias and detection
bias)
Blinding of outcome assessors? All out-
comes
Unclear risk Comment: not stated.
Incomplete outcome data (attrition bias)
Drop-out rate described and acceptable -
All outcomes
Low risk Comment: Tables 4 and 5 showed there
were no drop-outs; all the randomised par-
ticipants were followed-up
Incomplete outcome data (attrition bias)
ITT analysis -All outcomes
Low risk Comment: ITT analysis was not reported,
but since no drop-outs were reported and
all the randomised participants completed
the study, ITTanalysiswas assumed tohave
been done and to be acceptable.
Selective reporting (reporting bias) Low risk Comment: the study protocol was not
available, but the important outcome mea-
sures stated in the methods section were re-
ported in the results
Other bias Unclear risk Comment: there was some baseline imbal-
ance in baseline characteristics. More par-
ticipants with burns to 16-25%TBSAwere
randomised to the SSD group (20 (50%)
vs 14 (35%)). The honey group had more
60Honey as a topical treatment for wounds (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Memon 2005 (Continued)
participants with burns 10-15% TBSA (18
(45%) vs 12 (30%). More participants in
the SSD group had deep-dermal burns (20
(50%) vs 16 (40%)), whereas more partic-
ipants in the honey group had superficial-
dermal burns (18 (45%) vs 12 (30%))
Mphande 2007
Methods Single-centred, 2-armed, quasi-randomised controlled trial.
Participants 40 participants with open or infected wounds (chronic osteomyelitis n = 7, post-surgical
n = 14, ulcer n = 8, trauma n = 9, abscess n = 2) recruited February-November 2005.
Setting: hospital with outpatient follow-up.
Country: Malawi.
Inclusion criteria: not reported.
Exclusion criteria: lived too far from hospital for follow-up
Interventions Group 1 (n = 22): honey-soaked gauze daily; frequency reduced after 1 week if wound
healing progressing.
Group 2 (n = 18): sugar covered with gauze dressing; frequency reduced after 1 week if
wound healing progressing.
Treatment duration: not reported.
Follow up duration: not reported.
Outcomes Median time to complete healing:
Group 1: 31.5 days (no SD);
Group 2: 56.0 days (no SD).
Notes Funding source: not reported but declarations of interest are noted as ’none’
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Quote: “Patients were randomised to re-
ceive a honey or sugar dressing. They were
allocated to one of the two groups on an
alternating basis at admission”.
Comment:method of generating sequence
was not random and, therefore, not ade-
quate
Allocation concealment (selection bias) High risk Quote: “They were allocated to one of the
two groups on an alternating basis at ad-
mission”.
Comment: allocation was judged to have
been inadequately concealed, as alternation
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was used
Blinding (performance bias and detection
bias)
Blinding of participants? All outcomes
Unclear risk Comment: not stated.
Blinding (performance bias and detection
bias)
Blinding of healthcare providers?All out-
comes
Unclear risk Comment: not stated.
Blinding (performance bias and detection
bias)
Blinding of outcome assessors? All out-
comes
Unclear risk Comment: not stated.
Incomplete outcome data (attrition bias)
Drop-out rate described and acceptable -
All outcomes
Unclear risk Comment: the study did not state whether
there were any drop-outs, or whether all the
randomised participants were followed-up
Incomplete outcome data (attrition bias)
ITT analysis -All outcomes
Unclear risk Comment: no drop outs or withdrawals
were reported. The total numbers of partic-
ipants assessed were also not reported. We
cannot judge whether an ITT analysis was
conducted
Selective reporting (reporting bias) Low risk Comment: the study protocol was not
available, but the important outcome mea-
sures stated in the methods section were re-
ported in the results
Other bias Unclear risk Quote: “The honey group comprised 22
patients (13 males and nine females) with
a mean age of 12.7 years (range 1-39).
The sugar group comprised 18 patients (12
males and six females) with a mean age of
13.8 years (range 3-53).There was a range
of causes of wounds, but their distribution
was similar between the two groups.”.
Comment: age, sex and types of wounds
similar between the two groups, but no in-
formation was reported on other baseline
characteristics
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Methods Single-centred, 2-armed, parallel group RCT.
Participants 100 participants with confirmed cutaneous Leishmaniasis.
Setting: skin disease and Leishmaniasis research centre.
Country: Iran.
Inclusion criteria: patients with confirmed cutaneous Leishmaniasis with direct smear,
no history of systemic or topical therapy for cutaneous Leishmaniasis, absence of malnu-
trition or severe predisposing disease such as cardiac, renal or hepatic disease and other
contraindication for glucantime.
Exclusion criteria: pregnant and lactating women, lesions < 3 months old, and patients
treated with drugs that interact with glucantime
Interventions Group 1 (n = 45): intralesional injection of meglumine antimoniate (glucantamine) once
weekly and dressed with honey-soaked gauze twice daily.
Group 2 (n = 45): intralesional injection of meglumine antimoniate (glucantamine) once
weekly.
Treatment duration:until complete healing of wounds, or maximum 6 weeks
Outcomes Complete healing:
Group 1: 23/45 (51.1%);
Group 2: 32/45 (71.1%).
Mean time to healing in days:
Group 1: 7.04 (± 3.09);
Group 2 : 6.30 (± 2.29)
However because not all participants healed, the mean time to healing data cannot be
used
Notes This RCT reported that, initially, 100 patients were confirmed with cutaneous Leish-
maniasis and were randomised into two groups. Further on, in the results section of the
abstract, the authors report that each group had 45 patients and stated that 10 patients
left the study. They also reported that 23 patients in the honey-treated group achieved
complete cure, whilst in the glucantime alone group 32 patients achieved complete cure.
13 patients from the honey-treated group left the study, as did 10 patients from the
glucantime group.
Funding source: Skin Disease and Leishmaniasis Research Center
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “The patients were randomised
into 2 groups, using Random allocation
software. (version 1.0, may 2004; Saghaei)
”.
Comment: method of generation of ran-
dom sequence adequate.
Allocation concealment (selection bias) Unclear risk Comment: not stated.
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Blinding (performance bias and detection
bias)
Blinding of participants? All outcomes
High risk Comment: not stated. However the differ-
ence in the interventions means that blind-
ing unlikely
Blinding (performance bias and detection
bias)
Blinding of healthcare providers?All out-
comes
High risk Comment: not stated. However the differ-
ence in interventions means that blinding
unlikely
Blinding (performance bias and detection
bias)
Blinding of outcome assessors? All out-
comes
Unclear risk Quote: “If the patients had not achieved
complete healing after 6 weeks of the treat-
ment, direct smear and culture were per-
formed
again. Diameter of the lesion and size of the
erythema, induration and ulcer were mea-
sured by use of themillimeter papers. These
evaluation performed by the investigators
whowere blinded to the type of treatment”.
Comment:The paper is ambiguously writ-
ten and could mean that outcome assessors
were only blinded after 6 weeks. Further-
more both Gethin and Jull have reported
how it was difficult or impossible to blind
outcome assessment due to discolouration
of peri-ulcer skin by honey. We have there-
fore classed all studies as either unclear or
high risk for blinding of outcome assessors
Incomplete outcome data (attrition bias)
Drop-out rate described and acceptable -
All outcomes
High risk Quote: “Overall, in the topical honey
treated group, 13 [out of 45] patients left
out [sic] the study. One patient (7.7%) left
out the study because of contact dermati-
tis to honey and 12 patients left out of the
study because of progression of their le-
sions. In the glucantime treated group, 10
patients [out of 45] left out [sic] the study
because of progression of their lesions”.
Comment: reasons for drop-outs provided,
but the rate was > 10%, and judged to be
unacceptable
Incomplete outcome data (attrition bias)
ITT analysis -All outcomes
High risk Comment: the study stated that 100 par-
ticipants were randomised, but there were
only 45 included in each arm (see table
1 baseline demography). Percentages were
inaccurate because the denominators used
were 45
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Selective reporting (reporting bias) Low risk Comment: the study protocol was not
available, but the important outcome mea-
sures stated in the methods section were re-
ported in the results
Other bias Unclear risk Comment: age, sex, number and location
of lesions similar between the two groups,
but no information reported on potentially
prognostic baseline characteristics, such as
size of lesions
Robson 2009
Methods Single-centred, parallel group, open-label RCT.
Participants 105 participants recruited September 2004-May 2007.
Patients comprised: 73/105 with leg ulcers (69.5%); 15/105 with breast wounds (14.
3%); 17/105 with “other” types of wound including donor sites, foot ulcers and surgical
wounds (16.2%).
Setting: large district hospital.
Country: United Kingdom.
Inclusion criteria: patients with a wound healing by secondary intention.
Exclusion criteria: patients with: diabetes, history of neuroses, psychoses or dementia,
known allergy to bee/honey products, venous ulcers of < 12 week duration, Grade 1 or
Grade 4 pressure ulcers (EPUAP grades), wounds containing exposed tendon, muscle or
bone, or wounds where malignancy was present or suspected; patients with an existing
wound infection requiring systemic antibiotics and those who had received antibiotic
therapy in the preceding 2 weeks
Interventions Group 1 (n = 52): manuka honey covered with low adherent dressing plus compression
where clinically indicated.
Group 2 (n = 53): conventional treatment; if wounds had slough or necrosis, they were
treated with hydrogel; compression when indicated
Duration of treatment 24 weeks.
Outcomes Healing rate at 24 weeks:
Group 1: 38/52 (72.7%);
Group 2: 34/53 (63.3%).
Healing rate at 12 weeks:
Group 1: 24/52 (46.2%);
Group 2: 18/53 (34.0%).
Unadjusted hazard ratio for healing (HR) 1.30 (0.77 to 2.19)
Adjusted for sex, wound type, age andwound area at start of treatment:HR1.51 (95%CI
0.88 to 2.58)
Notes 52 patients were randomized to receive honey and 53 to receive conventional treatment. 2
patients randomized to the honey group (3.8%) did not receive honey (1 as a result of the
patient’s decision, 1 as a result of a clinical decision), and 6 allocated to the conventional
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treatment group (11.3%) received honey (all except 1 as a result of a clinician’s decision)
Funding source: Aintree University Hospitals NHS Foundation Trust,The Florence
Nightingale Trust and Huntleigh
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Allocation to treatment was deter-
mined using blocked randomisation (with
sequence produced using computer soft-
ware (STATA version 8.2; StataCorp, Col-
lege \station, TX, USA) with randomly
varying block size), stratified by two fac-
tors, age (< 40 and ≥ 40 year old) and size
of wound (< 10 and ≥ 10 cm2)”.
Comment: method of generation of ran-
dom schedule adequate.
Allocation concealment (selection bias) Low risk Quote: “Sealed, opaque, serially numbered
envelopes were produced from the ran-
domisation sequence for each stratum sepa-
rately, and an independent third party with
access to the envelopes was contacted by
telephone to determine treatment alloca-
tion as patients were recruited”.
Comment: allocation concealed using
sealed, opaque, serially numbered en-
velopes and an independent central tele-
phone service
Blinding (performance bias and detection
bias)
Blinding of participants? All outcomes
High risk Quote: “The study was designed as a single
centre, open-label, randomized controlled
trial”.
Comment: open label RCT, so blinding of
participants not done.
Blinding (performance bias and detection
bias)
Blinding of healthcare providers?All out-
comes
High risk Quote: “The study was designed as a single
centre, open-label, randomized controlled
trial”.
Comment: open label RCT, so blinding of
healthcare providers not done
Blinding (performance bias and detection
bias)
Blinding of outcome assessors? All out-
comes
High risk Quote: “The study was designed as a single
centre, open-label, randomized controlled
trial”.
Comment: open label RCT, so blinding of
outcome assessors not done.
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Incomplete outcome data (attrition bias)
Drop-out rate described and acceptable -
All outcomes
Low risk Quote: “One patient in the honey group
(1.9%)was lost to followup (as theymoved
to an alternative hospital) and one patient
died in each group (1.9% in each group)”.
Comment: The three patients who were
lost to follow up were included in the anal-
ysis until they were lost. The small num-
bers are unlikely to impact on the results
Incomplete outcome data (attrition bias)
ITT analysis -All outcomes
Low risk Quote: “Statistical analysis was carried out
on an intention to treat (ITT) basis, retain-
ing patients in their randomised treatment
groups regardless of the actual treatment re-
ceived and including protocol violators and
ineligible patients”.
Comment: ITT analysis was done, as all
the randomised participants were included
in the final results
Selective reporting (reporting bias) Low risk Comment: the study protocol was not
available, but the important outcome mea-
sures stated in the methods section were re-
ported in the results
Other bias Low risk Comment: there was no imbalance in
the baseline characteristics, and the study
seemed to be free from other forms of bias
Shukrimi 2008
Methods Single-centered, 2-armed, parallel group RCT.
Participants 30 participants.
Setting: hospital.
Country: Malaysia.
Inclusion criteria: all non-Insulin dependent diabetes mellitus patients (NIDDM) with
Wagner grade II ulcers who were admitted for surgery were enrolled if the following
parameters were met: age 35-65, transcutaneous oxygen tension > 30 mmHg and serum
albumin level of > 35 g/dl.
Exclusion criteria: multiple medical co-morbidity, steroid therapy, neutrophil count <
2000/mm3
Interventions Group 1: clean non-sterile pure honey (for food), covered with gauze, applied daily.
Group 2: povidone-iodine soaked gauze applied daily.
Duration: until wound closure.
Outcomes Mean time to readiness for surgical closure or further debridement:
Group 1: 14.4 (no SD; range 7 to 26 days);
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Group 2: 15.4 (no SD; range 9 to 36 days).
Notes The study did not state the number of participants randomised to each arm, or the
percentage of wounds healed in each group
Funding source: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “The patients were randomised to
two dressing arms; honey dressing group
and standard dressing group”.
Comment: method of generating the ran-
dom schedule not reported.
Allocation concealment (selection bias) Unclear risk Comment: not stated.
Blinding (performance bias and detection
bias)
Blinding of participants? All outcomes
Unclear risk Comment: not stated.
Blinding (performance bias and detection
bias)
Blinding of healthcare providers?All out-
comes
Unclear risk Comment: not stated.
Blinding (performance bias and detection
bias)
Blinding of outcome assessors? All out-
comes
Unclear risk Quote: “All the wounds were assessed ev-
ery other day by a surgeon blinded to the
material of dressing”.
Comment: Both Gethin and Jull have re-
ported how it was difficult or impossible
to blind outcome assessment due to dis-
colouration of peri-ulcer skin by honey.We
have therefore classed all studies as either
unclear or high risk for blinding of outcome
assessors
Incomplete outcome data (attrition bias)
Drop-out rate described and acceptable -
All outcomes
Unclear risk Comment: the study did not report the
numbers allocated to each treatment, drop-
outs, or state whether all the randomised
participants were followed-up
Incomplete outcome data (attrition bias)
ITT analysis -All outcomes
Unclear risk Comment: the study did not report the
numbers allocated to each treatment, drop-
outs or withdrawals. The total numbers
of participants assessed were not reported
either. We cannot judge whether an ITT
analysis was conducted
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Selective reporting (reporting bias) Low risk Comment: the study protocol was not
available, but the important outcome mea-
sures stated in the methods section were re-
ported in the results
Other bias Unclear risk Comment: the baseline characteristics
were not reported, so there was insufficient
information to judge whether any impor-
tant form of bias existed
Subrahmanyam 1991
Methods Single-centred, 2-armed, parallel group RCT.
Participants 104 participants with burns < 40% TBSA (mean 26.5 and 27.2%) recruited July 1988-
December 1989. 43/50 and 41/52 had positive swab cultures at baseline
Setting: hospital.
Country: India.
Inclusion criteria: superficial burns.
Exclusion criteria: not reported.
Interventions Group 1 (n = 52): unprocessed, undiluted honey dressings (pure undiluted unprocessed
honey covered with gauze); applied daily.
Group 2 (n = 52): SSD-impregnated gauze daily.
Treatment duration: until healed.
Outcomes Mean time to healing:
Group 1: 9.4 days (SD 2.3);
Group 2: 17.2 days (SD 3.2).
Notes Information on allocationmethod, allocation concealment, blinding, meanTBSA,mean
time to healing and standard deviation for mean time to healing were provided by the
author
Funding source: not reported.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “The cases were allocated at ran-
dom to two groups”.
Comment: method of generating random
sequence not reported. Author provided in-
formation that the sequence was generated
by the “chit method”, which is a method
of drawing lots however the information
provided was minimal and lacked detail to
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sufficiently reassure us that themethod was
truly random
Allocation concealment (selection bias) Unclear risk Comment: not stated, but author provided
information that allocation concealment
was by means of sequentially-numbered,
sealed envelopes, although it is not clear
whether the envelopes were opaque
Blinding (performance bias and detection
bias)
Blinding of participants? All outcomes
High risk Comment: not stated in study report, but
author responded to request for further in-
formation by stating the patients were not
blinded
Blinding (performance bias and detection
bias)
Blinding of healthcare providers?All out-
comes
Unclear risk Comment: not stated in study report, but
author responded to request for further
information by stating the investigators
and outcome assessors were blinded. Both
Gethin and Jull have reported how it was
difficult or impossible to blind outcome as-
sessment due to discolouration of peri-ul-
cer skin by honey.We have therefore classed
all as unclear risk for blinding of outcome
assessors
Blinding (performance bias and detection
bias)
Blinding of outcome assessors? All out-
comes
Unclear risk Comment: not stated in study report, but
author responded to request for further
information by stating the investigators
and outcome assessors were blinded. How
blinding was achieved was not described
in the response. However both Gethin and
Jull have reported how it was difficult or
impossible to blind outcome assessment
due to discolouration of peri-ulcer skin by
honey.We have therefore classed all studies
as at either unclear or high risk for blinding
of outcome assessors
Incomplete outcome data (attrition bias)
Drop-out rate described and acceptable -
All outcomes
Low risk Comment: Table 2 showed there were no
drop-outs, and that all the randomised par-
ticipants were followed-up
Incomplete outcome data (attrition bias)
ITT analysis -All outcomes
Low risk Comment: ITT analysis was not reported,
but since no drop-outs were reported, and
all the randomised participants completed
the study, ITTanalysiswas assumed tohave
been done and to be acceptable.
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Selective reporting (reporting bias) Low risk Comment: the study protocol was not
available, but the important outcome mea-
sures stated in the methods section were re-
ported in the results
Other bias Low risk Comment: there was no imbalance in base-
line characteristics, and the study seemed
to be free from other forms of bias
Subrahmanyam 1993a
Methods Single-centred, 2-armed, parallel group RCT.
Participants 92 participants with burns < 40% TBSA (mean 22.8 and 22,6%) recruited January
1990-January 1991. 10/46 and 9/46 had positive swab cultures at baseline.
Setting: hospital.
Country: India.
Inclusion criteria: treated within 6 h of injury, partial-thickness burns.
Exclusion criteria: not reported.
Interventions Group 1 (n = 46): unprocessed, undiluted, honey-impregnated gauze, changed on day
2 and then alternate days.
Group 2 (n = 46): polyurethane film (OpSite) left intact until day 8, unless evidence of
infection, excessive exudate or leakage.
Treatment duration: until healed.
Outcomes Mean time to healing:
Group 1: 10.8 days (SD 3.93);
Group 2: 15.3 days (SD 2.98).
Notes Information on allocationmethod, allocation concealment, blinding, meanTBSA,mean
time to healing and standard deviation for mean time to healing provided by author
Funding source: not reported.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “After initial management, patients
were allotted at random to two groups”.
Comment: method of generation of ran-
dom sequence not reported. Author in-
formed us that the sequence was generated
by the “chit method”, which is a method
of drawing lots however the detail provided
by the authors was minimal and not suffi-
cient to reassure us that the sequence was
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truly random
Allocation concealment (selection bias) Unclear risk Comment: not stated, but author provided
information that allocation concealment
was via sequentially-numbered sealed en-
velopes, although it is not clear whether the
envelopes were opaque
Blinding (performance bias and detection
bias)
Blinding of participants? All outcomes
High risk Comment: not stated in study report, but
author responded to request for further in-
formation by stating the investigators and
outcome assessorswere blinded, but not pa-
tients
Blinding (performance bias and detection
bias)
Blinding of healthcare providers?All out-
comes
Unclear risk Comment: not stated in study report, but
author responded to request for further
information by stating the investigators
and outcome assessors were blinded. Both
Gethin and Jull have reported how it was
difficult or impossible to blind outcome as-
sessment due to discolouration of peri-ul-
cer skin by honey.We have therefore classed
all as unclear risk for blinding of outcome
assessors
Blinding (performance bias and detection
bias)
Blinding of outcome assessors? All out-
comes
Unclear risk Comment: not stated in study report, but
author responded to request for further in-
formation by stating the investigators and
outcome assessors were blinded. However
both Gethin and Jull have reported how
honey stained the peri-ulcer skin making
blinding of outcome assessment difficult
and we have therefore rated all studies as at
either unclear or high risk of detection bias
Incomplete outcome data (attrition bias)
Drop-out rate described and acceptable -
All outcomes
Low risk Comment: Table 1 showed that there were
no drop-outs, and that all the randomised
participants were followed-up
Incomplete outcome data (attrition bias)
ITT analysis -All outcomes
Low risk Comment: ITT analysis was not reported,
but since no drop-outs were reported, and
all the randomised participants completed
the study, ITTanalysiswas assumed tohave
been done and to be acceptable.
Selective reporting (reporting bias) Low risk Comment: the study protocol was not
available, but the important outcome mea-
sures stated in the methods section were re-
ported in the results
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Other bias Unclear risk Comment: few baseline characteristics
were reported, so there was insufficient in-
formation available to judge whether any
important form of bias existed
Subrahmanyam 1993b
Methods Single-centred, 2-armed, parallel group RCT.
Participants 100 participants with burns or ulcers (27 old burns, 23 fresh burns, 20 traumatic ulcers,
14 bed sores, 8 diabetic ulcers, 6 varicose ulcers, 2 trophic ulcers), recruited January
1989-January 1990. 43/50 and 41/50 had positive swabs at baseline
Setting: hospital.
Country: India.
Inclusion criteria: not reported.
Exclusion criteria: not reported.
Interventions Group 1 (n = 50): unprocessed, undiluted, honey, covered with gauze daily.
Group 2 (n = 50): SSD-impregnated gauze daily.
Treatment duration: until healed.
Outcomes Mean time to healing:
Group 1: 9.5 days (SD 6.2);
Group 2: 22.5 days (SD 5.2).
Notes Information on allocation method, allocation concealment, blinding, mean time to
healing and standard deviation for mean time to healing provided by author
Funding source: not reported.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Patients were divided into two
groups and they were distributed at ran-
dom”.
Comment: method of generating random
sequence was not reported. Author pro-
vided information that the sequence was
generated by the “chit method”, which is a
method of drawing lots, however the infor-
mation supplied by the author lacked detail
and was insufficient for us to judge whether
the sequence was truly random
Allocation concealment (selection bias) Unclear risk Comment: not stated, but author provided
information that allocation concealment
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was by means of sequentially-numbered,
sealed envelopes, although it is not clear
whether the envelopes were opaque
Blinding (performance bias and detection
bias)
Blinding of participants? All outcomes
High risk Comment: not stated in study report, but
author responded to request for further in-
formation by stating the investigators and
outcome assessorswere blinded, but not pa-
tients
Blinding (performance bias and detection
bias)
Blinding of healthcare providers?All out-
comes
Unclear risk Comment: not stated in study report, but
author responded to request for further
information by stating the investigators
and outcome assessors were blinded. How
blinding was achieved was not described in
the response
Blinding (performance bias and detection
bias)
Blinding of outcome assessors? All out-
comes
Unclear risk Comment: not stated in study report, but
author responded to request for further
information by stating the investigators
and outcome assessors were blinded. How
blinding was achieved was not described in
the response. Both Gethin and Jull have re-
ported how it was difficult or impossible
to blind outcome assessment due to dis-
colouration of peri-ulcer skin by honey.We
have therefore classed all studies as at either
unclear or high risk of detection bias
Incomplete outcome data (attrition bias)
Drop-out rate described and acceptable -
All outcomes
Low risk Comment: Table 3 showed there were no
drop-outs, and that all the randomised par-
ticipants were followed-up
Incomplete outcome data (attrition bias)
ITT analysis -All outcomes
Low risk Comment: ITT analysis was not reported,
but since no drop-outs were reported, and
all the randomised participants completed
the study, ITTanalysiswas assumed tohave
been done and to be acceptable.
Selective reporting (reporting bias) Low risk Comment: the study protocol was not
available, but the important outcome mea-
sures stated in the methods section were re-
ported in the results
Other bias Unclear risk Comment: there was no baseline imbal-
ance with respect to patients’ age between
two groups, however, other baseline char-
acteristics were not reported, so there was
insufficient information to judge whether
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any important risk of bias existed
Subrahmanyam 1994
Methods Single-centred, 2-armed, parallel group RCT.
Participants 100 participants with partial-thickness burns; TBSA mean 18.5 and 19.4%; treated
within 6h of burn; recruited June 1991-July 1992. 28/40 (70%) and 19/24 (79%) had
positive swabs at baseline
Setting: hospital.
Country: India.
Inclusion criteria: treated within 6 h of injury, TBSA burnt < 40%.
Exclusion criteria: not reported.
Interventions Group 1 (n = 40): unprocessed, undiluted, honey-impregnated gauze changed every 2nd
day.
Group 2 (n = 24): amniotic membrane left intact until day 8, and then changed every
2nd day.
Treatment duration: until healed.
Outcomes Mean time to healing:
Group 1: 9.4 days (SD 2.52);
Group 2: 17.5 days (SD 6.66).
Notes Information about allocation method, allocation concealment, blinding, and standard
deviation for mean time to healing provided by author
Funding source: not reported.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “After initial treatment, patients
were allotted to two groups at random”.
Comment: method of generating the ran-
dom sequence not reported. Author pro-
vided information that the sequence was
generated by the “chit method”, which is a
method of drawing lots however the infor-
mation provided was minimal and lacked
detail to sufficiently reassure us that the
method was truly random
Allocation concealment (selection bias) Unclear risk Comment: not stated, but author provided
information that allocation concealment
was by means of sequentially-numbered,
sealed envelopes, although it is not clear
whether the envelopes were opaque
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Blinding (performance bias and detection
bias)
Blinding of participants? All outcomes
High risk Comment: not stated in study report, but
author responded to request for further in-
formation by stating the patients were not
blinded
Blinding (performance bias and detection
bias)
Blinding of healthcare providers?All out-
comes
Low risk Comment: not stated in study report, but
author responded to request for further in-
formation by stating the investigators and
outcome assessors were blinded
Blinding (performance bias and detection
bias)
Blinding of outcome assessors? All out-
comes
Unclear risk Comment: not stated in study report, but
author responded to request for further
information by stating the investigators
and outcome assessors were blinded. How
blinding was achieved was not described in
the response. Both Gethin and Jull have re-
ported how it was difficult or impossible
to blind outcome assessment due to dis-
colouration of peri-ulcer skin by honey.We
have therefore classed all studies as at either
unclear or high risk of detection bias
Incomplete outcome data (attrition bias)
Drop-out rate described and acceptable -
All outcomes
Low risk Comment: Tables 2 and 3 show that there
were no drop-outs, all the randomised par-
ticipants were followed-up
Incomplete outcome data (attrition bias)
ITT analysis -All outcomes
Low risk Comment: ITT analysis was not reported,
but since no drop-outs were reported, and
all the randomised participants completed
the study, ITTanalysiswas assumed tohave
been done and to be acceptable.
Selective reporting (reporting bias) Low risk Comment: the study protocol was not
available, but the important outcome mea-
sures stated in the methods section were re-
ported in the results
Other bias Low risk Comment: there was no imbalance in
the baseline characteristics, and the study
seemed to be free from other risk of bias
Subrahmanyam 1996a
Methods Single-centred, 2-armed, parallel group RCT.
Participants 900 participants with partial-thickness burns recruited July 1987-December 1993, 90%
within 6h of burn. TBSAmean 24.5 and 26.2%; wound infections at baseline not stated.
Setting: hospital.
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Country: India.
Inclusion criteria: TBSA burnt < 40%.
Exclusion criteria: not reported.
Interventions Group 1 (n = 450): pure, unprocessed, undiluted, honey, covered with gauze, changed
every 2nd day.
Group 2 (n = 450): Soframycin (90 participants), Vaseline-impregnated gauze (90 par-
ticipants), OpSite (90 participants), sterile gauze (90 participants) or left exposed (90
participants). “Dressings were replaced on alternative days, except in the case of OpSite,
which was continued until the wounds healed... sterile linen changed at frequent inter-
vals.” Frequency of dressing change is not mentioned with respect to the sterile gauze
group.
Treatment duration: until healed.
Outcomes Mean time to healing:
Group 1: 8.8 days (SD 2.1);
Group 2: 13.5 days (SD 4.1).
Notes Information about allocation method, allocation concealment, blinding, and standard
deviation for mean time to healing provided by author
Funding source: not reported.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “After initial treatment, the cases
were divided at random into a study group
treated with honey dressing and a control
group treated with conventional dressing”.
Comment: method of generating the ran-
dom sequence not reported. Author pro-
vided information that the sequence was
generated by the “chit method”, which is a
method of drawing lots however the infor-
mation provided was minimal and lacked
detail to sufficiently reassure us that the
method was truly random
Allocation concealment (selection bias) Unclear risk Comment: not stated, but author provided
information that allocation concealment
was by means of sequentially-numbered,
sealed envelopes, although it is not clear
whether the envelopes were opaque
Blinding (performance bias and detection
bias)
Blinding of participants? All outcomes
High risk Comment: not stated in study report, but
author responded to request for further in-
formation by stating the patients were not
blinded
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Blinding (performance bias and detection
bias)
Blinding of healthcare providers?All out-
comes
Low risk Comment: not stated in study report, but
author responded to request for further in-
formation by stating the investigators and
outcome assessors were blinded
Blinding (performance bias and detection
bias)
Blinding of outcome assessors? All out-
comes
Unclear risk Comment: not stated in study report, but
author responded to request for further
information by stating the investigators
and outcome assessors were blinded. How
blinding was achieved was not described in
the response. Both Gethin and Jull have re-
ported how it was difficult or impossible
to blind outcome assessment due to dis-
colouration of peri-ulcer skin by honey.We
have therefore classed all studies as at either
unclear or high risk of detection bias
Incomplete outcome data (attrition bias)
Drop-out rate described and acceptable -
All outcomes
Low risk Comment: Table 1 showed that there were
no drop-outs; all the randomised partici-
pants were followed-up
Incomplete outcome data (attrition bias)
ITT analysis -All outcomes
Low risk Comment: ITT analysis was not reported,
but since were no drop-outs were reported,
and all the randomised participants com-
pleted the study, ITT analysis was assumed
to have been done and to be acceptable.
Selective reporting (reporting bias) Low risk Comment: the study protocol was not
available, but the important outcome mea-
sures stated in the methods section were re-
ported in the results
Other bias Unclear risk Comment: the baseline characteristics
were not reported, so there was insufficient
information to judge whether any impor-
tant form of bias existed
Subrahmanyam 1996b
Methods Single-centred, 2-armed, parallel group RCT.
Participants 100participantswith partial-thickness burns recruited July 1992-December 1993.TBSA
mean 16.5 and 17.2%; 40/50 and 42/50 had positive swabs at baseline.
Setting: hospital.
Country: India.
Inclusion criteria: treated within 6 h of injury, TBSA burnt < 40%.
Exclusion criteria: not reported.
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Interventions Group 1 (n = 50): pure, unprocessed, undiluted honey, covered with gauze every 2nd
day.
Group 2 (n = 50): potato peel bandages every 2nd day.
Treatment duration: until healed.
Outcomes Mean time to healing:
Group 1: 10.4 days (SD 2.2);
Group 2: 16.2 days (SD 2.3).
Notes Information about allocation method, allocation concealment, blinding, and standard
deviation for mean time to healing provided by author
Funding source: not reported.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “After initial management, patients
were allotted at random to two groups”.
Comment: method of generating the ran-
dom sequence not reported. Author pro-
vided information that the sequence was
generated by the “chit method”, which is a
method of drawing lots however the infor-
mation provided was minimal and lacked
detail to sufficiently reassure us that the
method was truly random
Allocation concealment (selection bias) Unclear risk Comment: not stated, but author pro-
vided information that allocation conceal-
ment was by means of sequentially-num-
bered sealed envelopes, although it is not
clear whether the envelopes were opaque
Blinding (performance bias and detection
bias)
Blinding of participants? All outcomes
High risk Comment: not stated in study report, but
author responded to request for further in-
formation by stating the patients were not
blinded
Blinding (performance bias and detection
bias)
Blinding of healthcare providers?All out-
comes
Low risk Comment: not stated in study report, but
author responded to request for further in-
formation by stating the investigators and
outcome assessors were blinded
Blinding (performance bias and detection
bias)
Blinding of outcome assessors? All out-
comes
Unclear risk Comment: not stated in study report, but
author responded to request for further
information by stating the investigators
and outcome assessors were blinded. How
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blinding was achieved was not described in
the response. Both Gethin and Jull have re-
ported how it was difficult or impossible
to blind outcome assessment due to dis-
colouration of peri-ulcer skin by honey.We
have therefore classed all studies as at either
unclear or high risk of detection bias
Incomplete outcome data (attrition bias)
Drop-out rate described and acceptable -
All outcomes
Low risk Comment: Table 1 showed that there were
no drop-outs; all randomised participants
were followed-up
Incomplete outcome data (attrition bias)
ITT analysis -All outcomes
Low risk Comment: ITT analysis was not reported,
but since no drop-outs were reported, and
all randomised participants completed the
study, ITT analysis was assumed to have
been done and to be acceptable.
Selective reporting (reporting bias) Low risk Comment: the study protocol was not
available, but the important outcome mea-
sures stated in the methods section were re-
ported in the results
Other bias Low risk Comment: there was no imbalance in
the baseline characteristics, and the study
seemed to be free from other forms of bias
Subrahmanyam 1998
Methods Single-centred, 2-armed, parallel group RCT.
Participants 50 participants with superficial thermal burns recruited June 1995-December 1996.
TBSA mean 14.5 and 15.6%; treated within 6h of burn; 23/25 and 22/25 had positive
swabs at baseline
Setting: hospital.
Country: India.
Inclusion criteria: present within 6 h of injury, TBSA burnt < 40%.
Exclusion criteria: not reported.
Interventions Group 1 (n = 25): pure, unprocessed, undiluted honey,covered with pads and bandages;
applied every 2nd day.
Group 2 (n = 25): SSD-impregnated gauze, applied daily (c.f. alternate day application
of honey).
Treatment duration: until healed.
Outcomes Mean time to healing:
Group 1: 4.92 days (SD 3.61);
Group 2: 8.22 days (SD 8.31).
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Notes Information about allocation method, allocation concealment, blinding, mean time to
healing and standard deviation for mean time to healing provided by author
Funding source: not reported.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “After initial management, patients
were allotted at random to two groups”.
Comment: method of generation of ran-
dom sequence not reported. Author pro-
vided information that the sequence was
generated by the “chit method”, which is a
method of drawing lots however the infor-
mation provided was minimal and lacked
detail to sufficiently reassure us that the
method was truly random
Allocation concealment (selection bias) Unclear risk Comment: not stated, but author pro-
vided information that allocation conceal-
ment was by means of sequentially-num-
bered sealed envelopes, although it is not
clear whether the envelopes were opaque
Blinding (performance bias and detection
bias)
Blinding of participants? All outcomes
High risk Comment: not stated in study report, but
author responded to request for further in-
formation by stating the patients were not
blinded
Blinding (performance bias and detection
bias)
Blinding of healthcare providers?All out-
comes
Low risk Comment: not stated in study report, but
author responded to request for further in-
formation by stating the investigators and
outcome assessors were blinded
Blinding (performance bias and detection
bias)
Blinding of outcome assessors? All out-
comes
Unclear risk Comment: not stated in study report, but
author responded to request for further
information by stating the investigators
and outcome assessors were blinded. How
blinding was achieved was not described in
the response. Both Gethin and Jull have re-
ported how it was difficult or impossible
to blind outcome assessment due to dis-
colouration of peri-ulcer skin by honey.We
have therefore classed all studies as at either
unclear or high risk of detection bias
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Incomplete outcome data (attrition bias)
Drop-out rate described and acceptable -
All outcomes
Low risk Comment: Table 2 showed that there were
no drop-outs; all randomised participants
were followed-up
Incomplete outcome data (attrition bias)
ITT analysis -All outcomes
Low risk Comment: ITT analysis not reported, but
since no drop-outs were reported, and
all randomised participants completed the
study, ITT analysis was assumed to have
been done and to be acceptable.
Selective reporting (reporting bias) Low risk Comment: the study protocol was not
available, but the important outcome mea-
sures stated in the methods section were re-
ported in the results
Other bias Low risk Comment: there was no imbalance in
the baseline characteristics, and the study
seemed to be free from other forms of bias
Subrahmanyam 1999
Methods Single-centred, 2-armed, parallel group RCT.
Participants 50 participants with mixed-depth (partial- and full-thickness) burns recruited January
1996-December 1997.TBSA mean 24 and 23%; full thickness TBSA 13 and 12%. 41/
123 swabs (not patients) and 7/71 were positive at baseline.
Setting: hospital.
Country: India.
Inclusion criteria: aged 10-40 years, haemodynamically stable, no systemic illness or
smoke inhalation injury, TBSA burnt < 30%.
Exclusion criteria: not reported.
Interventions Group 1 (n = 25): unprocessed honey, covered with gauze every 2nd day, then (delayed)
autologous skin grafting as required (in 11/22 patients; 3 died).
Group 2 (n = 25): early tangential excision and skin grafting 3-6 days after admission.
Treatment duration: until healed.
Outcomes Mean time to healing:
Group 1: 32.0 days (SD 8.1);
Group 2: 18.4 days (SD 4.2).
Notes Information about allocation method, allocation concealment, blinding, mean time to
healing and standard deviation for mean time to healing provided by author.
3 participants in the honey-treated group died, and 1 in the early tangential excision
group
Funding source: not reported.
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Twenty five patients were ran-
domly assigned to the TE group”.
Comment: method of generation of the
random sequence was not reported. Author
provided information that the sequence
was generated by the “chit method”, which
is a method of drawing lots however the
information provided was minimal and
lacked detail to sufficiently reassure us that
the method was truly random
Allocation concealment (selection bias) Unclear risk Comment: not stated, but author pro-
vided information that allocation conceal-
ment was by means of sequentially-num-
bered sealed envelopes, although it is not
clear whether the envelopes were opaque
Blinding (performance bias and detection
bias)
Blinding of participants? All outcomes
High risk Comment: not stated in study report, but
author responded to request for further in-
formation by stating the patients were not
blinded
Blinding (performance bias and detection
bias)
Blinding of healthcare providers?All out-
comes
Low risk Comment: not stated in study report, but
author responded to request for further in-
formation by stating the investigators and
outcome assessors were blinded
Blinding (performance bias and detection
bias)
Blinding of outcome assessors? All out-
comes
Unclear risk Comment: not stated in study report, but
author responded to request for further
information by stating the investigators
and outcome assessors were blinded. How
blinding was achieved was not described in
the response. Both Gethin and Jull have re-
ported how it was difficult or impossible
to blind outcome assessment due to dis-
colouration of peri-ulcer skin by honey.We
have therefore classed all studies as at either
unclear or high risk of detection bias
Incomplete outcome data (attrition bias)
Drop-out rate described and acceptable -
All outcomes
Low risk Quote: “One TE patient died, from status
asthaticus, while 3 HT patients died with
septicaemia”.
Comment: overall the number of drop-
outs was < 10%, however, drop-outs were
due to death, which is of some concern
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given that the burns were described as
“moderate”
Incomplete outcome data (attrition bias)
ITT analysis -All outcomes
Unclear risk Comment: the study did not state whether
all the randomised participants were fol-
lowed-up and included in the final analysis,
hence, we cannot judge if an ITT analysis
was conducted
Selective reporting (reporting bias) Low risk Comment: the study protocol was not
available, but the important outcome mea-
sures stated in the methods section were re-
ported in the results
Other bias Unclear risk Comment: few baseline characteristics
were reported, so there was insufficient in-
formation available to judge whether any
important form of bias existed
Subrahmanyam 2001a
Methods Single-centred, 2-armed, parallel group RCT.
Participants 100 participants with mixed-depth (partial- and full-thickness) burns recruited June
1998-December 1999. TBSA mean 22.5 and 23.5%; mean full thickness TBSA 3.2 and
4.7%. 44/50 and 42/50 had positive swabs at baseline.
Setting: hospital.
Country: India.
Inclusion criteria: treated within 6 h of injury, TBSA burnt < 40%.
Exclusion criteria: not reported.
Interventions Group 1 (n = 50): unprocessed, undiluted, monofloral (Jambhul) honey, covered with
gauze, every 2nd day (skin grafting required in 4 patients)
Group 2 (n = 50): SSD-impregnated gauze every 2nd day (skin grafting required in 11
patients).
Treatment duration: until healed.
Outcomes Mean time to healing:
Group 1: 15.4 days (SD 3.2)
Group 2: 17.2 days (SD 4.3).
Notes Information about allocation method, allocation concealment, blinding, and standard
deviation for mean time to healing provided by author
Funding source: not reported.
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Unclear risk Quote: “The patients were allocated at ran-
dom to two groups, the initial management
being the same”.
Comment: method of generation of ran-
dom sequence not reported. Author pro-
vided information that the sequence was
generated by the “chit method”, which is a
method of drawing lots however the infor-
mation provided was minimal and lacked
detail to sufficiently reassure us that the
method was truly random
Allocation concealment (selection bias) Unclear risk Comment: not stated, but author pro-
vided information that allocation conceal-
ment was by means of sequentially-num-
bered sealed envelopes, although it is not
clear whether the envelopes were opaque
Blinding (performance bias and detection
bias)
Blinding of participants? All outcomes
High risk Comment: not stated in study report, but
author responded to request for further in-
formation by stating the patients were not
blinded
Blinding (performance bias and detection
bias)
Blinding of healthcare providers?All out-
comes
Low risk Comment: not stated in study report, but
author responded to request for further in-
formation by stating the investigators and
outcome assessors were blinded
Blinding (performance bias and detection
bias)
Blinding of outcome assessors? All out-
comes
Unclear risk Comment: not stated in study report, but
author responded to request for further
information by stating the investigators
and outcome assessors were blinded. How
blinding was achieved was not described in
the response. Both Gethin and Jull have re-
ported how it was difficult or impossible
to blind outcome assessment due to dis-
colouration of peri-ulcer skin by honey.We
have therefore classed all studies as at either
unclear or high risk of detection bias
Incomplete outcome data (attrition bias)
Drop-out rate described and acceptable -
All outcomes
Low risk Quote: “Thus, all the patients in this
group, the wound healed by day 21” (pa-
tients treated with honey).
Quote: “In the group treated with sulphur
sulphadiazine, the wounds healed in 4 pa-
tients by day 7, in 22 patients by 14 day,
and in 24 patients by day 21”.
Comment: no drop-outs, as all the partic-
ipants randomised were followed-up
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Incomplete outcome data (attrition bias)
ITT analysis -All outcomes
Low risk Comment: ITT analysis was not reported,
but since no drop-outs were reported, and
all the randomised participants completed
the study, ITTanalysiswas assumed tohave
been done and to be acceptable.
Selective reporting (reporting bias) Low risk Comment: the study protocol was not
available, but the important outcome mea-
sures stated in the methods section were re-
ported in the results
Other bias Low risk Comment: there was no imbalance in
the baseline characteristics, and the study
seemed to be free from other forms of bias
Subrahmanyam 2004
Methods Single-centred, 2-armed, blinded (outcome assessor), parallel group RCT
Participants 30 consecutive males with Fournier’s gangrene recruited April 2001-May 2003. All
patients had infected wounds at baseline.
Setting: hospital.
Country: India.
Inclusion criteria: not reported.
Exclusion criteria: not reported.
Interventions Group 1 (n = 14): unprocessed, undiluted, monofloral (Jamun) honey (gauze dipped in
honey), daily.
Group 2 (n = 16): Edinburgh Solution of Lime- (EUSOL) soaked gauze daily.
Treatment duration: until healed.
Outcomes Mean time to healing:
Group 1: 18.5 days (SD 2.1);
Group 2: 26.5 days (SD 3.2).
Notes Information about allocation method, allocation concealment, blinding, mean time to
healing and standard deviation for mean time to healing provided by author.
3 participants died: 1 in the honey-treated group and 2 in the EUSOL-treated group
Funding source: not reported.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “For assessing the beneficial effects
of local dressings, the patients were divided
into two groups by randomisation”.
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Subrahmanyam 2004 (Continued)
Comment: method of generating the ran-
dom sequence not reported. Author pro-
vided information that the sequence was
generated by the “chit method”, which is a
method of drawing lots however the infor-
mation provided was minimal and lacked
detail to sufficiently reassure us that the
method was truly random
Allocation concealment (selection bias) Unclear risk Comment: not stated, but author provided
information that allocation concealment
was bymeans of sequentially numbered en-
velopes, although it is not clear whether
they were sealed or opaque
Blinding (performance bias and detection
bias)
Blinding of participants? All outcomes
High risk Quote: “The assessor was not aware of the
treatment given (single blind)”.
Comment: blinding of participants was
not done.
Blinding (performance bias and detection
bias)
Blinding of healthcare providers?All out-
comes
High risk Quote: “The assessor was not aware of the
treatment given (single blind)”.
Comment: blinding of providers was not
done.
Blinding (performance bias and detection
bias)
Blinding of outcome assessors? All out-
comes
Unclear risk Quote: “The assessor was not aware of the
treatment given (single blind)”.
Comment: blinding of outcome assessors
was done and it was unlikely that the blind-
ing could have been broken. Both Gethin
and Jull have reported how it was difficult
or impossible to blind outcome assessment
due to discolouration of peri-ulcer skin by
honey.We have therefore classed all studies
as at either unclear or high risk of detection
bias
Incomplete outcome data (attrition bias)
Drop-out rate described and acceptable -
All outcomes
Low risk Comment: 3 deaths reported: 1 in the
honey-treated group and 2 in the EUSOL-
treated group. The causes of death were
not mentioned, but the drop-out rate was
< 10%, which was acceptable
Incomplete outcome data (attrition bias)
ITT analysis -All outcomes
Unclear risk Comment: the information available was
not sufficient to judge whether an ITT
analysis had been conducted
Selective reporting (reporting bias) Low risk Comment: the study protocol was not
available, but the important outcome mea-
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Subrahmanyam 2004 (Continued)
sures stated in the methods section were re-
ported in the results
Other bias Unclear risk Comment: the baseline characteristics
were not reported, so there was insufficient
information available to judge whether any
important form of bias existed
Weheida 1991
Methods Single-centred, 2-armed, parallel group RCT.
Participants 40 participants with grade I or II pressure ulcers; honey 20/20 (100%) grade I; saline
16/20 (80%) grade I
Setting: hospital.
Country: Egypt.
Inclusion criteria: orthopaedic patients aged≥ 21 years, ulcer≥ 2 cm in diameter, ulcer
uninfected, haemoglobin ≥ 10 g/dL, oral temperature ≤ 37.5 oC, restricted to bed or
wheelchair for at least 2 weeks
Exclusion criteria: debilitant co-morbidities e.g. diabetes, cancer
Interventions Group 1 (n = 20): honey dressing changed daily.
Group 2 (n = 20): saline-soaked gauze changed daily.
Treatment duration: 10 days.
Follow-up duration: three months.
Outcomes Healing rate at 10 days:
Group 1: 20/20 (100%);
Group 2: 14/20 (70%).
Notes Grade I ulcer defined as moist irregular partial-thickness ulcer confined to epidermis
and dermis. Grade II ulcer defined as full-thickness ulcer descending into subcutaneous
tissue
Funding source: not reported.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Subjects of the study were ran-
domly recruited to one of the two treat-
ment groups”.
Comment: method of generation of ran-
domisation schedule not reported
Allocation concealment (selection bias) Unclear risk Comment: not stated.
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Weheida 1991 (Continued)
Blinding (performance bias and detection
bias)
Blinding of participants? All outcomes
Unclear risk Comment: not stated.
Blinding (performance bias and detection
bias)
Blinding of healthcare providers?All out-
comes
Unclear risk Comment: not stated.
Blinding (performance bias and detection
bias)
Blinding of outcome assessors? All out-
comes
Unclear risk Comment: not stated.
Incomplete outcome data (attrition bias)
Drop-out rate described and acceptable -
All outcomes
Unclear risk Comment: the study did not state whether
therewere any drop-outs orwhether all ran-
domised participants were followed-up
Incomplete outcome data (attrition bias)
ITT analysis -All outcomes
Unclear risk Comment: the study did not state whether
all randomised participants were followed-
up and included in the final analysis, hence,
we cannot judge whether an ITT analysis
was conducted
Selective reporting (reporting bias) Low risk Comment: the study protocol was not
available, but the important outcome mea-
sures stated in the methods section were re-
ported in the results
Other bias High risk Quote: “Eighty percent of group I [saline]
had ulcers grade I before treatment ... For
group II [honey], all the subjects had ulcers
grade I, and all of which were completely
healed after treatment [sic]”.
Comment: there was a baseline imbalance
in ulcer grades between 2 groups; all grade
II ulcers were in the saline dressing group,
while all ulcers in the honey dressing group
were grade I ulcers. Therefore, the ulcers
in the saline dressing group were more se-
vere. In addition, there were fewer males
and pressure ulcers developed at later times
from admission in the honey group
Abbreviations
> = greater/more than
≥ = greater than or equal to
< = less than
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≤ = less than or equal to
ABI = ankle-brachial index
EUSOL = Edinburgh solution of lime
h = hour(s)
ITT = intention-to-treat analysis
RCT = randomised controlled trial
TBSA = total body surface area
SSD = silver sulfadiazine
vs = versus
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Abdelatif 2008 Not a randomised or controlled clinical trial.
Ahmed 2003 Not a randomised or controlled clinical trial.
Al Waili 2003 Participants did not have wounds; trial of honey mixture for atopic dermatitis or psoriasis
Al Waili 2004a Animal-model study.
Al Waili 2004b Animal-model study.
Al Waili 2004c Not a randomised or controlled clinical trial.
Al Waili 2005 Not a randomised or controlled clinical trial.
Albietz 2006 Participants did not have wounds.
Bangroo 2005 Insufficient information on healing - no response to attempts to contact corresponding author
Berchtold 1992 Did not use honey.
Biswal 2003 Participants did not have wounds; trial of honey for radiation-induced mucositis
Bose 1982 Not a randomised or controlled clinical trial.
Calderon Espina 1989 Could not be obtained for assessment.
Chokotho 2005 No information on healing. No response to attempts to contact investigator
Dunford 2004 Not a randomised or controlled clinical trial.
Freeman 2010 Not a randomised or controlled clinical trial.
Gad 1988 No information on healing. No response to attempts to contact investigator
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(Continued)
Gethin 2005 Not a randomised or quasi-randomised controlled trial.
Heidari 2013 No healing data reported.
Jeffery 2008 No information on healing.
Johnson 2005 Participants did not have wounds; trial of honey to prevent catheter-associated infections in haemodialysis
patients
Lund-Nielsen 2011 No information on healing.
Lusby 2002 Not a randomised or quasi-randomised controlled trial.
Malik 2010 Unit of analysis issue - wounds randomised, not patients.
Marshall 2002 Not a randomised or quasi-randomised controlled trial.
Mat Lazim 2013 No healing data (as per specified primary outcomes) reported
Mayer 2014 Not a randomised or controlled trial; no control group.
Misirligou 2003 Not a randomised or controlled clinical trial.
Moghazy 2010 Not a randomised or controlled trial; no control group.
Molan 2002 Not a randomised or controlled clinical trial.
Molan 2006 Not a randomised or controlled clinical trial.
Muller 1985 Did not use honey.
Mwipatayi 2004 Not a randomised or controlled clinical trial.
Nagane 2004 Not a randomised or controlled clinical trial.
Okeniyi 2005 Unit of analysis issue - wounds randomised, not participants. 32 participants had 43 wounds and individual
participants may have been treated by both honey and the comparator (EUSOL). Healing rate provided by
wound, not by participant
Oluwatosin 2000 Unit of analysis issue. No information on healing.
Pascoe 2013 Protocol for RCT of study on prevention of catheter associated infection in peritoneal dialysis (not a wound
healing study)
Quadri 1998 Participants did not have wounds; trial of honey to prevent catheter-associated infections in haemodialysis
patients. Duplicate study
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(Continued)
Quadri 1999 Participants did not have wounds; trial of honey to prevent catheter-associated infections in haemodialysis
patients
Rivero Varona 1999 Could not be obtained.
Robson 2002 Not a randomised or controlled clinical trial.
Robson 2012 Neither of healing primary outcomes reported (focus is on MRSA)
Rogers 2010 Insufficient information on healing.
Rucigaj 2006 Insufficient information on healing - corresponding author unwilling to provide information until study
published
Saha 2012 Neither of healing primary outcomes reported.
Schumacher 2004 Not a randomised or controlled clinical trial.
Somaratne 2012 No method of allocation stated so unlikely to be RCT; no data on wound healing (only swabs for MRSA)
Subrahmanyam 1993 Not a randomised or controlled clinical trial.
Subrahmanyam 1996c This RCT was a comparison of honey with honey plus vitamins A, C and polyethyline glycol. As the
systematic difference between study arms was neither the presence of honey nor different types of honey,
this study was ineligible
Subrahmanyam 2001b Animal-model study.
Subrahmanyam 2003 No data on healing - biochemical data only.
Thurnheer 1983 Not a randomised or controlled clinical trial.
Tostes 1994 Not a randomised or controlled clinical trial.
Ur-Rehman 2013 Neither of healing primary outcomes reported, only change in area
Vijaya 2012 Not a randomised or controlled clinical trial.
Visscher 1996 Not a randomised or controlled clinical trial.
Yapucu Gunes 2007 Unit of analysis issue - outcomes reported by pressure injury, not by participant
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Characteristics of studies awaiting assessment [ordered by study ID]
Askarpour 2009
Methods Unclear how participants were allocated.
Participants People undergoing laparotomy.
Interventions Honey vs no honey
Outcomes Granulation tissue formation; appears neither of primary outcomes reported
Notes Awaiting clarification from authors.
Jan 2012
Methods Unclear how participants were allocated.
Participants People with diabetic foot ulcers (Wagner’s Grade I to IV)
Interventions Daily honey dressings vs. pyodine soaked surgical gauze dressings
Outcomes Ulcer healing and amputation.
Notes Awaiting clarification from authors.
Maghsoudi 2011
Methods Single-centred, 2-armed, parallel group RCT
Participants 100 participants with partial-thickness burns recruited March 2010-March 2011.
Setting: hospital.
Country: Iran.
Inclusion criteria: TBSA burnt < 40%.
Exclusion criteria: not reported.
Interventions Group 1 (n = 50): 16-30 ml unprocessed, undiluted honey dressings changed on alternate days.
Group 2 (n = 50): mafenide acetate-impregnated gauze changed daily.
Treatment duration: until healed.
Outcomes Mean time to healing and standard deviation not available.
Notes Attempting to contact authors.
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D A T A A N D A N A L Y S E S
Comparison 1. Minor acute wounds: honey vs. no honey (conventional dressings)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Time to healing 3 213 Mean Difference (IV, Random, 95% CI) 2.26 [-3.09, 7.61]
2 Adverse events 1 82 Risk Ratio (M-H, Fixed, 95% CI) 1.19 [0.69, 2.05]
3 Infection 2 151 Risk Ratio (M-H, Fixed, 95% CI) 0.91 [0.13, 6.37]
Comparison 2. Partial thickness burns: honey vs no honey (conventional dressings)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Time to healing (days) 2 992 Mean Difference (IV, Fixed, 95% CI) -4.68 [-5.09, -4.28]
2 Adverse events 2 992 Risk Ratio (M-H, Random, 95% CI) 0.56 [0.15, 2.06]
3 Negative swab at Day 7-8 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
Comparison 3. Burns: honey with delayed graft PRN vs early excision & grafting (no honey)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Time to healing (days) 1 46 Mean Difference (IV, Fixed, 95% CI) 13.60 [9.82, 17.38]
2 Mean duration of antibiotic
therapy (days)
1 50 Mean Difference (IV, Fixed, 95% CI) 16.0 [8.85, 23.15]
Comparison 4. Burns: honey vs silver sulfadiazine (SSD)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Time to healing (days) 4 Mean Difference (Random, 95% CI) Subtotals only
1.1 Time to healing (days) 4 332 Mean Difference (Random, 95% CI) -5.12 [-9.51, -0.73]
2 Proportion burns completely
healed
6 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Burns: honey vs SSD at 4
to 6 weeks
6 462 Risk Ratio (M-H, Random, 95% CI) 1.0 [0.98, 1.02]
3 Adverse events 5 412 Risk Ratio (M-H, Random, 95% CI) 0.29 [0.20, 0.42]
4 Negative swab at Day 7 5 412 Risk Ratio (M-H, Random, 95% CI) 3.92 [1.32, 11.63]
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Comparison 5. Burns: honey vs. no honey (atypical dressings)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Time to healing (days) 2 Mean Difference (IV, Random, 95% CI) Subtotals only
Comparison 6. Mixed acute and chronic wounds
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Time to healing (days) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
2 Negative swab at Day 7 2 Risk Ratio (M-H, Random, 95% CI) Totals not selected
Comparison 7. Chronic wounds
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Proportion healed 6 Risk Ratio (M-H, Random, 95% CI) Totals not selected
1.1 Infected post-op wounds 1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
1.2 Pressure ulcers (grade I
and II) at 10 days
1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
1.3 Leishmaniasis at 4 months
(16 weeks)
1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
1.4 Venous leg ulcers at 12
weeks
2 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
1.5 Diabetic foot ulcers 1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2 Time to healing (days) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
2.1 Fournier’s gangrene 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Venous ulcers: proportion healed
at 12 weeks
2 476 Risk Ratio (M-H, Fixed, 95% CI) 1.15 [0.96, 1.38]
4 Venous ulcers: infection 2 476 Risk Ratio (M-H, Fixed, 95% CI) 0.71 [0.49, 1.04]
5 Mixed wounds: proportion
healed
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
5.1 Mixed wounds healing 2’
intention at 12 weeks
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.2 Mixed wounds healing 2’
intention at 24 weeks
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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Analysis 1.1. Comparison 1 Minor acute wounds: honey vs. no honey (conventional dressings), Outcome 1
Time to healing.
Review: Honey as a topical treatment for wounds
Comparison: 1 Minor acute wounds: honey vs. no honey (conventional dressings)
Outcome: 1 Time to healing
Study or subgroup Honey Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Ingle 2006 40 16.5 (8.4) 42 16.9 (11.3) 48.2 % -0.40 [ -4.70, 3.90 ]
McIntosh 2006 47 40.3 (18.21) 40 39.98 (25.42) 22.0 % 0.32 [ -9.12, 9.76 ]
Marshall 2005 23 33 (15.71) 21 25 (8.7) 29.8 % 8.00 [ 0.58, 15.42 ]
Total (95% CI) 110 103 100.0 % 2.26 [ -3.09, 7.61 ]
Heterogeneity: Tau2 = 10.65; Chi2 = 3.76, df = 2 (P = 0.15); I2 =47%
Test for overall effect: Z = 0.83 (P = 0.41)
Test for subgroup differences: Not applicable
-50 -25 0 25 50
Favours honey Favours control
Analysis 1.2. Comparison 1 Minor acute wounds: honey vs. no honey (conventional dressings), Outcome 2
Adverse events.
Review: Honey as a topical treatment for wounds
Comparison: 1 Minor acute wounds: honey vs. no honey (conventional dressings)
Outcome: 2 Adverse events
Study or subgroup Honey Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ingle 2006 (1) 17/40 15/42 100.0 % 1.19 [ 0.69, 2.05 ]
Total (95% CI) 40 42 100.0 % 1.19 [ 0.69, 2.05 ]
Total events: 17 (Honey), 15 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.63 (P = 0.53)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours honey Favours control
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(1) Honey versus hydrogel
Analysis 1.3. Comparison 1 Minor acute wounds: honey vs. no honey (conventional dressings), Outcome 3
Infection.
Review: Honey as a topical treatment for wounds
Comparison: 1 Minor acute wounds: honey vs. no honey (conventional dressings)
Outcome: 3 Infection
Study or subgroup Honey Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Marshall 2005 1/27 0/24 25.3 % 2.68 [ 0.11, 62.81 ]
McIntosh 2006 0/52 1/48 74.7 % 0.31 [ 0.01, 7.39 ]
Total (95% CI) 79 72 100.0 % 0.91 [ 0.13, 6.37 ]
Total events: 1 (Honey), 1 (Control)
Heterogeneity: Chi2 = 0.90, df = 1 (P = 0.34); I2 =0.0%
Test for overall effect: Z = 0.10 (P = 0.92)
Test for subgroup differences: Not applicable
0.002 0.1 1 10 500
Favours honey Favours no honey
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Analysis 2.1. Comparison 2 Partial thickness burns: honey vs no honey (conventional dressings), Outcome 1
Time to healing (days).
Review: Honey as a topical treatment for wounds
Comparison: 2 Partial thickness burns: honey vs no honey (conventional dressings)
Outcome: 1 Time to healing (days)
Study or subgroup Honey Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Subrahmanyam 1993a 46 10.8 (3.93) 46 15.3 (2.98) 8.2 % -4.50 [ -5.93, -3.07 ]
Subrahmanyam 1996a 450 8.8 (2.1) 450 13.5 (4.1) 91.8 % -4.70 [ -5.13, -4.27 ]
Total (95% CI) 496 496 100.0 % -4.68 [ -5.09, -4.28 ]
Heterogeneity: Chi2 = 0.07, df = 1 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 22.51 (P < 0.00001)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours honey Favours control
Analysis 2.2. Comparison 2 Partial thickness burns: honey vs no honey (conventional dressings), Outcome 2
Adverse events.
Review: Honey as a topical treatment for wounds
Comparison: 2 Partial thickness burns: honey vs no honey (conventional dressings)
Outcome: 2 Adverse events
Study or subgroup Honey Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Subrahmanyam 1993a 4/46 3/46 36.9 % 1.33 [ 0.32, 5.63 ]
Subrahmanyam 1996a 33/450 99/450 63.1 % 0.33 [ 0.23, 0.48 ]
Total (95% CI) 496 496 100.0 % 0.56 [ 0.15, 2.06 ]
Total events: 37 (Honey), 102 (Control)
Heterogeneity: Tau2 = 0.67; Chi2 = 3.34, df = 1 (P = 0.07); I2 =70%
Test for overall effect: Z = 0.88 (P = 0.38)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours honey Favours control
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Analysis 2.3. Comparison 2 Partial thickness burns: honey vs no honey (conventional dressings), Outcome 3
Negative swab at Day 7-8.
Review: Honey as a topical treatment for wounds
Comparison: 2 Partial thickness burns: honey vs no honey (conventional dressings)
Outcome: 3 Negative swab at Day 7-8
Study or subgroup Honey Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Subrahmanyam 1993a 38/46 29/46 1.31 [ 1.01, 1.70 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 38 (Honey), 29 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
0.01 0.1 1 10 100
Favours PU Film Favours Honey
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Analysis 3.1. Comparison 3 Burns: honey with delayed graft PRN vs early excision & grafting (no honey),
Outcome 1 Time to healing (days).
Review: Honey as a topical treatment for wounds
Comparison: 3 Burns: honey with delayed graft PRN vs early excision % grafting (no honey)
Outcome: 1 Time to healing (days)
Study or subgroup Honey
Early
excision %
graft
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Subrahmanyam 1999 22 32 (8.1) 24 18.4 (4.2) 100.0 % 13.60 [ 9.82, 17.38 ]
Total (95% CI) 22 24 100.0 % 13.60 [ 9.82, 17.38 ]
Heterogeneity: not applicable
Test for overall effect: Z = 7.05 (P < 0.00001)
Test for subgroup differences: Not applicable
-20 -10 0 10 20
Favours honey Favours control
Analysis 3.2. Comparison 3 Burns: honey with delayed graft PRN vs early excision & grafting (no honey),
Outcome 2 Mean duration of antibiotic therapy (days).
Review: Honey as a topical treatment for wounds
Comparison: 3 Burns: honey with delayed graft PRN vs early excision % grafting (no honey)
Outcome: 2 Mean duration of antibiotic therapy (days)
Study or subgroup Honey
Early
excision %
graft
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Subrahmanyam 1999 25 32 (18) 25 16 (3) 100.0 % 16.00 [ 8.85, 23.15 ]
Total (95% CI) 25 25 100.0 % 16.00 [ 8.85, 23.15 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.38 (P = 0.000012)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours honey Favours early excision
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Analysis 4.1. Comparison 4 Burns: honey vs silver sulfadiazine (SSD), Outcome 1 Time to healing (days).
Review: Honey as a topical treatment for wounds
Comparison: 4 Burns: honey vs silver sulfadiazine (SSD)
Outcome: 1 Time to healing (days)
Study or subgroup Honey
Silver
sulfadiazine
(SSD) Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Random,95% CI IV,Random,95% CI
1 Time to healing (days)
Baghel 2009 37 41 -14.5 (7.28031312) 7.4 % -14.50 [ -28.77, -0.23 ]
Subrahmanyam 1991 52 52 -7.8 (0.5465) 32.9 % -7.80 [ -8.87, -6.73 ]
Subrahmanyam 1998 25 25 -3.3 (1.8121) 27.5 % -3.30 [ -6.85, 0.25 ]
Subrahmanyam 2001a 50 50 -1.8 (0.758) 32.3 % -1.80 [ -3.29, -0.31 ]
Subtotal (95% CI) 164 168 100.0 % -5.12 [ -9.51, -0.73 ]
Heterogeneity: Tau2 = 14.99; Chi2 = 44.43, df = 3 (P<0.00001); I2 =93%
Test for overall effect: Z = 2.29 (P = 0.022)
Test for subgroup differences: Not applicable
-20 -10 0 10 20
Favours Honey Favours SSD
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Analysis 4.2. Comparison 4 Burns: honey vs silver sulfadiazine (SSD), Outcome 2 Proportion burns
completely healed.
Review: Honey as a topical treatment for wounds
Comparison: 4 Burns: honey vs silver sulfadiazine (SSD)
Outcome: 2 Proportion burns completely healed
Study or subgroup Honey Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Burns: honey vs SSD at 4 to 6 weeks
Baghel 2009 37/37 41/41 15.8 % 1.00 [ 0.95, 1.05 ]
Mashood 2006 25/25 25/25 6.7 % 1.00 [ 0.93, 1.08 ]
Memon 2005 40/40 40/40 16.8 % 1.00 [ 0.95, 1.05 ]
Subrahmanyam 1991 52/52 52/52 28.1 % 1.00 [ 0.96, 1.04 ]
Subrahmanyam 1998 25/25 25/25 6.7 % 1.00 [ 0.93, 1.08 ]
Subrahmanyam 2001a 50/50 50/50 26.0 % 1.00 [ 0.96, 1.04 ]
Subtotal (95% CI) 229 233 100.0 % 1.00 [ 0.98, 1.02 ]
Total events: 229 (Honey), 233 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.0, df = 5 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.0 (P = 1.0)
0.5 0.7 1 1.5 2
Favours SSD Favours Honey
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Analysis 4.3. Comparison 4 Burns: honey vs silver sulfadiazine (SSD), Outcome 3 Adverse events.
Review: Honey as a topical treatment for wounds
Comparison: 4 Burns: honey vs silver sulfadiazine (SSD)
Outcome: 3 Adverse events
Study or subgroup Honey Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Subrahmanyam 1991 2/52 16/52 6.9 % 0.13 [ 0.03, 0.52 ]
Subrahmanyam 2001a 1/50 5/50 3.1 % 0.20 [ 0.02, 1.65 ]
Memon 2005 12/40 37/40 60.3 % 0.32 [ 0.20, 0.52 ]
Mashood 2006 0/25 2/25 1.6 % 0.20 [ 0.01, 3.97 ]
Baghel 2009 7/37 26/41 28.0 % 0.30 [ 0.15, 0.60 ]
Total (95% CI) 204 208 100.0 % 0.29 [ 0.20, 0.42 ]
Total events: 22 (Honey), 86 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.91, df = 4 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 6.49 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 4.4. Comparison 4 Burns: honey vs silver sulfadiazine (SSD), Outcome 4 Negative swab at Day 7.
Review: Honey as a topical treatment for wounds
Comparison: 4 Burns: honey vs silver sulfadiazine (SSD)
Outcome: 4 Negative swab at Day 7
Study or subgroup Honey SSD Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Subrahmanyam 1991 48/52 14/52 22.9 % 3.43 [ 2.18, 5.40 ]
Subrahmanyam 1998 17/25 19/25 23.3 % 0.89 [ 0.63, 1.27 ]
Subrahmanyam 2001a 46/50 8/50 22.1 % 5.75 [ 3.03, 10.91 ]
Memon 2005 40/40 8/40 22.3 % 4.76 [ 2.62, 8.68 ]
Baghel 2009 24/37 0/41 9.4 % 54.16 [ 3.41, 860.28 ]
Total (95% CI) 204 208 100.0 % 3.92 [ 1.32, 11.63 ]
Total events: 175 (Honey), 49 (SSD)
Heterogeneity: Tau2 = 1.29; Chi2 = 67.17, df = 4 (P<0.00001); I2 =94%
Test for overall effect: Z = 2.46 (P = 0.014)
Test for subgroup differences: Not applicable
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Analysis 5.1. Comparison 5 Burns: honey vs. no honey (atypical dressings), Outcome 1 Time to healing
(days).
Review: Honey as a topical treatment for wounds
Comparison: 5 Burns: honey vs. no honey (atypical dressings)
Outcome: 1 Time to healing (days)
Study or subgroup Honey Atypical dressing
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Subrahmanyam 1994 40 9.4 (2.52) 24 17.5 (6.66) -8.10 [ -10.88, -5.32 ]
Subrahmanyam 1996b 50 10.4 (2.2) 50 16.2 (2.3) -5.80 [ -6.68, -4.92 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.0, df = 0 (P<0.00001); I2 =0.0%
Test for overall effect: Z = 0.0 (P < 0.00001)
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Analysis 6.1. Comparison 6 Mixed acute and chronic wounds, Outcome 1 Time to healing (days).
Review: Honey as a topical treatment for wounds
Comparison: 6 Mixed acute and chronic wounds
Outcome: 1 Time to healing (days)
Study or subgroup Honey
Silver
sulfadiazine
(SSD)
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Subrahmanyam 1993b 50 9.5 (6.2) 50 22.5 (5.2) -13.00 [ -15.24, -10.76 ]
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Analysis 6.2. Comparison 6 Mixed acute and chronic wounds, Outcome 2 Negative swab at Day 7.
Review: Honey as a topical treatment for wounds
Comparison: 6 Mixed acute and chronic wounds
Outcome: 2 Negative swab at Day 7
Study or subgroup Honey Control Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Subrahmanyam 1993b 46/50 12/50 3.83 [ 2.33, 6.32 ]
Mphande 2007 17/22 11/18 1.26 [ 0.82, 1.95 ]
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Analysis 7.1. Comparison 7 Chronic wounds, Outcome 1 Proportion healed.
Review: Honey as a topical treatment for wounds
Comparison: 7 Chronic wounds
Outcome: 1 Proportion healed
Study or subgroup Honey Control Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Infected post-op wounds
Al Waili 1999 22/26 12/24 1.69 [ 1.10, 2.61 ]
2 Pressure ulcers (grade I and II) at 10 days
Weheida 1991 20/20 14/20 1.41 [ 1.05, 1.90 ]
3 Leishmaniasis at 4 months (16 weeks)
Nilforoushzadeh 2007 23/50 32/50 0.72 [ 0.50, 1.04 ]
4 Venous leg ulcers at 12 weeks
Jull 2008 104/187 90/181 1.12 [ 0.92, 1.36 ]
Gethin 2007 24/54 18/54 1.33 [ 0.82, 2.16 ]
5 Diabetic foot ulcers
Kamaratos 2014 31/32 28/31 1.07 [ 0.94, 1.22 ]
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Analysis 7.2. Comparison 7 Chronic wounds, Outcome 2 Time to healing (days).
Review: Honey as a topical treatment for wounds
Comparison: 7 Chronic wounds
Outcome: 2 Time to healing (days)
Study or subgroup Honey Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Fournier’s gangrene
Subrahmanyam 2004 13 18.5 (2.1) 14 26.5 (3.2) -8.00 [ -10.03, -5.97 ]
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Analysis 7.3. Comparison 7 Chronic wounds, Outcome 3 Venous ulcers: proportion healed at 12 weeks.
Review: Honey as a topical treatment for wounds
Comparison: 7 Chronic wounds
Outcome: 3 Venous ulcers: proportion healed at 12 weeks
Study or subgroup Honey Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Gethin 2007 24/54 18/54 16.4 % 1.33 [ 0.82, 2.16 ]
Jull 2008 104/187 90/181 83.6 % 1.12 [ 0.92, 1.36 ]
Total (95% CI) 241 235 100.0 % 1.15 [ 0.96, 1.38 ]
Total events: 128 (Honey), 108 (Control)
Heterogeneity: Chi2 = 0.45, df = 1 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 1.55 (P = 0.12)
Test for subgroup differences: Not applicable
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Analysis 7.4. Comparison 7 Chronic wounds, Outcome 4 Venous ulcers: infection.
Review: Honey as a topical treatment for wounds
Comparison: 7 Chronic wounds
Outcome: 4 Venous ulcers: infection
Study or subgroup Honey Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Gethin 2007 6/54 12/54 22.8 % 0.50 [ 0.20, 1.24 ]
Jull 2008 32/187 40/181 77.2 % 0.77 [ 0.51, 1.18 ]
Total (95% CI) 241 235 100.0 % 0.71 [ 0.49, 1.04 ]
Total events: 38 (Honey), 52 (Control)
Heterogeneity: Chi2 = 0.74, df = 1 (P = 0.39); I2 =0.0%
Test for overall effect: Z = 1.76 (P = 0.078)
Test for subgroup differences: Not applicable
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Analysis 7.5. Comparison 7 Chronic wounds, Outcome 5 Mixed wounds: proportion healed.
Review: Honey as a topical treatment for wounds
Comparison: 7 Chronic wounds
Outcome: 5 Mixed wounds: proportion healed
Study or subgroup Honey Usual care Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Mixed wounds healing 2’ intention at 12 weeks
Robson 2009 24/52 18/53 1.36 [ 0.84, 2.19 ]
2 Mixed wounds healing 2’ intention at 24 weeks
Robson 2009 38/52 34/53 1.14 [ 0.88, 1.48 ]
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A D D I T I O N A L T A B L E S
Table 1. Frequency of adverse events reported in venous ulcer trial (Jull 2008)
Adverse event Honey treatment Control treatment
Ulcer pain 47/187 18/181
Bleeding 3/187 3/181
Dermatitis 8/187 8/181
Deterioration of ulcer 19/187 9/181
Erythema 6/187 4/181
Oedema 4/187 1/181
Increased exudate 5/187 1/181
Deterioration of surrounding skin 5/187 3/181
New ulceration 16/187 15/181
Other 6/187 3/181
Cardiovascular 4/187 3/181
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Table 1. Frequency of adverse events reported in venous ulcer trial (Jull 2008) (Continued)
Cancer 2/187 2/181
Neurological 4/187 1/181
Gastrointestinal 4/187 2/181
Injury 10/187 9/181
Musculoskeletal 13/187 9/181
Respiratory 6/187 3/181
Other 3/187 8/181
A P P E N D I C E S
Appendix 1. Search Methods for Original Review - 2008
Electronic searches
Searches of the following electronic databases were undertaken:
Cochrane Wounds Group Specialised Register (Searched 27/5/08)
The Cochrane Central Register of Controlled Trials (CENTRAL) - The Cochrane Library Issue 2 2008
Ovid MEDLINE - 1950 to May Week 2 2008
Ovid EMBASE - 1980 to 2008 Week 21
Ovid CINAHL - 1982 to May Week 4 2008
The following search strategy was used in the CENTRAL and adapted where appropriate for other databases :
#1 MeSH descriptor Skin Ulcer explode all trees
#2 MeSH descriptor Pilonidal Sinus explode all trees
#3 MeSH descriptor Wounds, Penetrating explode all trees
#4 MeSH descriptor Lacerations explode all trees
#5 MeSH descriptor Burns explode all trees
#6 MeSH descriptor Wound Infection explode all trees
#7 MeSH descriptor Surgical Wound Dehiscence explode all trees
#8 MeSH descriptor Bites and Stings explode all trees
#9 MeSH descriptor Cicatrix explode all trees
#10 ((plantar or diabetic or heel* or foot or feet or ischaemic or ischemic or venous or varicose or stasis or arterial or decubitus or
pressure or skin or leg or mixed or tropical or rheumatoid or sickle
cell) NEAR/5 (wound* or ulcer*)):ti,ab,kw
#11 (bedsore* or (bed NEXT sore*)):ti,ab,kw
#12 (pilonidal sinus* or pilonidal cyst*):ti,ab,kw
#13 (cavity wound* or sinus wound*):ti,ab,kw
#14 (laceration* or gunshot stab or stabbing or stabbed or bite*):ti,ab,kw
#15 (“burn” or “burns” or “burned” or scald*):ti,ab,kw
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#16 (surg* NEAR/5 infection*):ti,ab,kw
#17 (surg* NEAR/5 wound*):ti,ab,kw
#18 (wound* NEAR/5 infection*):ti,ab,kw
#19 (malignant wound* or experimental wound* or traumatic wound*):ti,ab,kw
#20 (infusion site* or donor site* or wound site* or surgical site*):ti,ab,kw
#21 (skin abscess* or skin abcess*):ti,ab,kw
#22 (hypertrophic scar* or keloid*):ti,ab,kw
#23 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR
#12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22)
#24 MeSH descriptor Honey explode all trees
#25 honey:ti,ab,kw
#26 (#24 OR #25)
#27 (#23 AND #26)
The MEDLINE search was combined with the Cochrane Highly Sensitive Search Strategy for identifying randomised trials in MED-
LINE: sensitivity- and precision-maximizing version (2008 revision); Ovid format. The EMBASE and CINAHL searches were com-
bined with the trial filters developed by the Scottish Intercollegiate Guidelines Network. Additionally, LILACS (1982 to October
2006), AMED (1985 to October 2006) and Google Scholar were searched using the text word “honey”.
Searching other resources
Contact was made with experts in the field, authors of the included trials and manufacturers of honey products for wound care (Comvita
NZ Ltd and MediHoney Australia Pty Ltd). The bibliographies of all obtained studies and review articles were searched for potentially
eligible trials. No language or date restrictions were applied to the trials and both published and unpublished trials were sought.
Appendix 2. Search strategies for Medline, Embase and CINAHL
Ovid Medline
1 exp Skin Ulcer/ (18230)
2 exp Pilonidal Sinus/ (543)
3 exp Wounds, Penetrating/ (14308)
4 exp Lacerations/ (1423)
5 exp Burns/ (17087)
6 exp Wound Infection/ (14097)
7 exp Surgical Wound Dehiscence/ (2829)
8 exp “Bites and Stings”/ (7739)
9 exp Cicatrix/ (13623)
10 ((plantar or diabetic or heel$ or foot or feet or ischaemic or ischemic or venous or varicose or stasis or arterial or decubitus or pressure
or skin or leg or mixed or tropical or rheumatoid or sickle cell) adj5 (wound$ or ulcer$)).ti,ab. (18800)
11 (bedsore$ or bed sore$).ti,ab. (239)
12 (pilonidal sinus$ or pilonidal cyst$).ti,ab. (437)
13 (cavity wound$ or sinus wound$).ti,ab. (37)
14 (laceration$ or gunshot or stab or stabbing or stabbed or bite$).ti,ab. (19976)
15 (burn or burns or burned or scald$).ti,ab. (19171)
16 (surg$ adj5 wound$).ti,ab. (5431)
17 (surg$ adj5 infection$).ti,ab. (8723)
18 (wound adj5 infection$).ti,ab. (10745)
19 (malignant wound$ or experimental wound$ or traumatic wound$).ti,ab. (428)
20 (infusion site$ or donor site$ or wound site$).ti,ab. (7460)
21 (skin abscess$ or skin abcess$).ti,ab. (162)
22 (hypertrophic scar$ or keloid scar$).ti,ab. (1595)
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23 or/1-22 (130992)
24 exp Honey/ (1328)
25 honey.ti,ab. (3036)
26 or/24-25 (3160)
27 23 and 26 (249)
Ovid Embase
1 exp Skin Ulcer/ (30058)
2 exp Pilonidal Sinus/ (883)
3 exp Penetrating Trauma/ (5303)
4 exp Laceration/ (4283)
5 exp Skin Abrasion/ (2135)
6 exp Burns/ (25289)
7 exp Wound Infection/ (17999)
8 exp Surgical Wound/ (3060)
9 exp Wound Dehiscence/ (6273)
10 exp Bite Wound/ (340)
11 exp Scar/ (28923)
12 ((plantar or diabetic or heel$ or foot or feet or ischaemic or ischemic or venous or varicose or stasis or arterial or decubitus or pressure
or skin or leg or mixed or tropical or rheumatoid or sickle cell) adj5 (wound$ or ulcer$)).ti,ab. (26847)
13 (bedsore$ or bed sore$).ti,ab. (397)
14 (pilonidal sinus$ or pilonidal cyst$).ti,ab. (628)
15 (cavity wound$ or sinus wound$).ti,ab. (50)
16 (laceration$ or gunshot or stab or stabbing or stabbed or bite$).ti,ab. (26569)
17 (burn or burns or burned or scald$).ti,ab. (26981)
18 (surg$ adj5 wound$).ti,ab. (7562)
19 (surg$ adj5 infection$).ti,ab. (12748)
20 (wound adj5 infection$).ti,ab. (15320)
21 (malignant wound$ or experimental wound$ or traumatic wound$).ti,ab. (559)
22 (infusion site$ or donor site$ or wound site$).ti,ab. (9548)
23 (skin abscess$ or skin abcess$).ti,ab. (278)
24 (hypertrophic scar$ or keloid scar$).ti,ab. (2338)
25 or/1-24 (183396)
26 exp Honey/ (2368)
27 honey.ti,ab. (4323)
28 or/26-27 (4693)
29 25 and 28 (337)
EBSCO CINAHL
S29 S25 and S28
S28 S26 or S27
S27 TI honey or AB honey
S26 (MH “Honey”)
S25 S1 or S2 or S3 or S4 or S5 or S6 or S7 or S8 or S9 or S10 or S11 or S12 or S13 or S14 or S15 or S16 or S17 or S18 or S19 or S20
or S21 or S22 or S23 or S24
S24 TI ( hypertrophic scar* or keloid scar* ) or AB ( hypertrophic scar* or keloid scar* )
S23 TI ( skin abscess* or skin abcess* ) or AB ( skin abscess* or skin abcess* )
S22 TI ( infusion site* or donor site* or wound site* ) or AB ( infusion site* or donor site* or wound site* )
S21 TI ( malignant wound* or experimental wound* or traumatic wound* ) or AB ( malignant wound* or experimental wound* or
traumatic wound* )
S20 TI wound* N5 infect* or AB wound* N5 infect*
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S19 TI surg* N5 infection* or AB surg* N5 infection*
S18 TI surg* N5 wound* or AB surg* N5 wound*
S17 TI ( burn or burns or burned or scald* ) or AB ( burn or burns or burned or scald* )
S16 TI (laceration* or gunshot or stab or stabbing or stabbed or bite*) or AB (laceration* or gunshot or stab or stabbing or stabbed or
bite*)
S15 TI ( cavity wound* or sinus wound* ) or AB ( cavity wound* or sinus wound* )
S14 TI ( pilonidal sinus* or pilonidal cyst* ) or AB ( pilonidal sinus* or pilonidal cyst*)
S13 TI ( bedsore* or bed sore* ) or AB ( bedsore* or bed sore* )
S12 AB ( plantar or diabetic or heel* or foot or feet or ischemia or ischemic or venous or varicose or stasis or arterial or crural or
decubitus or pressure or skin or leg or mixed or tropical or rheumatoid or sickle cell ) and AB ulcer*
S11 TI ( plantar or diabetic or heel* or foot or feet or ischemia or ischemic or venous or varicose or stasis or arterial or crural or decubitus
or pressure or skin or leg or mixed or tropical or rheumatoid or sickle cell ) and TI ulcer*
S10 (MH “Cicatrix+”)
S9 (MH “Bites and Stings+”)
S8 (MH “Surgical Wound Dehiscence”)
S7 (MH “Surgical Wound”)
S6 (MH “Wound Infection+”)
S5 (MH “Burns+”)
S4 (MH “Tears and Lacerations”)
S3 (MH “Wounds, Penetrating+”)
S2 (MH “Diabetic Foot”)
S1 (MH “Skin Ulcer+”)
Appendix 3. Risk of bias assessment criteria
1. Was the allocation sequence randomly generated?
Low risk of bias
The investigators describe a random component in the sequence generation process such as: referring to a random number table; using
a computer random number generator; coin tossing; shuffling cards or envelopes; throwing dice; drawing of lots.
High risk of bias
The investigators describe a non-random component in the sequence generation process. Usually, the description would involve some
systematic, non-random approach, for example: sequence generated by odd or even date of birth; sequence generated by some rule
based on date (or day) of admission; sequence generated by some rule based on hospital or clinic record number.
Unclear
Insufficient information about the sequence generation process to permit judgement of Yes or No, as above.
2. Was the treatment allocation adequately concealed?
Low risk of bias
Participants and investigators enrolling participants could not foresee assignment because one of the following, or an equivalent
method, was used to conceal allocation: central allocation (including telephone, web-based and pharmacy-controlled randomisation);
sequentially-numbered drug containers of identical appearance; sequentially-numbered, opaque, sealed envelopes.
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High risk of bias
Participants or investigators enrolling participants could possibly foresee assignments and thus introduce selection bias, such as allocation
based on: using an open random allocation schedule (e.g. a list of random numbers); assignment envelopes without appropriate
safeguards (e.g. envelopes that were unsealed, non-opaque or not numbered sequentially); alternation or rotation; date of birth; case
record number; any other explicitly unconcealed procedure.
Unclear
Insufficient information to permit judgement of Yes or No, as above. This is usually the case if the method of concealment is not
described, or not described in sufficient detail to allow a definite judgement, for example if the use of assignment envelopes is described,
but it remains unclear whether envelopes were sequentially-numbered, opaque and sealed.
3. Blinding was knowledge of the allocated interventions adequately prevented during the study?
Low risk of bias
Any one of the following:
• No blinding, but the review authors judge that the outcome and the outcome measurement are not likely to be influenced by
lack of blinding.
• Blinding of participants and key study personnel ensured, and unlikely that the blinding could have been broken.
• Either participants or some key study personnel were not blinded, but outcome assessment was blinded and the non-blinding of
others was unlikely to introduce bias.
High risk of bias
Any one of the following:
• No blinding, or incomplete blinding, and the outcome or outcome measurement was likely to be influenced by lack of blinding.
• Blinding of key study participants and personnel attempted, but likely that the blinding could have been broken.
• Either participants or some key study personnel were not blinded, and the non-blinding of others was likely to introduce bias.
Unclear
Either of the following:
• Insufficient information to permit judgement of Yes or No, as above.
• The study did not address this outcome.
4. Were incomplete outcome data adequately addressed?
Low risk of bias
Any one of the following:
• No missing outcome data.
• Reasons for missing outcome data unlikely to be related to true outcome (for survival data, censoring unlikely to be introducing
bias).
• Missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups.
• For dichotomous outcome data, the proportion of missing outcomes compared with observed event risk not high enough to
have a clinically relevant impact on the intervention effect estimate.
• For continuous outcome data, plausible effect size (difference in means or standardised difference in means) among missing
outcomes not enough to have a clinically relevant impact on observed effect size.
• Missing data have been imputed using appropriate methods.
114Honey as a topical treatment for wounds (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
High risk of bias
Any one of the following:
• Reason for missing outcome data likely to be related to true outcome, with either imbalance in numbers or reasons for missing
data across intervention groups.
• For dichotomous outcome data, the proportion of missing outcomes compared with observed event risk is high enough to
induce clinically relevant bias in intervention effect estimate.
• For continuous outcome data, plausible effect size (difference in means or standardized difference in means) among missing
outcomes enough to induce clinically relevant bias in observed effect size.
• As-treated analysis done with substantial departure of the intervention received from that assigned at randomisation.
• Potentially inappropriate application of simple imputation.
Unclear
Either of the following:
• Insufficient reporting of attrition/exclusions to permit judgement of Yes or No, as above (e.g. number randomised not stated, no
reasons for missing data provided).
• The study did not address this outcome.
5. Are reports of the study free of suggestion of selective outcome reporting?
Low risk of bias
Either of the following:
• The study protocol is available and all of the study’s pre-specified (primary and secondary) outcomes that are of interest in the
review have been reported in the pre-specified way.
• The study protocol is not available, but it is clear that the published reports include all expected outcomes, including those that
were pre-specified (convincing text of this nature may be uncommon).
High risk of bias
Any one of the following:
• Not all of the study’s pre-specified primary outcomes have been reported.
• One or more primary outcomes reported using measurements, analysis methods or subsets of the data (e.g. subscales) that were
not pre-specified.
• One or more reported primary outcomes not pre-specified (unless clear justification for their reporting is provided, such as an
unexpected adverse effect).
• One or more outcomes of interest in the review reported incompletely so that they cannot be entered in a meta-analysis.
• The study report fails to include results for a key outcome that would be expected to have been reported for such a study.
Unclear
Insufficient information to permit judgement of Yes or No, as above. It is likely that the majority of studies will fall into this category.
6. Other sources of potential bias:
Low risk of bias
The study appears to be free of other sources of bias.
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High risk of bias
There is at least one important risk of bias. For example, the study:
• had a potential source of bias related to the specific study design used; or
• stopped early due to some data-dependent process (including a formal-stopping rule); or
• had extreme baseline imbalance; or
• has been claimed to have been fraudulent; or
• had some other problem.
Unclear
There may be a risk of bias, but there is either:
• insufficient information to assess whether an important risk of bias exists; or
• insufficient rationale or evidence that an identified problem will introduce bias.
F E E D B A C K
Authors’ conclusions, 14 June 2013
Summary
Email received from Barry Wolfenson on behalf of Derma Sciences expressing concern at the wording of the Authors’ conclusions - as
follows:
“There is insufficient evidence to guide clinical practice in other types of wounds, and purchasers should refrain from providing honey
dressings for routine use until sufficient evidence of effect is available.”
Reply
Andrew Jull, Author; Nicky Cullum, Coordinating Editor CWG; Sally Bell-Syer Managing Editor CWG.
Thank you for your feedback. this statement has been present in the Authors’ conclusions since the review was first published in 2008.
However this is a valid point and does contravene Cochrane guidance from the Handbook which states “ The primary purpose of
the review should be to present information, rather than to offer advice”. As a result we have modified this section to read: “There
is insufficient evidence to guide clinical practice in other areas, health services may wish to consider avoiding routine use of honey
dressings until sufficient evidence of effect is available”
Contributors
Barry J. Wolfenson, Group President, Advanced Wound Care & Drug Development, Derma Sciences.
Andrew Jull, Author; Nicky Cullum, Coordinating Editor CWG; Sally Bell-Syer Managing Editor CWG.
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Feedback questions from Derma Sciences, 4 September 2013
Summary
Email received from Barry Wolfenson, Group President, Advanced Wound Care & Drug Development, Derma Sciences.
Q1. Can you please let me know, regarding the 132 Cochrane Reviews on the topic of Wounds, aside from the one titled “Honey as a
topical treatment for wounds”, how many include studies within the review that are authored by authors of the Cochrane Review itself?
Authors response: This is a very general question; you have not identified the 132 reviews you are referring to and we do not routinely
record that information outside of the review. However, any included trial which has a trialist who is also an author of the Cochrane
review must declare this in the Declaration of Interests section of the review.
Q2. Given that one of your stated core principles is to minimize bias, can you please let me know your organizational guidelines
regarding authorship of reviews and whether or not authors should be able to review their own studies? To a lay person, there seems to
be quite a potential for conflict here.
Authors response: In the CochraneWounds Group we adhere strictly to the policy that if an author of a Cochrane review is also a trialist
of an included trial in that same review they must declare this in the Declaration of Interests section of the review. This declaration is
also made in the online Declaration of Interests form which has to be completed by all authors before a protocol or a review can be
published on the Cochrane Library.
Q3. As reviewers of the Jull et al study (Randomized clinical trial of honey-impregnated dressings for venous leg ulcers), how did you
judge the relative bias of the study author’s ad hoc decision to remove incidence of infections from the adverse events table?
Authors response: This question is directly with respect to a trial we conducted, not the systematic review. We did not remove incidence
of infections from adverse events. The incidence of infection was analysed separately as specified a priori in the protocol and statistical
analysis plan in response to interest in whether honey may prevent infections in venous leg ulcers.
Q4. With regard to the above, the removal of infections from the adverse events section somehow allowed the study authors to also
remove the costs associated with hospitalizations associated with those infections from their overall cost of care analysis. However, the
other costs associated with hospitalization (not having to do with infection) remained. When the costs associated with hospitalizations
due to infection were included in the analysis, the honey arm was less expensive. Only after the costs associated with the additional
hospitalizations associated with infection were removed (ad hoc) was the honey arm more expensive. Given that the decision to remove
infections was ad hoc, how did you judge the relative bias of the statement by the study authors that the honey arm was likely more
expensive?
Authors response: This question is directly with respect to a trial we conducted, not the systematic review. Incidence of infection was
included in all the cost analyses. An analysis for sensitivity of the base case (all costs for ulcer treatment) to the small number of patients
hospitalized for treatment related to their ulcer was undertaken. We do not know what the exact purpose of the hospitalization was
i.e. whether it was related to infection or not, only that it was self-reported by the patients as related to their ulcer. As explained in the
paper, the difference was likely due to random variability rather than use of honey or not. The decision to sensitivity test the base case
was not ad hoc.
Q5. As reviewers of the Jull et al study, how did you judge the relative bias of the study regarding the author’s conclusion that honey
dressings should not be considered for venous leg ulcer healing given that all the primary and secondary endpoints favored the honey
arm (although not statistically)? It would seem, based on the results of the study, that honey should be included into the control group of
alginate, hydrofiber, hydrocolloid, foam, non-adherent, iodine, and silver-based dressings as dressings that have demonstrated efficacy
as adjuvants to compression therapy. Again, given the positive nature of the evidence derived in this study, how did you judge the
potential bias within the authors’ conclusion?
Authors response: This question is directly with respect to a trial we conducted, not the systematic review. There were no statistically
significant differences between the groups on the primary outcome, nor on any of the secondary outcomes. In fact the results for the
blinded verification of healing suggest barely any difference between groups (absolute difference 0.5%, 95%CI -10.6% to 11.3%) on
the primary outcome. Routine use of honey dressings is therefore not superior to other dressings for promoting healing compared to
usual care. This conclusion does not preclude non-routine use of honey.
Q6. You included a second study in your Cochrane Review to address the management of venous leg ulcers. This second study, by
Gethin et al, allowed only those wounds with greater than 50% slough coverage. In the larger Jull et al study of potentially likely to heal
venous leg ulcers, the authors stated that the positive results (not statistically significant) favoring honey should be “generalizable” to all
venous leg ulcers, regardless of wound bed appearance, unless new data shows otherwise. In the Gethin study, the wounds in both arms
had average slough coverage ranging from 78% - 86%, and had average wound areas of 9.9cm2 to 10.5cm2. However, in the Jull study,
there is no notation of slough coverage and the wounds ranged in average area from only 2.6cm2 to 2.7cm2. Thus, the wound bed
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appearance was dramatically different between these two studies. If the authors of the Jull study thought it was wise to view different
wound bed appearance as indicative of a different patient set, why did you chose to combine results of these two vastly different studies?
It should be noted that in the Gethin study on harder-to-heal wounds, even a much smaller number of patients resulted in the honey
arm providing statistically significant healing benefit over control. Based on what the authors of the Jull et al study stated, shouldn’t
your conclusions from these two studies have been: Honey provides a non-significant healing benefit for routine venous leg ulcers, and
provides a significant healing benefit for non-routine venous leg ulcers?
Authors response: The commentator states two studies were “vastly different” but mistakenly compares median ulcer size reported in
Jull et al to mean ulcer size reported in Gethin & Cowman, two statistics that are not comparable. The median ulcer area reported in
Gethin & Cowman was 5.4 and 4.2 cm2. Ulcer duration is also an important consideration when considering likelihood of healing.
The mean duration of ulceration prior to enrolment in the Gethin and Cowman study was 39 weeks and 30 weeks, which was similar
to the means in Jull et al (39 and 48 weeks). To suggest therefore that Gethin & Cowman recruited harder-to-heal wounds compared
to Jull et al is not accurate. These studies were not dissimilar in terms of populations and there is no evidence to suggest that they were
different in terms of wound bed appearance - one trial provided information on this factor, another did not. In the Gethin & Cowman
study, the statistically significant difference only emerged in the adjusted analysis. The unadjusted analysis for Gethin and Cowman is
presented in the systematic review and shows no significant difference (RR 1.33, 95%CI 0.82 - 2.16).
Q7. Regarding honey versus SSD, why should the results of these studies be disregarded as you suggest due to other studies having
shown benefit of hydrocolloids and silicone based dressings over SSD? Does this mean that you recommend that no other studies be
done comparing one arm to SSD in the treatment of partial thickness burns?
Authors response: There is evidence that suggests SSD cream applied from time treatment initiated until healing may delay healing.
(Thomas SS et al. J Wound Care 1995;4:218-20. Wyatt D et al. J Trauma 1990;30:857-65. Bugmann P et al. Burns 1998;24:609-12.)
It appears the issue may be how SSD cream is used, not whether it is used. Our focus in the review was in trying to understand whether
honey conferred a benefit. Using an appropriate comparator is pertinent to such an analysis and it is not clear that SSD applied daily
from treatment initiation to healing is an appropriate comparator.
Q8. Regarding the above, which do you think is the more commonly used product on partial thickness burns, SSD or hydrocolloids?
Are you aware of the commonplace usage on SSD in burn centers? If so, why would you suggest disregarding the results of studies
which show a benefit over SSD? If not, and you find this to be true (that SSD is still commonly used in burn centers), would you
change your decision to disregard the evidence derived from studies utilizing SSD as a control arm?
Authors response: See above
Q9. Also regarding the honey vs SSD studies, can you provide a more thorough clarification on why the CHIT method employed by
the investigator disqualified these studies from your analysis?
Authors response: The use of the chit method did not disqualify any trial from consideration. Authors of trials that did not describe
the method for generating the random sequence were approached for further information. The author of 11 trials replied stating the
sequence was “manually generated random numbers by the chit method”, without providing any further information about what was
meant by this approach with respect to sequence generation. We sought the advice of broadly experienced senior biostatistician who
could not infer from this response what method of sequence generation was used. We therefore stated in the Risk of bias tables “method
of generation of random sequence not reported. The author informed us that the sequence was generated by the ‘chit method’, but it
is not clear what this method is.”
Q10. Of the 6 additional studies cited as rationale for this “updated” Cochrane Review, 5 out of the 6 are positive in favor of honey.
Why is only the one negative study included in your updated conclusion? How did the biases of this study, as well as the overall structure
of the study, compare with the other 5 studies which were not included in your updated conclusion? Were these differences the reason
you only cited the negative study?
Authors response: When a review is updated we run the searches again and assess the resulting output. For this update we identified
six additional studies which met the inclusion criteria published in the review, and all six studies were included in the review with the
results of those studies presented.
Q11. Would someone be wrong if they stated it appears as though your inclusion of only the one negative study, and lack of inclusion
of the 5 positive studies, appears to be “cherry picking”?
Authors response: A systematic review is conducted according to a defined, peer reviewed and published protocol to minimize bias.
Any studies which are excluded have to be identified in the Table of Excluded studies and the reasons for the exclusion made clear.
I am assuming you are referring to the six additional studies which were included in the last update of this review. All six studies are
“included studies”.
Q12. Regarding the one negative study, which was on the treatment of cutaneous Leishmaniasis (a wound resulting from a bite from a
sand fly indigenous to the Middle East), the study authors note that further studies should be done using standardized medical grade
honeys, such as Leptospermum Scoparium (Manuka Honey). They acknowledge the fact that they used plain local honey could have
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been the reason for not achieving positive results. Why did you not include this in your conclusions or anywhere in your description
of the study?
Authors response: The purpose of the review was to summarise the available evidence, not to restate authors’ interpretations.
Q13. Regarding the negative study on honey vs early excision and grafting of mixed partial and full thickness ulcers, to the best of your
knowledge, how many studies do you know that compare one dressing vs this surgical standard and show improved results? Given the
rest of the consistently positive results of the other honey studies cited for management of partial thickness burns, do you think the
results of the early excision and grafting study suggest that honey would in any way be dangerous to use on partial thickness wounds
that do not require early excision and grafting? If so, why?
Authors response: This review does not set out to present results of any dressing when compared with early excision and grafting of
mixed partial and full thickness ulcers. Clearly there was sufficient equipoise for a trial to be conducted comparing early excision and
grafting versus treatment with honey and delayed grafting as necessary. This trial was therefore included in the review.
Q14. Can you please provide the total numbers of the following: How many studies cited in your review had a statistically significantly
positive outcome for the honey arm? How many studies cited in your review had a positive outcome (although not significantly) for
the honey arm? How many studies had a negative outcome (although not significantly) for the honey arm? How many studies had a
statistically significantly negative outcome for the honey arm?
Authors response: The data extracted from the trials and presented in the results section is provided in the review. Counting the number
of statistically significant studies is not a sensible approach to summarising evidence when meta-analysis is possible.
Q15. Given the numbers above, why did you feel that it was important to include in your updated conclusion the following statement;
“…purchasers should refrain from providing honey dressings for routine use until sufficient evidence of effect is available”? This
statement seems cautionary in its advice. What is the caution that you believe purchasing agents should take into account when
considering routine use of honey based dressings?
Authors response: In the light of insufficient evidence a cautionary approach is warranted. Routine use of honey dressings refers to use
of honey as a first line dressing.
Q16. Given that Andrew Jull is not only is the author of the key study cited in the Cochrane Review, but that he is also on the editorial
board for the wounds group reviewing all Cochrane Reviews on wound care, this question is directed specifically to him in his role as
an editor: Due to the lack of well controlled RCTs, the vast majority of Cochrane Reviews on wound dressings / technologies (with
the exception of total contact casts) have negative conclusions. The majority of these conclusions all seem to have a “boiler plate”
type of statement, basically stating “there is not enough evidence to suggest the use of one product over another.” Given the recent
updated conclusion in the review of honey dressings, do you think, if any of the other reviews are similarly “updated” (including those
on negative pressure, silver based dressings, alginates, hydrocolloids, foams, etc.), without any meaningful positive results from well
controlled studies, do you think that clinicians should similarly be advised to refrain from routine use of those dressings/technologies
for routine use until sufficient evidence of effect is available? If not, then why?
Authors response: Andrew Jull is an Editor of the Cochrane Wounds Group; he does not review all Cochrane reviews in wound care
and reviews are distributed amongst all the editors and each review is peer reviewed by a number of editors and reviewers. It is not
appropriate for the authors of this review to suggest how other authors should write their reviews.
Q17. Why was the statement, “purchasers should refrain from providing honey dressings for routine use until sufficient evidence of
effect is available” subsequently changed?
Authors response: This change was in response to feedback received from Barry Wolfenson on behalf of Derma Sciences (14th June
2013) expressing concern at the wording of the Authors’ conclusions - as follows: “There is insufficient evidence to guide clinical practice
in other types of wounds, and purchasers should refrain from providing honey dressings for routine use until sufficient evidence of
effect is available.” This statement had been present in the Authors’ conclusions since the review was first published in 2008. Cochrane
guidance from the Handbook states “The primary purpose of the review should be to present information, rather than to offer advice”.
Having considered the feedback and received the advice of the Cochrane Collaboration, we havemodified this section to read: “…There
is insufficient evidence to guide clinical practice in other areas, and health services may wish to consider avoiding routine use of honey
dressings until sufficient evidence of effect is available”. Although the primary purpose of a review is to present information, rather
than to offer advice, review authors are invited to interpret the findings of their review in the “implications for practice” section. This
section is clearly labelled as “authors’ conclusions”.
Q18. Do you believe the following statement is intended to provide advice; “…Health services may wish to consider avoiding routine
use of honey dressings until sufficient evidence of effect is available”? If not, how do you interpret this statement to not be providing
advice on usage?
Authors response: Review authors are invited to interpret the findings of their review in the “implications for practice” section and these
are clearly labelled as “authors’ conclusions”. It seems perfectly reasonable where no compelling evidence of benefit has been identified
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to suggest that decision makers consider this finding. The use of the terms “consider” and “routine” clearly indicate that this is not
intended to be a didactic recommendation, simply something for consideration by decision makers.
Q19. How many times is this type of advice given in any of the other Cochrane Reviews regarding wound dressings? Please only limit
your response to those Cochrane Reviews that had negative conclusions, such as on alginates, foams, silver dressings, negative pressure,
etc… If the answer is 0 (zero), what do you think is the distinction between the evidence presented for honey-based dressings and the
evidence presented for these other dressings/technologies?
Authors response: There is no blueprint for the precise wording of this section, and it is not unusual for Cochrane Reviews to present
text that provides guidance that decision makers should consider the absence of high quality evidence of benefit when making treatment
decisions.
Q20. Specifically regarding your statement in the Cochrane Review that clinicians may consider refraining from routine use on honey-
based dressings, can you please clarify:
20.1 For routine venous leg ulcers: Should clinicians refrain from using honey-based dressings? If so, why?
Authors response: It is reasonable to highlight the apparent failure of routine use honey dressings to deliver such an important outcome
as healing rate.
20.2 For chronic/stalled venous leg ulcers: Should clinicians refrain from using honey-based dressings? If so, why?
Authors response: All venous leg ulcers are chronic. The evidence from the trials does not address “stalled” venous ulcers.
20.3 For other routine ulcers such as pressure ulcers: Should clinicians refrain from using honey-based dressings? If so, why?
Authors response: The results of the review demonstrate clear uncertainty in respect of this outcome.
20.4 For other chronic/stalled ulcers such as pressure ulcers: Should clinicians refrain from using honey-based dressings? If so, why?
Authors response: The evidence from the single available trial does not address “stalled” pressure ulcers.
20.5 For partial thickness burns that do not require early excision and grafting: Should clinicians refrain from using honey-based
dressings? If so, why?Authors response: The
results of the review demonstrate clear uncertainty in respect of this outcome.
20.6 For any challenging wounds where a clinician would typically use negative pressure, silver-based dressings, iodine-based dressings,
alginates, or foams: Should clinicians refrain from using honey-based dressings? If so, why?
Authors response: There were no trials where the wounds were defined as ‘challenging’.
20.7 Do you consider chronic wounds (whether they be venous leg ulcers, diabetic foot ulcers, pressure ulcers, or dehisced surgical
wounds) to be “routine”?
Authors response: It is not clear what is meant by “routine” in this context - none of the conditions are uncommon.
20.8 Do you consider partial thickness burns that are treated in a burn center to be “routine”?
Authors response: It is not clear what is meant by “routine” in this context.
Reply
The authors of the review have responded to this feedback giving a point by point response to the questions above.
Contributors
Barry Wolfenson, Group President, Advanced Wound Care & Drug Development, Derma Sciences.
Declaration of interest: I am the President of Advanced Wound Care at Derma Sciences. Thus, I clearly have involvement with an
organization with a financial interest in the subject matter of my feedback.
Andrew Jull, Author; Nicky Cullum, Coordinating Editor CWG; Sally Bell-Syer Managing Editor CWG.
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Feedback questions from Laura Bolton, 27 September 2013
Summary
Comment: I strongly support evidence-based practice and was trained as a Cochrane reviewer in 1995. Am concerned that this SR is
eroding Cochrane credibility as so many wound care professionals have asked me to clarify issues in it. Please help correct the following
errors as quickly and thoroughly as possible:
1. Errors in describing the studies (omission of important facts or perspective),
2. Arbitrary emphasis on non-statistically significant or irrelevant or inappropriate findings in abstract and conclusions
3. Omitting statistically significant RCT healing results favorable to honey in abstract and conclusions
4. Statements in the Authors conclusion and Abstract do not seem to reflect the results reported in the body of the SR
5. Inappropriate recommendations to avoid honey use that usurp clinician’s point of care decisions rather than inform them of level
of evidence supporting honey use for various indications, which appears no less sufficient than that for many other wound care
interventions.
My Cochrane trainers insisted we avoid recommending and simply describe levels of evidence to empower clinical decision making.
Has this changed?
To clarify the issues Dr. Janice Beitz and I presented a webinar with more detail on each issue accessible at:
http://www.dermasciences.com/pdf/Scientific-Review-of-Cochrane-Review-Honey-as-Topical-Treatment-for-Wounds-Dr.-Bolton-
and-Dr.%20Beitz.pdf
Thank you and the hard working Cochrane Wounds Group for your immediate attention to help uphold Cochrane credibility!
Reply
The authors of the review have considered the feedback and are pleased to report that the review has been fully updated, a new
search conducted with two additional studies included. All the data have been checked and the evidence assessed using the GRADE
approach and four Summary of Findings Tables added. The Results section has been restructured to bring all outcomes together for
each comparison and the conclusions of the review have been slightly amended. This updated review has been peer reviewed.
Contributors
Laura Bolton, Adjunct Associate Professor of Surgery, Rutgers University Medical School.
Declaration of interest: I certify that I consult on evidence-based product development and study design for EuroMed, Derma Sciences
and Systagenix, but have never received any corporate funding for honey-related consulting or speaking nor for my part in presenting
the Webinar described.
Andrew Jull, Author; Nicky Cullum, Coordinating Editor CWG; Sally Bell-Syer Managing Editor CWG.
Comment from Joy Schank, 26 October 2013
Summary
I was concerned to learn of the recent negative review regarding honey and treating wounds. The review did not seem to provide a
balance of the available literature. Thank you for considering this comment.
Reply
The authors have carefully considered and incorporated the observations and items of feedback submitted through the “Submit
Comments” facility on the Cochrane Library for this review. These comments and the replies from the authors have been retained in
this version of the review. This is to enable readers to follow the exchange and to form their own interpretation of the evidence that is
now available.
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Contributors
Joy Schank, Private Practice, Nurse Practitioner.
I certify that I have no affiliations with or involvement in any organization or entity with a financial interest in the subject matter of
my feedback.
Andrew Jull, Author; Nicky Cullum, Coordinating Editor CWG; Sally Bell-Syer Managing Editor CWG.
Comment from Jennifer Gardner, 27 March 2014
Summary
Dear Editor: As a CertifiedWound Specialist, a Doctor of Physical Therapy with aMasters in Healthcare Administration, and a director
of both inpatient and outpatient wound care services at Inspira Health Network in New Jersey I have recently read the Cochrane
Review “Honey as a Topical Treatment for Wounds” by Jull et al, 2013. A sales representative that does not sell honey products pointed
out the conclusion of the Cochrane review to me stating “health services may wish to consider avoiding routine use of honey dressing
until sufficient evidence is available”. For many years I have been using honey dressings on a variety of wounds including pressure
ulcers, venous leg ulcers, arterial ulcers, surgical wounds and diabetic foot ulcers. I have authored and presented multiple case series
at international wound congresses demonstrating my success with the use of these dressings on a variety of wounds. I have treated
hundreds of wounds with honey and have found these dressings to be helpful in the healing of these wounds and have never noted any
severe adverse reactions. I was extremely surprised to see that the conclusion to “avoid” usage and question how this recommendation
can be made when I have not been able to find evidence nor have experienced any negative issues. Uponmy concern with the conclusion
I then read with great interest the entire published review.
Pertaining to the author’s recommendation to “avoid” usage seems to indicate a safety or efficacy concern. In the AE table published in
the review, “ulcer pain” is the only difference in the number of AEs. However, in the review authors’ own study incorporated into the
review (HALT study by Jull et al 2007), the authors note that while pain on dressing changes was more frequent in the honey arm, the
pain was not severe enough to cause patients to exit the study, suggesting it was well tolerated. This is similar to my own experience,
where if a patient does feel pain upon dressing changes, it is short in duration and well tolerated. Additionally, it has been my experience
that application of honey helps to reduce the chronic wound pain commonly suffered by venous leg ulcer patients, potentially due to
a reduction in inflammation. Thus, I do not see how this could possibly be an issue with regard to use of honey dressings. Can you
please clarify what is the reason for authors’ recommendation to avoid usage? There were only four articles out of 25 reviewed that did
not favor honey so please clarify what specific concern the authors have that led to that recommendation.
I would like to commend the Editors of the Cochrane Review on providing the health care community with a balanced review of clinical
information that is helpful in making decisions regarding the treatment of our patients with new procedures and medical products.
Unfortunately, this review is inconsistent with my clinical experience as well as the long established excellence of the Cochrane Review.
I believe the authors’ conclusion needs to be made clearer. I did agree with the vast majority of the studies having more favorable results
in the honey arms of the study but I would also note that the recommendation itself seems out of place in a Cochrane review, and I
was very surprised to find it in the review at all.
Reply
The authors of the review have considered the feedback and are pleased to report that the review has been fully updated, a new
search conducted with two additional studies included. All the data have been checked and the evidence assessed using the GRADE
approach and four Summary of Findings Tables added. The Results section has been restructured to bring all outcomes together for
each comparison and the conclusions of the review have been slightly amended. This updated review has been peer reviewed.
Contributors
Jennifer A. Gardner, PT DPT MHA CWS. Manager, Wound Care Services. Inspira Medical Center Woodbury.
I certify that I have no affiliations with or involvement in any organization or entity with a financial interest in the subject matter of
my feedback.
Andrew Jull, Author; Nicky Cullum, Coordinating Editor CWG; Sally Bell-Syer Managing Editor CWG.
122Honey as a topical treatment for wounds (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Comment from Kevin Foster, 26 March 2014
Summary
Dear Editor in Chief,
I am Burn Surgeon and the Director of one of the largest burn centers in the US, which treats thousands of patients annually. I recently
had the pleasure of reviewing your 2013 publication Honey as a topical treatment for wounds (Review) written by Drs. Jull, Walker
and Deshpande. While I did enjoy reading the review, I would like to express my concern about the Authors’ Conclusions.
As a clinicianwho regularly treats patients who have suffered frompartial-thickness and full-thickness burns, I do not share the sentiment
expressed by the authors that “health services may wish to consider avoiding routine use of honey dressings until sufficient evidence of
effect is available.” In my personal experience, communication with other physicians and reviews of available literature, I have found
that honey dressings are quite effective, especially where previous treatments have failed to provide benefit.
Additionally, I believe that the authors have put significant weight in their conclusion on one study (Subrahmanyam 1999) which
evaluated the use of honey dressings compared to the industry standard for moderate to severe partial-thickness and full-thickness
burns. It is my opinion, given the vast amount of supportive literature from this author as well as others, that although the results
of this study were not in favor of the use of honey dressings, results should not be used to discredit their use. As early excision and
grafting is an established practice, it is my opinion that the author was attempting to evaluate honey as an alternative remedy for more
troublesome burn injuries. The fact that the study failed to show positive results in this setting informs an upper limit for defining
honey dressings as a standard of care treatment in burns and validates the practice of grafting rather than discrediting the use of honey
dressings in less severe clinical scenarios.
It is evident that honey dressings are not a panacea for all wound types and severity, however, the recommendation that the medical
community avoid the use of such dressings is confusing as it is not founded by the clinical safety and efficacy evidence (or lack thereof )
provided in the review. Therefore, I would ask that you consider revising the aforementioned conclusion.
Thank you for your time and consideration.
Reply
The authors of the review have considered the feedback and are pleased to report that the review has been fully updated, a new
search conducted with two additional studies included. All the data have been checked and the evidence assessed using the GRADE
approach and four Summary of Findings Tables added. The Results section has been restructured to bring all outcomes together for
each comparison and the conclusions of the review have been slightly amended. This updated review has been peer reviewed.
Contributors
Kevin Foster, MD, MBA, FACS. Director Burn Services. The Arizona Burn Center at Maricopa Burn Center Phoenix, Arizona.
I certify that I have the affiliations/involvement as described. I have spoken to the sales force for Medihoney, describing my experience
with its use. I received an honorarium and travel expenses.
Andrew Jull, Author; Nicky Cullum, Coordinating Editor CWG; Sally Bell-Syer Managing Editor CWG.
Comment from Dimitrios Lintzeris, 27 March 2014
Summary
To the Editors of the Cochrane Collaboration,
After reviewing one of your recent publications, Honey as a topical treatment for wounds (Review), I have become very concerned
about some of the language used in the Authors’ Conclusions regarding “avoiding use” of honey dressings.
I am a practicing doctor of osteopathy and Medical Director at Wayne Memorial Wound Care Center in North Carolina. Over 120
patients are seen in our clinic on a weekly basis. I regularly use impregnated honey dressings and honey gel for diabetic, venous and
pressure ulcers as well as acute and chronic wounds. I have personally experienced positive patient outcomes and no safety or efficacy
issues with this intervention. Additionally I have found honey dressings to be cost efficient to go along with a high patient compliance
rate.
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In reading the review, the data presented seems to point towards a positive effect of honey, which correlates with my personal experience.
For example, in the pressure ulcer study cited (Weheida 1991), the mean time to healing favored honey with statistical significance.
Also in the Diabetic foot ulcer study cited (Shukrimi 2008) the endpoint of time to healing also favored honey.
Therefore, it is confusing to see this conclusion and recommendation that “There is insufficient evidence to guide clinical practice
in other areas, and health services may wish to consider avoiding routine use of honey dressings until sufficient evidence of effect is
available.” It inaccurately gives the reader - especially those who do not read the full review - the impression that this intervention is
not safe and efficacious; an impression which is not supported by the data presented or my experience in clinical practice.
It would like to suggest that you consider revising the current conclusion to help readers have a more balanced perspective of the body
of evidence supporting honey base wound care.
I appreciate your consideration of this matter.
Reply
The authors of the review have considered the feedback and are pleased to report that the review has been fully updated, a new
search conducted with two additional studies included. All the data have been checked and the evidence assessed using the GRADE
approach and four Summary of Findings Tables added. The Results section has been restructured to bring all outcomes together for
each comparison and the conclusions of the review have been slightly amended. This updated review has been peer reviewed.
Contributors
Dr. Dimitrios Lintzeris, DO, CWS. Medical Director. Wayne Memorial Wound Care Center.
I certify that I have no affiliations with or involvement in any organization or entity with a financial interest in the subject matter of
my feedback.
Andrew Jull, Author; Nicky Cullum, Coordinating Editor CWG; Sally Bell-Syer Managing Editor CWG.
Comment from Margarita Simon, 8 October 2013
Summary
Comment: I was handed a copy of the Cochrane Report on medihoney by the Santyl rep in our area. He of course espoused the
report’s statement that clinicians should cease use of the product as stated in the report. This prompted me to assess carefully tow of the
patients which I was overseeing their complex wounds and using medihoney. I can tell you that the wound made outstanding progress
with medihoney - in fact remarkable considering both patients were complex and compromised - one with active cancer undergoing
radiation and chemontherapy and the other had breast cancer several years before with reconstructive surgery. At no time did they have
any failure of their wound care and I have the photos to prove their excellent results. I am appalled at the campaign Smith & Nephew/
Healthpoint has directed at medihoney based on the Cochrane Report - a report that is riddled with inconsistencies.
Reply
The authors of the review have considered the feedback and are pleased to report that the review has been fully updated, a new
search conducted with two additional studies included. All the data have been checked and the evidence assessed using the GRADE
approach and four Summary of Findings Tables added. The Results section has been restructured to bring all outcomes together for
each comparison and the conclusions of the review have been slightly amended. This updated review has been peer reviewed.
Contributors
Margarita Simon, MS, FNP-BC, CWCN. wound care consultant. Simon WOund Consulting, PLLC.
I certify that I have no affiliations with or involvement in any organization or entity with a financial interest in the subject matter of
my feedback.
Andrew Jull, Author; Nicky Cullum, Coordinating Editor CWG; Sally Bell-Syer Managing Editor CWG.
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9. Comment from Herbert B. Slade, 29 May 2015
Summary
Comment: The March 2015 update includes a paper by Gethin (2009, J Clin Nursing) which was retracted in July 2014, and thus
it should not be included. The unpublished thesis by Gethin (2007) is only available by visiting the library at the Royal College of
Surgeons in Dublin. It should be read and the data carefully evaluated if it is to be included, as readers of the review won’t easily be able
to draw their own independent conclusions.
Reply
Thank you for your comment. We were aware of the article’s retraction and the reason for the retraction. As noted in the review history,
review notes, and the references, we used Gethin’s 2007 PhD thesis as a primary source of information for description of the trial,
risk of bias assessment, and outcome data on healing rates and infections. It is worth noting that the extracted data for risk of bias
assessments, healing rates, and infections is not in dispute. We used Dr Gethin’s data as an input into a meta-analysis that produced
a summary statistic for the two trials being pooled. Our interpretations are based on our meta-analysis, not any other analyses from
primary sources.
Contributors
Herbert B. Slade MD (Email Address: bert.slade@smith-nephew.com).
Affiliation: Univ of North Texas Health Sciences Center, Smith & Nephew. Role: Assoc Clin Prof Pediatrics (UNT), Chief Medical
Officer (S&N).
I have modified the conflict of interest statement below to declare my interests:
I am the chief scientific and medical officer of a medical devices company which markets products for wounds.
Andrew Jull, Author.
WH A T ’ S N E W
Last assessed as up-to-date: 15 October 2014.
Date Event Description
9 June 2015 Feedback has been incorporated Feedback submitted and review author response added to the review
H I S T O R Y
Protocol first published: Issue 1, 2005
Review first published: Issue 4, 2008
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Date Event Description
17 February 2015 Feedback has been incorporated The authors have carefully considered and incorpo-
rated the observations and items of feedback submit-
ted through the “Submit Comments” facility on the
Cochrane Library for this review. These comments and
the replies from the authors have been retained in this
version of the review. This is to enable readers to follow
the exchange and to form their own interpretation of
the evidence that is now available
17 February 2015 New search has been performed New search: two new studies included (Gulati 2014;
Kamaratos 2014), all evidence assessed using the
GRADE approach and four Summary of Findings Ta-
bles added. Results section restructured to bring all out-
comes together for each comparison
17 February 2015 New citation required and conclusions have changed Conclusions slightly amended.
4 February 2014 Feedback has been incorporated Response to feedback
3 October 2013 Feedback has been incorporated Feedback received, author team to respond
19 June 2013 Feedback has been incorporated Text edits in response to feedback
13 June 2012 New citation required and conclusions have changed Six additional studies included (Baghel 2009; Mashood
2006; Memon 2005; Nilforoushzadeh 2007; Robson
2009; Shukrimi 2008), conclusions updated. New au-
thor contributed to the review update (Sohan Desh-
pande) and Anthony Rodgers who contributed to the
original review has not contributed to the update
13 June 2012 New search has been performed New search, risk of bias assessment completed on all
included studies; primary reference for Gethin 2007
changed to Gethin 2007.
11 August 2009 Amended Contact details updated.
13 May 2009 Amended Contact details updated.
28 March 2008 Amended Converted to new review format.
126Honey as a topical treatment for wounds (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
C O N T R I B U T I O N S O F A U T H O R S
Andrew Jull: designed and co-ordinated the review. Extracted data (first review), reviewed risk of bias assessments and data extraction
(this update). Analysed or interpreted data and performed statistical analysis, wrote to study author/experts/companies, completed or
reviewed the drafts, revisions, and the final review (first review and this update). He is guarantor of the review.
Nicky Cullum: checked others’ data extraction and extracted data (this update); checked others’ risk of bias assessment and conducted
risk of bias assessments (this update). Analysed and interpreted data; constructed summary of findings tables (this update); completed
drafts and revisions of the review and approved the final version of this update prior to publication.
Jo Dumville: checked others’ data extraction and extracted data (this update); checked others’ risk of bias assessment and conducted
risk of bias assessments (this update). Analysed and interpreted data; constructed summary of findings tables (this update); completed
drafts and revisions of the review and approved the final version of this update prior to publication.
Maggie Westby: checked others’ data extraction and extracted data (this update); checked others’ risk of bias assessment and conducted
risk of bias assessments (this update). Analysed and interpreted data; constructed summary of findings tables (this update); completed
drafts and revisions of the review and approved the final version of this update prior to publication.
Natalie Walker: designed the review and checked studies to be included, checked risk of bias assessment and the quality of statistical
analysis (first review), performed part of writing or editing of the review (first review and first update). Approved final review prior to
submission (first review and all updates).
Sohan Deshpande: checked studies to be included, extracted data, performed risk of bias assessments and contributed to writing (first
update).
Contributions of editorial base:
Nicky Cullum: for the original review and first update - edited the review, advised on methodology, interpretation and review content;
approved the final review prior to submission.
Liz McInnes, Editor: approved the first review update prior to submission.
Sally Bell-Syer: co-ordinated the editorial process; advised on methodology, interpretation and content; edited the review and the
updated versions of the review.
Ruth Foxlee: designed the search strategy and edited the search methods section.
David Tovey (Editor in Chief ) approved the final version of this updated review (second update).
Toby Lasserson (Senior Editor) of the Cochrane Editorial Unit advised on the Summary of Findings Tables and approved the final
version of this updated review (second update).
D E C L A R A T I O N S O F I N T E R E S T
Andrew Jull, Natalie Walker and Anthony Rodgers were investigators in the Honey as Adjuvant Leg ulcer Treatment (HALT) trial
(ISRCTN 06161544), one of the trials included in this review. The Clinical Trials Research Unit, which employed Andrew Jull, Natalie
Walker and Antony Rodgers received a small, unconditional cash contribution from a manufacturer of honey dressings for the conduct
of the HALT trial.
Dr Walker is supported by a Heart Foundation Douglas Senior Fellowship in Heart Health (Prevention). She has provided consultancy
to the manufacturers of smoking cessation medications, received honoraria for speaking at a research meeting and received benefits in
kind and travel support from a pharmaceutical company that makes smoking cessation medications. She has also received product in
kind from a pharmaceutical company that makes smoking cessation medications, for use in an investigator initiated phase III clinical
trial. She has been contracted by two companies to undertake clinical trials for them - one company wanted her to evaluate a treatment
for leg ulcers (but this was not honey) and the second was an asthma trial for a New Zealand Crown entity that decides, on behalf of
District Health Boards, which medicines and pharmaceutical products are subsidised for use in the community and public hospitals.
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S O U R C E S O F S U P P O R T
Internal sources
• Senior Health Research Scholarship, University of Auckland, New Zealand.
• School of Nursing, Midwifery and Social Work, University of Manchester, UK.
External sources
• This project was supported by the National Institute for Health Research, via Cochrane Infrastructure, Cochrane Programme
Grant or Cochrane Incentive funding to Cochrane Wounds. The views and opinions expressed therein are those of the authors and
do not necessarily reflect those of the Systematic Reviews Programme, NIHR, NHS or the Department of Health, UK.
• The Douglas Senior Fellowship in Heart Health (Prevention), New Zealand.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
In the first version of the review, two trials that compared active interventions allocated wounds to the interventions rather than
participants (Oluwatosin 2000; Okeniyi 2005). The participants had multiple wounds in many cases, and some participants would
have received both interventions. In this update, a trial that required participants to have two burns (Malik 2010), and a trial that may
have randomised participants but appears to have reported healing by pressure injury rather than by participant (Yapucu Gunes 2007),
were excluded. The data in these trials were presented by wound and thus could not be combined (if possible) with trials where data
were presented by participant in both the first version of the review and this update. Such methods were not foreseen in the protocol,
where it was assumed that data would be presented by participant. Randomising by wound breaches the assumption of independence
that underpins inferential testing, increases the weight of a study inappropriately if included in a meta-analysis (by doubling the
denominator) and thereby artificially improves the precision of the confidence interval for the summary statistic. Additionally, a trial
requiring participants to have two wounds that randomises one wound to each treatment is not clinically generalisable as it has reduced
between-patient variability. Between-patient variability in pragmatic trials drives external validity. The inclusion criteria have been
adjusted in this update to reflect this change.
N O T E S
The authors have carefully considered and incorporated the observations and items of feedback submitted through the “Submit
Comments” facility on the Cochrane Library for this review. These comments and the replies from the authors have been retained in
this version of the review. This is to enable readers to follow the exchange and to form their own interpretation of the evidence that is
now available.
During the updating of this review the review authors became aware that the publication Gethin G, Cowman S. Manuka honey vs.
hydrogel - a prospective, open label, multicentre, randomised controlled trial to compare desloughing efficacy and healing outcomes in
venous ulcers. Journal of Clinical Nursing 2009;18(3):466-74 (http://onlinelibrary.wiley.com/doi/10.1111/jocn.12652/abstract) has
been retracted by agreement between the journal Editor-in-Chief, the authors and John Wiley & Sons, Ltd. The retraction has been
agreed due to errors in the data analysis which affect the article’s findings. The review authors would like to confirm that the data
in this updated review is taken from the source: Gethin G. Manuka honey versus hydrogel - a prospective, open label, multicentre,
randomised controlled trial to compare desloughing efficacy and healing outcomes in venous ulcers. Unpublished PhD thesis 2007.
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